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REGULATION OF IL-4 MEDIATED SIGNALLING IN PRIMARY
HUMAN BRONCHIAL FIBROBLASTS BY IL-13R2
by Gemma Campbell-Harding
Fibroblasts are key eector cells involved in airway inammation and
remodelling in asthma. Interleukin (IL)-4 and IL-13 are important cytokines
in the asthma phenotype which act on broblasts and other cell types. These
cytokines exhibit overlapping functions through use of a common receptor,
IL-4R:IL-13R1. Another receptor, IL-13 Receptor  2 (IL-13R2), orig-
inally thought to be a decoy receptor for IL-13, has recently been shown to
attenuate responses to IL-4 as well as IL-13, by an unknown mechanism.
In this thesis, I tested the hypothesis that IL-13R2 is responsible for
the regulation of IL-4 mediated signalling in bronchial broblasts and that
regulation by IL-13R2 is altered in asthma.
The expression of IL-4 and IL-13 receptors on human bronchial broblasts
(HBFs) was highly dynamic. IL-13R2 expression was signicantly increased
in response to both IL-4 and IL-13 over 24 hours, requiring de novo protein
synthesis. A signicant rapid reduction in IL-4R expression was also
observed in response to either ligand, although levels rapidly returned to
normal after removal of the stimulus. Use of a neutralizing antibody showed
that induction of IL-13R2 suppressed STAT-6 activation and the pro-
inammatory eects of IL-4 and IL-13. No dierence was observed in receptor
expression levels or the regulatory eects of IL-13R2 between healthy and
asthmatic subjects.
IL-13R2 was also up-regulated by a range of Th1 stimuli including IFN
and IFN, as well as double stranded RNA (dsRNA), with no disease-related
dierences. The up-regulation of IL-13R2 in response to dsRNA hampered
attempts to knock down surface expression of IL-13R2 using siRNA, but
revealed a potential role for IL-13R2 in the anti-viral response due to its
ability to down-regulate responses to IL-4 and IL-13.
An over-expression model of IL-13R2 identied the potential for IL-4 to
cause activation of STAT3 mediated by IL-13R2. In HBFs naturally
expressing high levels of IL-13R2, addition of IL-4, but not IL-13, signi-
cantly increased activation of STAT3, a transcription factor associated with
cell survival.
Whilst IL-13R2 may have benecial anti-inammatory eects by sup-
pressing STAT-6 mediated responses, further work is required to determine
potential pro-brotic consequences of IL-4/IL-13R2 mediated STAT3 acti-
vation in HBFs. Since no dierence was observed in IL-13R2 expression or
in its anti-inammatory ecacy in HBFs from normal or asthmatic donors,
these data suggest that the atopic environment is more important than
intrinsic dierences in the ability of asthma-derived broblasts to respond
to IL-4 and IL-13.Contents
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Introduction
1.1 Asthma
Asthma is a chronic respiratory disease classically characterised by reversible
airow obstruction, airway hyperresponsiveness (AHR) to various innocuous
stimuli, signicant airway remodelling and inammation. 1 Asthma mani-
fests as recurrent episodes of breathlessness, wheezing, coughing and chest-
tightness due to widespread airow obstruction, which is generally reversible,
either spontaneously or with treatment. However there is much heterogeneity
of symptoms between patients and with severe asthma, for example, the
reversibility may be reduced to xed airway obstruction. 2 The aetiology of
asthma has not been clearly dened, although it is considered to be a multi-
factoral disease involving a range of genetic and environmental triggers. 3
Approximately 300 million people worldwide suer from asthma, and
gures released by Asthma UK suggest that currently 5.2 million asthmatics
in the UK require treatment. Of these, 1.1 million (1 in 10) are children
and 4.2 million (1 in 12) are adults. 4 The socio-economic impact of asthma
is substantial. This is not only due to direct healthcare costs, such as
medications and hospital admissions, and indirect burdens such as absence
from work but also the reduction in quality of life, all of which aect not only
the patient but also their family and friends. The costs of asthma increase
with symptom and disease severity. This is particularly pronounced in more
1Chapter 1. Introduction
severe cases, where the disease is poorly controlled and frequent emergency
care is often required. 5{9 At present, 2.6 million people in the UK suer from
severe symptoms associated with asthma, of which 500,000 people are not
eectively treated by the traditional therapy of steroids. 10 Recent attempts
to develop novel therapeutics for asthma have been relatively unsuccessful
with very few reaching clinical trials, therefore there is an unmet clinical
need.
1.2 Symptoms of Asthma
Asthma is characterised by episodic airow obstruction resulting in shortness
of breath, wheezing, chest tightness or cough, with symptoms often occurring
in the early morning hours, however the heterogeneity of asthma means the
severity of symptoms experienced diers between patients.
As these symptoms are episodic, asthmatic patients experience cycles
of stability with few to no symptoms interspersed with acute periods of
symptom exacerbation. The severity of these exacerbations varies greatly
between patients, ranging from slight dyspnoea, wheeze or cough to sig-
nicant airow reduction impacting on normal day to day tasks such as
gentle exercise and speech. These symptoms may resolve on their own, but
often require treatment with a 2-agonist to relax the airway smooth muscle.
Whilst asthmatic airow obstruction is generally considered to be totally
reversible, in more severe cases only partial reversibility with treatment may
be observed.
Asthma exacerbations can be triggered by a variety of innocuous stimuli
and asthma is often categorised as either extrinsic (allergic) or intrinsic (non-
atopic) in origin. 11 With extrinsic asthma, allergens derived from pollen,
house dust mites, mould and animal dander can trigger an exacerbation,
whilst intrinsic asthma is more commonly associated with other trivial stimuli
such as cold air and pollutants.
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Extrinsic asthma generally becomes apparent during childhood and may
only occur transiently, with few or no symptoms in adulthood. In allergic
asthma allergen avoidance can reduce the requirement for medication. 12
Intrinsic asthma tends to have a later age of onset and is associated with
no history of atopy. 11,13
One of the main clinically dened signs of asthma exacerbation is a rapid
decrease in FEV1. Forced expiratory volume in one second (FEV1) is a
key measurement of lung function, which can also be used to determine
the reversibility of the airow obstruction by monitoring the FEV1 both
before and after administration of a bronchodilator. The ratio of the FEV1
and the forced vital capacity (FVC), another measurement of lung function,
(FEV1/FVC) can be used to determine airow limitation and is necessary
for ruling out other respiratory conditions which can easily be confused
with asthma, such as chronic obstructive pulmonary disease (COPD) or
bronchitis. 14,15
Asthmatic airway hyperresponsiveness (AHR) to innocuous stimuli can
also be measured using provocation tests, where a known stimuli, such as
methacholine, is administered and the patient is monitored for the drop in
FEV1. 16
1.3 Airway Structure
The airway consists of several histologically distinct layers: the epithelium,
submucosa and smooth muscle layer (Figure 1.1).
The epithelial layer lines the airway lumen. This layer includes a variety
of distinct epithelial cell types, including ciliated epithelia, basal cells, clara
cells and goblet cells, each with discrete functions and localisations. 17{19
These epithelial cells act as the rst line of defence against allergens, viruses
and pollutants as they form a highly protective structural barrier. 20 Goblet
cells and mucus glands interspersed within this layer produce a viscous
mucus which traps foreign particulates. This forms part of the mucociliary
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Ciliated epithelial
and goblet cells
Basal cells
Fibroblasts
Smooth muscle cells
Blood vessels
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Figure 1.1: Normal structure of the inner airway wall. The airway consists of
histologically distinct layers. The airway lumen is lined with epithelium, which
consists of a layer of ciliated epithelial cells, which may be interspersed with mucus
producing goblet cells, and subtended by basal cells, forming a physical, chemical
and immunological barrier. Beneath this layer, lies the structural cells, in the form
of broblasts and smooth muscle, and the vasculature. Adapted from 16
escalator in conjunction with the cilia on the lumenal surface of the epithelia,
which facilitates removal of foreign particles. As well as passive defence
mechanisms, epithelial cells are also capable of mounting and modulating
the immune response. Viruses and bacteria can be internalised, resulting
in the release of cytotoxic and anti-microbial peptides. 20 Epithelial cells
can also produce a series of cytokines and chemokines including Tumour
Necrosis Factor (TNF) , Interleukin (IL)-1 and macrophage inammatory
protein (MIP) 2, reactive oxygen species (ROS), adhesion molecules such as
inter-cellular adhesion molecule 1 (ICAM-1), surfactant proteins, Toll-like
receptors (TLRs) and growth factor receptors. 16,21,22
Underneath the epithelial layer is the lamina propria, containing brob-
lasts, myobroblasts, extracellular matrix (ECM), nerves and capillaries. 19,22
Fibroblasts are mesenchymal cells, located directly below the basement mem-
brane, that play an important role in wound repair. These are structural cells
that produce ECM proteins, such as collagen, as well as matrix degrading
proteases, such as matrix metalloproteases (MMPs), which are involved in
4Chapter 1. Introduction
normal tissue turnover and repair after injury. 23,24 Fibroblasts also secrete
an array of cytokines and are important for regulating host defence mecha-
nisms as they recruit and activate leukocytes. 25{28 Upon stimulation with
Transforming Growth Factor (TGF) , broblasts can dierentiate into
myobroblasts, which are contractile cells, important in wound repair, that
secrete many cytokines. 29,30
Beneath the lamina propria is the submucosa, containing smooth muscle
cells, cartilage and connective tissue. This layer is of particular structural
importance in the lung, with the smooth muscle bundles and cartilage
providing support. 19
1.4 Pathophysiology of Asthma
In the asthmatic airway there are many changes associated with the disease
phenotype, involving a wide range of cell types. These phenotypic dierences
include signicant airway inammation as well as remodelling of the tissue,
although the degree of each can vary substantially between patients.
1.4.1 Airway Inammation
Asthma is considered an inammatory disease, traditionally characterised by
eosinophilia, mast cell activation and the predominance of type 2 T helper
(Th2) cells. 31 These cells also induce the production of a range of inamma-
tory mediators by macrophages, epithelial cells and broblasts. However,
as asthma covers a wide spectrum of clinical phenotypes there is varia-
tion observed between patients in the manifestation of this inammation.
For instance, many patients can be clustered as being either eosinophilic,
neutrophilic, or mixed in their inammation, whilst others are referred to as
paucicellular, where limited numbers of both eosinophils and neutrophils are
observed. 32
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Inammation in the asthmatic lung, unlike the episodic nature of the
symptoms, is persistent 33 and there has been debate regarding a link to the
severity of the disease. 2,34{36
There are many cells involved in the inammatory response within the
lung. These include eosinophils, T lymphocytes and mast cells.
Mast Cells
Mast cells store cytoplasmic granules containing a range of inammatory
mediators such as histamine, major basic protein (MBP), prostaglandins,
leukotrienes and cytokines, many of which induce bronchocontriction. 37
Whilst classically viewed as being activated by allergens via high anity
immunoglobulin E (IgE) receptors, these cells can also degranulate due to
changes in osmotic pressure which occur during exercise. Greater expression
of these cells in airway smooth muscle has been observed in asthmatic
patients and this has been linked to airway hyperresponsiveness. 38
Eosinophils
Eosinophilia is often observed in asthma. 34 Whilst increased eosinophil
numbers have been linked to disease severity, this does not appear to always
be the case, with recent observations of both discordant eosinophilia in the
absence of symptoms and clusters of non-eosinophilic patients with severe
asthma symptoms. 2,32,39 In allergic and asthmatic individuals, eosinophils,
however, have been found to exhibit increased migration, adhesiveness and
degranulation. 40{42
Like mast cells, eosinophils contain a range of toxic granule proteins,
including eosinophilic cationic protein (ECP), MBP, eosinophil peroxidase
(EPO) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN),
the release of which can cause serious tissue damage, and this is thought to
contribute to remodelling in the asthmatic lung. These cells also produce a
range of mediators and cytokines, such as leukotriene C4 (LTC4), eotaxin,
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Th2 cytokines and TGF, all of which are involved in furthering the inam-
matory and remodelling eects observed in asthma. 43
T Cells
Na ve T lymphocytes can dierentiate into either eector or regulatory T
cells depending on the surrounding cytokine milieux. 44 Eector T cells induce
clearance of pathogens, and can be further subdivided into Th1, Th2 or Th17
cells, each producing their own subset of cytokines, referred to as Th1, Th2
and Th17 cytokines. 16,44{46 The actions of these eector cells are controlled
by regulatory T cells (Tregs), which prevent excessive clearance of commensal
organisms and auto-immunity. 44
The Th1 phenotype (driven by the presence of IL-12) is associated with an
innate immune response to bacteria and viruses. 16 The Th2 humoral-immune
phenotype (driven by IL-4), on the other hand, is generally associated
with parasite clearance. 47{49 In many cases of asthma and allergy, this Th2
response appears to have been misdirected towards innocuous antigens. 16,46
Dierentiation of these eector T cells is not terminal and can be antag-
onised by the other Th phenotypes. For instance when low concentrations of
IL-4 are present Th2 cells trans-dierentiate into Th1, and the reverse occurs
in low concentrations of Interferon-, thus enabling self-regulation of each of
these phenotypes. 45,46
Antigen presentation can also aect the dierentiation pattern of na ve
T cells. 45,46 Allergens presented by dendritic cells result in decreased levels
of IL-12, leading to dierentiation to Th2. These cells subsequently release
IL-4, which has a positive feedback eect on the Th2 phenotype. These
Th2 cells release a variety of mediators, which act on B cells, eosinophils
and mast cells, triggering the release of further inammatory cytokines and
chemokines. 45
In particular, the Th2 lymphocytes produce an array of cytokines in-
cluding IL-3, IL-4, IL-5, IL-9, IL-13 and GM-CSF (granulocyte-macrophage
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colony-stimulating factor), which are important in the aetiology of the
asthma phenotype. 50{56
Fibroblasts
Fibroblasts are structural cells, which are important in airway remodelling,
however they also play a role in the inammation aspects of the disease,
due to their ability to produce a wide range of inammatory mediators.
These include eotaxin, a chemoattractant for eosinophils, thymic stromal
lymphopoietin (TSLP), which triggers dendritic cell-mediated Th2 inam-
mation and IL-6, which is a pro-inammatory cytokine with broad ranging
eects. 57{59 The production of these mediators occurs in response to the Th2
cytokines and aects a range of cell types, including eosinophils, T cells and
mast cells, propagating the eects of the inammation. 57,59
Early & Late Phase Response
In asthma this inammatory response can be separated into an early and a
late phase (Figure 1.2). 16
The early phase (Figure 1.2), occurs within 30 minutes and resolves within
2 hours of exposure to an allergen or other trivial stimuli. 16,22 This results
in a rapid decrease in the FEV1 due to smooth muscle contraction caused
by IgE-dependent degranulation of mast cells, 60,61 leading to the release
of many inammatory mediators, including leukotrienes, which are particu-
larly problematic in asthma. 62,63 These lipids, also produced by leukocytes,
eosinophils, monocytes and macrophages, promote localised inammation
at the site of tissue injury and cause bronchial smooth muscle contraction,
eosinophil chemotaxis and oedema by opening up tight junctions between
the cells. 63,64
The late phase response occurs several hours after exposure to the allergen
or trivial stimulus and generally resolves by 24 hours. 16,22 During this period
the initial stimuli is no longer present, instead the response is caused by
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the mediators released by the mast cells in the early phase (Figure 1.2).
These mediators cause a sustained decrease in FEV1 and an inltration of the
airways with inammatory cells. These cells include eosinophils, Th2 cells,
neutrophils and monocytes, all of which release Th2-type cytokines. 65{69
These Th2 cytokines are pro-inammatory, which cause further smooth mus-
cle contraction, 70 epithelial damage, 71 increased mucus production 72 and an
increase in adhesion molecules on the endothelium resulting in recruitment
of leukocytes. 25,26
Whilst these inammatory mechanisms are essential for wound repair,
in asthma this process appears to be misdirected. When inammation
becomes unregulated it can lead to long term airway damage in the form
of remodelling. 1
1.4.2 Airway Remodelling
Many cell types are dysregulated in the asthmatic lung, which leads to
airway remodelling, resulting in loss of lung function (Figure 1.3). The
alterations in the airway structure observed in asthma include disruption of
the airway epithelium due to epithelial shedding and goblet cell hyperplasia,
subepithelial brosis, in particular with thickening of the submucosa due to
increased deposition of extracellular matrix proteins, as well as increased
numbers of myobroblasts and enhanced vascularisation.
Epithelial Barrier
Loss of barrier function caused by bronchial epithelial shedding and disrup-
tion of tight junction proteins is commonly observed in asthma, resulting in
increased permeability, aecting the integrity of the underlying tissue. 73,74
Under normal conditions, the tight junction proteins, such as occludin,
zonula occludens 1{3, claudins, and junctional adhesion molecules, maintain
the structural integrity and apical{basal polarity of the epithelial cell barrier.
However, in asthma the tight junction is disrupted, 74 resulting in epithelial
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Reduced barrier function,
increased epithelial shedding,
goblet cell hyperplasia
Airway remodelling
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deposition
Smooth muscle hyperplasia
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Figure 1.3: Airway remodelling in asthma. Signicant changes to the airway
architecture are observed in asthmatics, including epithelial shedding, goblet
cell hyperplasia and increase production of mucus. Due to this damage there
is an increase in the number of myobroblasts present, resulting in increased
extracellular matrix deposition leading to subepithelial brosis. These cells also
produce Th2 cytokines resulting in a perpetuation of the inammatory immune
response at allergens, pollutants and other innocuous stimuli. Adapted from 16
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desquamation and reducing the eectiveness of this layer as a physical,
chemical and immunological barrier. 20 This loss of the epithelial barrier
increases susceptibility to viral and bacterial infections and allows inltration
of leukocytes, which combined with excessive production of inammatory
mediators causes damage resulting in airway remodelling. 71,75
In asthma, these epithelial cells demonstrate increased expression of
growth factor receptors, such as broblast growth factor, keratinocyte growth
factor, and epidermal growth factor receptor, and their ligands. 20,73,76 These
growth factors play a role in wound repair, but this process may be dysreg-
ulated in asthma resulting in aberrant airway remodelling. 77 In addition, in
response to this damage the epithelium becomes stressed, leading to increased
activation of NF-B and thus the increased production of a range of inam-
matory mediators, such as IL-6, IL-8 and TSLP, a known chemoattractant
for, and activator of, dendritic cells. 77,78
Within the epithelial layer, goblet cell hyperplasia has been attributed to
the predominance of Th2 cytokines, in the asthmatic lung. 79{83 The increased
number of goblet cells and their hypersecretion of mucus, 31 reduces airow
and results in luminal occlusion, which combined with airway oedema and
bronchoconstriction results in chest tightness and breathlessness. 82
Angiogenesis
Increased vasculature within the asthmatic airway is thought to be an
important aspect of asthma disease pathogenesis, with increased expression
of angiogenic mediators and receptors correlating to disease severity and
acceleration of lung function decline. 84{86
For instance, vascular endothelial growth factor (VEGF), angiogenin and
angiopoietin-1 are potent proangiogenic factors, which promote proliferation
and migration of endothelial cells as well as tubule formation, and are
elevated in asthmatic subjects. 87 Also, the eosinophil-derived MBP, which
causes generalised tissue damage, has recently been found to induce angio-
genesis in vitro. 88
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Fibroblasts & Myobroblasts
Fibroblasts are important structural cells in the airways, however in asthma
they are the cause of many of the aspects of remodelling, due to their
production and deposition of collagen and proteoglycans and their ability
to dierentiate into myobroblasts.
Myobroblasts are highly contractile cells which secrete larger quantities
of extracellular matrix proteins than their broblast counterparts. These cells
play an important role in tissue repair, with their contractile nature aiding
wound closure. However, whilst these cells are vital for wound repair, they
have negative eects in the asthmatic lung, resulting in secretion of collagens,
pro-inammatory cytokines and increased contractility, which perpetuates
the inammation and constriction observed in asthma. 23,30,89,90
Myobroblasts are found in greater number in the asthmatic airway, 89,91
where the enhanced levels of TGF present results in the increased dieren-
tiation of broblasts to myobroblasts. 29,92,93 Several other sources have also
been proposed for the increased numbers of myobroblasts in the asthmatic
lung. These include dedierentiation of smooth muscle cells and a migration
out of the muscle bundles, an inux of brocytes from the circulation or
epithelial to mesenchymal transition. The latter is known to occur during
development as well as in cancer and has been hypothesised in the asthmatic
airway, however in asthma the basement membrane is normal and there is
no evidence of invasion of epithelial cells into the subepithelial layer. 30,94{96
The increase in the number of broblasts and myobroblasts results in
thickening of the airways walls in asthma, with enhanced deposition of many
extracellular matrix proteins such as collagens I, III and IV and proteoglycans
within the lamina reticularis. 91 Previous studies have reported an inverse
relationship between both the airway wall thickness with FEV1 and the level
of extracellular matrix protein present. 97 This increase in extracellular matrix
is also associated with increased subepithelial brosis.
Airway remodelling in the form of smooth muscle hyperplasia and hyper-
trophy leads to AHR in response to innocuous stimuli causing diculty in
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breathing. 14 This increased airway wall thickening leads to further airow
obstruction, which limits lung function.
Epithelial-Mesenchymal Trophic Unit (EMTU)
With the epithelium and underlying mesenchymal layer both undergoing sub-
stantial changes due to the inammation and remodelling aspects of asthma,
this results in the production of a large number of autocrine and paracrine
mediators which perpetuate these eects. The involvement of both epithelial
and mesenchymal cells in the regulation of the airway microenvironment,
normally observed during lung development and wound repair, is described
as the EMTU and this appears to be reactivated in asthma. 98,99 In this
hypothesis, broblasts, especially those in close proximity to the epithelium,
are proposed as the main regulator of localised inammation by acting as
sentinel cells (Figure 1.4). 98
It is thought that continued activation of this EMTU occurs in response
to damage to the airway, with epithelial cells producing TGF, which
induces a phenotypic change of broblasts to myobroblasts, which in turn
produce a wide range of inammatory and brotic mediators. Therefore, this
continuous wound healing scenario is thought to perpetuate remodelling and
in some patients lead to xed airow obstruction. 1,98{101
Aetiology of Airway Remodelling
The aetiology of the airway remodelling observed in asthma is unclear. It
is unknown whether this is caused by the persistent inammation seen in
the asthmatic airways resulting in continuous cycles of damage and repair or
whether this actually occurs prior to any asthmatic symptoms. There have
been recent paediatric studies in children as young as 3 where signicant
airway remodelling, such as broblast proliferation and increased collagen
deposition leading to thickening of the laminar reticularis, is observed before
the development of asthma symptoms. 102,103 Studies investigating the air-
ways of children with moderate 102 and severe 104 asthma indicate thickened
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Figure 1.4: The role of the Epithelial-Mesenchymal Trophic Unit (EMTU) in
asthma. In response to epithelial damage, the EMTU appears to be reactivated
in asthma, resulting in increased communication between the epithelium and
mesenchymal cells. The enhanced production of Th2 cytokines and growth factors
such as transforming growth factor  (TGF) and epidermal growth factor (EGF)
induces broblast proliferation and activation of myobroblasts. In turn, these
broblasts induce further inammation and remodelling eects, which are key in
the pathogenesis of asthma. 1,100,101
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basement membranes present in these children is comparable to that in adult
asthma, which again is indicative of a rapid early remodelling response. 102,104
Recent investigations in mild asthmatics have also highlighted that
bronchoconstriction in the absence of eosinophilic inammation induces air-
way remodelling. Here patients challenged with methacholine demonstrated
similar increases in both epithelial TGF and goblet cell staining as well as
increased collagen band thickness to those patients challenged with allergen,
where eosinophil recruitment was also observed. 105
1.5 Classication of Asthma
As the severity of symptoms and the frequency of asthma exacerbations
can vary dramatically between patients, organisations such as the Global
Initiative for Asthma (GINA), the British Thoracic Society (BTS) and the
American Thoracic Society (ATS) have each produced guidelines which can
be used by physicians when treating asthmatic patients. Whilst there
are some dierences between the classications, these generally result in
patients grouped into 4 or 5 steps, each with diering levels of treatment.
The treatment protocols described by these organisations require constant
monitoring of patients in order to maintain control of the asthma symptoms,
whilst taking the least medication possible. 14,15
The GINA guidelines describe four levels of asthma, as determined by
the frequency of exacerbations and the symptom severity. The drugs used to
manage asthma vary depending on whether the disease is mild intermittent,
mild persistent, moderate persistent or severe. 14
In recent years because of the heterogeneity of symptoms observed be-
tween asthma patients, there has been a signicant interest in development
of a non-biased method of categorising patients using cluster analysis. These
clusters have been established in populations in Europe via U-BIOPRED
(Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) and
the USA via the Severe Asthma Research Program (SARP). 106,107 These
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studies have looked at a large number of healthy and asthmatic subjects
(>1500 in SARP alone) to try to distinguish dierences between the groups,
with the aim of better identifying treatments based on these clusters. 106
1.6 Treatments for Asthma
Current asthma therapies (Table 1.1) reduce the symptoms associated with
the disease but are unable to provide an absolute cure. With the correct use
of these medications many patients will only suer from occasional symptoms
and fewer exacerbations, 108 however this is not the case for all patients and
many asthmatics are not adequately treated with conventional therapies.
Treatments
Mild
Intermittent
Mild
Persistent
Moderate
Persistent
Severe
Persistent
Short Acting 2 Agonist as required
ICS Dose Low Med/High High
LABA     + +
OCS     Consider
short-course
+
LT Modier   +=  +=  += 
Other       Anti-IgE etc.
Table 1.1: Standard asthma therapy based on disease severity. ICS = Inhaled
Corticosteroids, LABA = Long Acting 2 Agonist, LT = Leukotriene, OCS =
Oral Corticosteroids. Adapted from 14
Patients with asthma require \reliever" medication for rapid symptomatic
relief in the event of an exacerbation. Short acting 2 adrenergic agonists
(SABA), such as salbutamol, act as smooth muscle relaxants to reverse the
contraction observed during asthma attacks. 109
As well as \reliever" medication, \controller" therapies are also required
by patients with more persistent asthma, which are designed to reduce
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symptoms and exacerbations. These include long acting forms of 2 agonists
(LABA), such as salmeterol, 110 as well as inhaled and oral corticosteroids. 14
Beclomethasone, an inhaled glucocorticosteroid (ICS) is prescribed in
more persistent asthma to suppress airway inammation and reduce AHR,
thus improving lung function. 14 Steroids suppress acute and chronic inam-
mation by targeting cytokine protein synthesis. In severe asthma cases when
inhaled steroids are not sucient, oral corticosteroids, such as prednisolone,
are also used. 14 These drugs only help in some cases of asthma, with many
severe asthmatics described as \steroid refractory" as these provide little
relief from their symptoms. 111 Both inhaled and oral corticosteroids have
many negative side eects including oral candidiasis and adrenal suppres-
sion. 70,112 Therefore, the minimum possible dose possible of these drugs is
given, and this is generally as a combination therapy with LABA to provide
better symptomatic relief. 14
As many severe asthmatics are not adequately treated by 2-agonists
or steroids, other drugs such as leukotriene modiers (such as Montelukast
or Zarleukast) or anti-IgE therapy (Omalizumab) are often used as an
adjuvant. These, again, aim to reduce the inammation aspects of the disease
by blocking some of the key inammatory mediators. 14,15
1.7 Aetiology of Asthma
Whilst the aetiology of asthma has been linked to childhood atopy in many
patients, this is not the case for all asthmatics. Evidence suggests that
asthma originates early in life and that the structural and molecular changes
that occur at this time lead to the characteristic symptoms of asthma.
Whilst airway remodelling has been characterised in young children who
later develop asthma, 103,113 it is unclear if these changes occur during in
utero development, or after birth.
Respiratory viruses have also been implicated in the aetiology of asthma,
however there is conicting data at present, with some reports suggesting that
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children who have documented respiratory syncytial virus (RSV) are more
prone to asthma. 114 However there have also been studies showing protection
from asthma from RSV infection. 115 More recently, rhinovirus (RV) infection
has been identied as an important early risk factor for asthma. 116 One
key study investigating the role of both RSV and RV in the aetiology of
asthma found that around 90% of children aged 3 who had experienced
wheezing with RV developed asthma by the age of 6. Whilst RSV-related
wheeze was also observed to increase this risk (relative risk of 2.6), it was
the RV-induced wheezing illness which had the greatest eect (relative risk
of 9.8). 117 Respiratory viruses have also been associated with a worsening
of asthma symptoms, as these viruses appear to target the lower airways of
asthmatics, compared with the higher airways in healthy individuals. It has
been estimated that approximately 50-75% of all asthma exacerbations are
due to RV infections. 118
As well as environmental risks such as viruses, there is also a strong
trend of heritability which has been observed in twin studies. 119{121 It has
therefore been postulated that asthma is a multifactorial disorder involving
the interaction of both environmental and genetic factors. 122,123
1.8 Asthma Genetics
There has been a considerable amount of work in recent years attempting
to determine which genes may be responsible for the symptoms of asthma.
However, asthma is a complex and heterogeneous disease, which cannot
be easily dened and attributed to a single gene. Instead it is likely that
combined polymorphisms in a variety of genes lead to a predisposition
towards asthma.
Through the use of candidate gene analysis positional cloning and genome
wide association studies, many genes have been linked to asthma susceptibil-
ity, including ADAM33, TNF, TGFB1, IL4R and IL13 124 but there has been
much debate over the identied genes and polymorphisms due to variations
in cohorts and environmental factors.
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1.8.1 ADAM33
An association between A Disintigrin And Metalloprotease (ADAM) 33 and
both asthma and AHR was rst established in 2002 via linkage analysis. 123
This has since been conrmed in several other populations, 125 however the
exact role of ADAM33 has yet to be determined.
A knockout mouse for ADAM33 was developed in an attempt to elucidate
the function and role in asthma, although no abnormalities were observed
and no dierences were found between wildtype and ADAM33  =  mice when
studying the ovalbumin model of allergic asthma. 126
In humans, on the other hand, ADAM33 polymorphisms have been found
to correlate with reduced lung function. 127,128 This has also been observed
in children at age 3 and 5, highlighting that dierences in the lungs of
asthmatic patients may happen before the cycles of persistent inammation
and remodelling occur. 129
ADAM33 is mainly mesenchymally located 130 but no dierences have
been observed in the pattern or level of expression between healthy and asth-
matic individuals. 131,132 However, a soluble form of ADAM33 (sADAM33)
has been detected in the bronchioalveolar lavage (BAL) uid of asthmatic
but not healthy individuals, and the levels correlated with both the severity
of asthma and decreased lung function, measured as % predicted FEV1. 133
Recently ADAM33 has been linked to remodelling and angiogenesis, and
production of sADAM33 was enhanced by TGF2, the expression of which
is also augmented in the asthmatic lung. 134{136
1.8.2 IL4 & IL13 Gene Cluster
Another key area of interest has been the IL-4 gene cluster. Located on
chromosome 5, the IL-4 gene cluster encodes the 2-adrenergic receptor
(ADRB2). 50{52 as well as the Th2 cytokines IL-3 (IL3), IL-4 (IL4), IL-5
(IL5), IL-9 (IL9), IL-13 (IL13), and GM-CSF (CSF2), 55,56 which are key
in the pathogenesis of asthma and allergic inammation.
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IL4 and IL13 are two of the most studied candidate genes for both allergic
inammation and asthma, with multiple single-nucleotide polymorphisms
(SNPs) detected in each.
IL13
SNPs have been found in clusters at both the 50 and 30 ends of the IL13
gene. In particular, two polymorphisms have been identied in the 50
promotor region. One such mutation, IL13-1512AC, which is also referred
to by the RefSNP accession ID (rs number) rs1881457, has been linked with
higher levels of IgE in skin prick test positive children. 137 IL13-1112CT
(rs1800925), on the other hand, has been associated with an increased risk
of allergic sensitisation, asthma, airway hyperresponsiveness, high levels of
IgE and atopic dermatitis, 137{141 although this has not been replicated in all
studies. 142,143 The presence of this mutation in the promotor region results
in increased transcription of the IL13 gene 144 leading to increased IL-13
secretion by Th2 polarised T cells. 145
IL13+2044GA (rs20541) is a non-conservative point mutation in exon 4 of
the gene, which results in the exchange of an arginine residue for glutamine
at position 130 (R130Q), resulting in an overactive IL-13 variant. 146 This
R130Q form of IL-13 is found in 20% of Caucasians and is more promi-
nent in asthmatics than healthy controls. 142,147 Associations have also been
observed with atopy, 142 total serum IgE levels 137,139,143,148,149 and atopic
dermatitis. 139,142,150,151 This gain of function mutation is also often found
to be co-expressed with the promotor polymorphism IL13-1112 resulting in
increased expression of an overactive IL13 variant. 152,153
Several polymorphisms have also been identied within the 30 untrans-
lated region (UTR) of the gene. Of particular interest is IL13+2525GA
(rs1295685), which has been associated with raised cord serum IgE levels, 154
which in turn is related to a higher risk of developing atopy or asthma by
age 4. 155,156
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IL4
SNPs within the IL4 gene have also been studied in detail. One such
polymorphism, IL4-589CT (rs2243250) located in the promoter region of
the gene and found in approximately 27% of Caucasians, 157 has been shown
as a risk factor for atopy, allergic rhinitis, and wheeze. 158,159 Whilst some
studies have found links between this polymorphism and both total IgE 157
and specic IgE for housedust mites, 158 this has not been replicated in all
studies. 160
This mutation is however, generally considered to be associated with
asthma. 157,159{162 In particular Sandford, Chagani et al. determined this as a
risk factor for severe near-fatal or fatal asthma 163 whilst Burchard, Silverman
et al. found associations to reduced FEV1 in asthmatic subjects. 164
When studying the eect of this polymorphism in vitro, Rosenwasser,
Klem et al. also found the presence of the T allele resulted in increased IL4
gene expression. 157
Related Genes
Polymorphisms identied in other genes associated with Th2 inammation
have also been linked to asthma and atopy.
One such gene is IL4RA, which is located on chromosome 16. The
IL4RA gene encodes IL-4R which is part of the IL-4 and IL-13 receptor
system. 53{56,165 SNPs identied in exon 12 of IL4RA include rs1805011,
rs1805015 and rs1801275, all of which result in mis-sense mutations within
the intracellular signalling portion of IL-4R, as well as rs1805010, which is
located extracellularly. 163,164,166{173
The mutation IL4RA+1902GA (rs1801275) is found in approximately
36% of Caucasians 166 and results in the the exchange of the polar, uncharged
amino acid glutamine at position 576 for positively charged arginine. This
SNP has been associated with atopy 166 and was reported to induce enhanced
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signal transduction through IL-4R, 166,174 although this could not be con-
rmed in other studies. 168,175 This polymorphism has also been associated
with hyper IgE syndrome, severe atopic asthma 166,169,173 and is considered
a risk factor for reduced lung function in asthmatics in some, but not all
populations. 163,173 Whilst some individual studies have reported no linkage
with atopic asthma in their cohorts, 170,176 meta-analysis of a number of
studies demonstrated a signicant association between the risk of asthma,
in particular atopic asthma and this polymorphism. 177
The IL4RA SNP rs1805010 located in exon 5 results in the exchange
of Ile for Val at position 50 in the extracellular portion of the receptor.
This mutation has been associated with atopic asthma as well as increased
responsiveness of IL-4R to IL-4 leading to increased STAT6 phospho-
rylation, resulting in enhanced cell proliferation and upregulation of IgE
synthesis. 167,175 This polymorphism was also found to associate with more
severe asthma. 178 However meta-analysis of nine individual studies found no
overall association with asthma. 177 This may be due to dierences between
cohorts, 173 or could be more strongly associated in certain populations. It
may be that the strong linkage disequilibrium observed between this and
other polymorphisms associated with asthma, such as IL4RA-Q551R, have
led to misleading results. 162,173
Gene-gene interactions between polymorphisms in IL4RA and IL13 have
also been observed in asthma. 171 One particular pair of SNPs includes
rs1805015, which results in exchange of polar uncharged serine for non-polar
hydrophobic proline at position 478 of IL4RA and rs1800925 in IL13, was
found to increase the risk of developing asthma ve-fold. 171
1.9 IL-4 & IL-13
Consistent with their genetic association with atopy and asthma, IL-4 and
IL-13 appear play a critical role in the pathogenesis of asthma and allergic
inammation. 53,54,165
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The Th2 humoral-immune phenotype, which is driven by IL-4, is gen-
erally associated with the clearance of parasitic worms. 179 Production of
IL-4 and IL-13 in response to helminth infections, such as Heligmosomoides
polygyrus or Schistosoma mansoni results in increased gut contractility and
mucus production, allowing rapid clearance of the infection, as well as the
production of a protective Th2 inammatory response, which downregulates
the otherwise pathological Th1 response. 179 Whilst the eects of IL-4 and
IL-13 are benecial in response to helminth infection, similar responses are
observed in the asthmatic lung, where these cytokines appear to have been
misdirected towards innocuous antigens, and are subsequently the driving
force of many of the symptoms observed.
Despite only sharing around 25% homology, consisting of a conserved
core of 25 amino acids, 53 IL-4 and IL-13 have similar but non-redundant roles
(Figure 1.5). These shared roles arise from the use of a common receptor,
IL-4R:IL-13R1. 180{182
IL-4 and IL-13 both cause eosinophilia (by inhibiting apoptosis and
increasing growth), eosinophil chemotaxis and eosinophilic inammation
through the production of eotaxin (also known as Chemokine (C-C motif)
ligand (CCL) 11) by broblasts. 161,184{186 IL-4 and IL-13 also contribute to
airway remodelling, a hallmark of asthma, by inducing goblet cell hyperplasia
and increasing mucin gene expression, resulting in the hypersecretion of
mucus. 80,161,187 Both cytokines have been shown to increase IgE levels by
acting on B lymphocytes, promoting class switch of immunoglobulins to
IgE and increasing expression, 188{190 as well as decreasing transcription of
Interferon-, 45 thereby encouraging a switch to the Th2, whilst also sup-
pressing the Th1 phenotype. 45,191
IL-4 and IL-13 also exhibit some distinct roles, for instance IL-4 promotes
dierentiation towards the Th2 phenotype, 192 therefore increasing the num-
ber of Th2 cells, whilst inhibiting dierentiation to Th1 cells, 16 which IL-13
is unable to do. IL-4 plays an important role in B cell activation by increasing
expression of Class II Major histocompatibility complex (MHC) molecules,
as well as promoting immunoglobulin (Ig) synthesis and class switch to IgG4
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Figure 1.5: The eects of IL-4 and IL-13 on the airway. IL-4 and IL-13 exert a
wide range of eects on the airway, both directly, and through the aid of other
mediators. Their shared functions are brought about by the fact that both IL-4
and IL-13 share a receptor IL-4R:IL-13R1. Adapted from 183
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and IgE. 188,189 IL-4 exerts its eects on monocytes and macrophages, and
promotes growth of mast cells, basophils and eosinophils. 193 IL-4 is also
involved in eosinophil recruitment, with the aid of Vascular Cell Adhesion
Molecule-1 (VCAM-1), 25 and induces broblast chemotaxis and activation. 55
IL-4 is derived from T lymphocytes, eosinophils and cells of basophil and
mast cell lineage. 55
IL-13, on the other hand, is synthesised by CD4+ and CD8+ T cells,
and unlike IL-4, IL-13 does not activate T cells and is unable to pro-
mote dierentiation to the Th2 phenotype. 55 IL-13 directs T lymphocytes,
monocytes, basophils and eosinophils to sites of inammation, resulting in
airow obstruction. 183 IL-13 also elicits eects on monocytes, resulting in
morphological changes and upregulation of both the low anity receptor for
IgE (FC"RII) and MHC II antigens. 194 IL-13 increases goblet cell density and
instigates goblet cell metaplasia, 195,196 and also induces VCAM-1, 25 thus
working synergistically with IL-4. IL-13 has also been shown to promote
brosis, by way of increased collagen deposition, resulting in airway remod-
elling in asthma. 161,197 In mice, overexpression of IL-13 specically induces
airway brosis and many of the inammatory features of asthma. 161
Various studies have found that asthma exacerbations, caused by allergen
challenge, result in an increase in both the number of cells expressing IL-4
and IL-13 mRNA within the BAL uid, 198,199 as well as an increase in levels
of these cytokines. 184,199
More recently there have been several studies investigating the levels
of both IL-4 and IL-13 present in the airways of healthy and asthmatic
volunteers. Brightling, Symon et al. found that both IL-4 and IL-13 were
present within the smooth muscle to a much greater extent in asthmatic sub-
jects than healthy controls. 200 In this group of asthmatic patients however,
approximately 20% did not show any measurable staining. 200 Berry, Parker
et al. found similar results within the submucosa when looking for IL-13
positive cells. 201 This investigation also measured sputum concentrations
of IL-13 and found higher concentrations in the sputum of mild asthmatic
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patients, although, as before, this seemed to only occur within a subset of
patients. 201
Saha, Berry et al. studied the levels of IL-13 in bronchial biopsies and
sputum from asthmatics with varying degrees of disease severity. 202 Here the
authors reported much greater staining of IL-13 in sputum obtained from
mild and severe asthmatics compared with healthy controls. Interestingly
though, there appeared to be less IL-13 present in sputum obtained from
moderate asthmatics and although this group was slightly smaller than the
others there was a signicant dierence between the mild and the moderate
asthmatic groups. When investigating the levels of IL-13 in the submucosa
and airway smooth muscle they again found increased IL-13 present in mainly
the mild and severe asthmatics. The authors also noted a correlation between
the subjects who demonstrated sputum eosinophilia and those who expressed
IL-13 positive cells. 202 In particular, these studies highlight some of the
variation observed between asthma phenotypes, suggesting that IL-13 may
be of particular importance in a subset of asthmatic subjects.
Recently Woodru, Modrek et al. have proposed Th2-driven inamma-
tion to be one of the dening phenotypes of one subgroup of asthmatics. 203
In this study the \Th2 high" group were found to express higher levels of
the Th2 cytokines IL-5 and IL-13, as well as MUC2 and MUC5AC than
the \Th2 low group". This \Th2 high" subset also exhibited greater airway
hyperresponsiveness, eosinophilia, subepithelial brosis and increased serum
IgE levels. In many of these cases the \Th2 low" group were indistinguishable
from the healthy control subjects. 203
Another interesting dierence between the two groups was the response
to steroids, as it was only in the \Th2 high" group that these were able to
improve lung function. 203 Whilst it is unclear what proportion of asthmatics
would fall into these two categories, and what the driving force behind the
\Th2 low" groups' symptoms may be, the Th2 phenotype driven by both
IL-4 and IL-13 is clearly important in the pathogenesis of asthma.
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1.9.1 Novel Asthma Therapeutic Approaches Target-
ing IL-4, IL-13 & Their Receptors
In recent years there has been extensive work investigating potential therapies
for asthma based on IL-4 and IL-13. These include monoclonal antibodies
(mAb) against either cytokine or one of their receptor subunits, a double
mutein form of IL-4, and both antisense oligonucleotides and small interfering
RNAs (siRNA) against IL-4R.
The initial results from the preclinical stages of these trials seemed
hopeful, however the results obtained during the clinical trials have been
broadly disappointing. More recent data has suggested that this is, at least
partially, due to the broad recruitment of patients and it is now thought
that a more stratied approach to asthma therapies may be more benecial
due to the heterogeneity of the disease phenotypes. As there is a subset
of asthmatics who appear to be driven by a Th2 phenotype, with IL-13 in
particular playing a key role in their asthma symptoms, 203,204 recent trials
have focussed on this specic group of patients and have been more successful.
The current status of these clinical trials is reviewed below. Where
available clinicaltrials.gov references are provided in brackets, last accessed
in October 2011.
Anti-IL-4R Monoclonal Antibodies
AMG-317 is a human MAb which binds to IL-4R preventing both IL-4 and
IL-13 signalling. In a recent phase 2 trial (NCT00436670), AMG-317 was
found to decrease levels of circulating IgE and reduce eosinophilia, however
this drug did not demonstrate clinical ecacy for reducing asthma symptoms
of the patient group studied. Although neither the primary or secondary
endpoints of this study were matched, some patients, particularly the most
severe asthmatics of the cohort, did appear to benet from this drug, with a
trend towards a decrease in asthma exacerbations. 205,206
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IL-4R Double Mutein
An IL-4 receptor  (IL-4R) antagonist, in the form of an IL-4 double mutein,
attenuates both IL-4 and IL-13 in vitro and is currently undergoing clinical
trials. 207 This drug has the benet of suppressing two key Th2 cytokines,
which is important due to redundancy of their actions.
This IL-4R antagonist, also known as Pitrakinra, consists of an IL-4
mutant (R121D/Y124D) which selectively binds the IL-4R subunit and
prevents both binding of the wildtype forms of IL-4 and IL-13, as well as
subsequent dimerisation with either c or IL-13R1, rending this receptor
incapable of signalling. 207,208
Initial randomised control trials (NCT00535028 and NCT00535031)
demonstrated a trend towards a decrease in asthma related adverse events, as
well as a signicant decrease in the number of exacerbations which required 2
agonist relief. The severity of the late asthmatic response was also decreased
with treatment, where a smaller reduction in FEV1 was observed in response
to allergen challenge in those who were given the drug compared with a
placebo. 207
Ecacy of this drug was observed against the allergen-provoked early-
and late-phase responses, but not against the acquired increase in bronchial
hyperresponsiveness, after both subcutaneous and inhaled administration,
although the latter appears to be the preferred method due to direct targeting
of the relevant tissues. 207,209
In a phase IIb trial, which nished in mid-2010, where pitrakinra was
given to more than 500 uncontrolled asthmatics, clinical ecacy was only
found in a subgroup of the population studied, which consisted of 125 patients
with eosinophilic asthma (NCT00801853). 210
Recently pharmacogenetic analysis has identied that IL-4R mutations
(including rs1801275 and rs1805011) may prevent the actions of pitrakinra
in certain patients (NCT00535431). As novel asthma therapies tend to
have greater cost implications than standard therapies this may need to be
considered before administration. 211
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Soluble Human IL-4R
Altrakincept, a soluble recombinant human form of IL-4R (sIL-4R) has
been tested for its ability to block the interaction between IL-4 and its
receptor by sequestration.
In an initial phase I study, patients with moderate asthma were with-
drawn from ICS therapy and treated with nebulized sIL-4R. Whilst the pa-
tients given the placebo experienced a reduction in lung function after steroid
withdrawal, this was not the case with the treatment group. 212 A subsequent
larger, 12 week phase II study in subjects with moderate and persistent
asthma who were withdrawn from steroids for the study (NCT00017693),
again demonstrated ecacy in preventing asthma symptoms and reduced
lung function associated with steroid withdrawal. One of the issues of this
study was patient retention, as between 47% and 69% of patients had to
withdraw from the study by day 84 (withdrawal was mandated after an
asthma exacerbation). 213
However, when this drug was taken to phase III trial it was not found to
provide clinical ecacy for the treatment of asthma, which may have been
due to the limited bioavailability or degradation in the airways. 214
IL-4R Antisense Oligonucleotides
A second-generation antisense oligonucleotide of IL-4R (AIR-645 and ISIS-
369645), which targets IL4RA mRNA, has been tested for its ability to act as
a dual inhibitor of IL-4 and IL-13. In mouse models this was found to reduce
not only IL-4R expression, but also both airway inammation and hyper-
responsiveness. In 2009 reports published from initial studies (NCT00658749
and NCT00941577) with this 20-O-methoxyethyl oligonucleotide found that
the drug was well tolerated, however as yet results have not been published
regarding the clinical ecacy of this drug in asthma. 215
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Anti-IL-4 Monoclonal Antibodies
Initial data from trials in non-human primates found that a humanized anti-
IL-4 mAb, pascolizumab, demonstrated clinical potential for the treatment of
asthma. 216 However, subsequent clinical trials in patients with symptomatic
corticosteroid-naive asthma (NCT00024544) failed to provide any clinical
benet.
Anti-IL-13 Monoclonal Antibodies
Anrukinzumab, also known as IMA-638, is a humanised monoclonal antibody
against IL-13. 217 In non-human primate studies, treatment with IMA-638
was found to reduce both the number of inammatory cells and the levels of
inammatory mediators within BAL after exposure to Ascaris suum, which
induces acute airway inammation. 218 However, when this antibody was
tested in a double-blind randomised, placebo-controlled trial of mild atopic
asthmatics, although a signicant attenuation in the early and late phase
asthmatic response was observed after 14 days, this was small and overall lit-
tle clinical benet of treatment was found, with no eect on allergen-induced
AHR or sputum eosinophil counts. This trial was run concomitantly with
one studying IMA-026, which also acts as an IL-13 mAb, but unlike IMA-
638 there was no benet even at 14 days. 219 This work was extended with
a larger, phase II study in patients with persistent asthma (NCT00425061)
monitoring changes in peak expiratory ow rate over 16 weeks, and again
this drug did not demonstrate clinical ecacy and is therefore not being
developed further. 214 Instead IMA-638 is currently being investigated as a
therapy for ulcerative colitis (NCT01284062).
Another IL-13 MAb, QAX576, is currently being evaluated in a phase II
randomised, double-blind trial as \add-on" intravenous therapy for persistant
asthmatics whose symptoms are not controlled by ICS and LABA. This study
is in the process of recruiting patients, and initial data is expected at the end
of 2011 (NCT01130064).
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CAT-354 (Tralokinumab), a humanized antiIL-13 mAb 220 has also under-
gone phase II trials for the treatment of moderate-to-severe asthma. Final
data collection for the rst phase II trial in asthma occurred in August 2010,
although no data has been published as of October 2011 (NCT00873860). A
larger 52 week, phase IIb, double-blind study to evaluate the ecacy of this
drug in severe uncontrolled asthma is due to start in 2011, with data due at
the beginning of 2014 (NCT01402986). This study aims to evaluate asthma
exacerbation rates as well as various measures of pulmonary function and
quality of life scores.
Recently lebrikizumab (MILR1444A), another monoclonal antibody
against IL-13, has also undergone clinical trials for asthma ranging from mild
to severe (NCT00781443, NCT00930163, NCT00971035 and NCT01423318).
The results from one of these studies (NCT00930163), where the cohort
consisted of severe, steroid refractory asthmatics, were published this year
and has been considered largely successful. 221
In this cohort total serum IgE and peripheral-blood eosinophil count
were used to distinguish asthmatics with predominantly Th2/IL-13 related
symptoms. Blood periostin levels were also used as a biomarker for this as it
is induced by IL-13. Here, patients with higher levels of periostin at baseline,
due to a predominance of IL-13-mediated inammation, responded better to
the drug than both the lower periostin and placebo groups. For example a
14% increase in the prebronchodilator FEV1 was observed after 12 weeks in
the high periostin group, compared with 5.1% in the low periostin and 4.3%
in the placebo groups.
The fact that better ecacy of this drug was found to be related to the
baseline periostin levels of the patients, where many other similar therapies
have failed, demonstrates that a stratied approach to therapy by directly-
targeting the patients with more Th2-mediated inammation may provide
greater benet.
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1.10 IL-4 & IL-13 Receptors
It has been suggested that the relatively low success rate of novel therapies
based on IL-4/IL-13 is due to their shared receptor complex. IL-4 and IL-13
receptors are present on many human airway cells and addition of either IL-4
or IL-13 leads to initiation of a phosphorylation cascade resulting in STAT6
activation. 27,183
IL-4 can signal through the type I receptor by binding to Interleukin-4
receptor  (IL-4R) and c, a chain that is common among several cytokine
receptors (Figure 1.6). 222,223 The type II receptor (IL-13R1:IL-4R) enables
IL-13 signalling and acts as an alternate receptor for IL-4 (Figure 1.6). 180,223
IL-13 binds to IL-13R1 and this complex recruits IL-4R for stabilisation
of the interaction. 224 IL-4, on the other hand, binds with high anity to the
IL-4R subunit and does not require the addition of either c or IL-13R1
to stabilise this interaction. 224,225 Addition of one of these two subunits to
the receptor complex is, however, required for signalling. 180,222 Interestingly,
IL-13 has a second receptor subunit, IL-13R2. This binds IL-13 with high
anity but is unable to activate the STAT6 pathway.
1.10.1 Intracellular Signalling
IL-4 and IL-13 signalling occurs through the Janus Kinase (JAK) Signal
Transducer and Activator of Transcription (STAT) pathway (Figure 1.6).
Upon ligand binding and receptor dimerisation the IL-4 and IL-13 receptors
autophosphorylate, enabling a subsequent signalling cascade. 226 JAK1 forms
a physical complex with the IL-4R subunit allowing signalling to occur. 227
JAK3, on the other hand, binds to the c chain, 228,229 whilst JAK2 and
Tyrosine kinase 2 (Tyk2) bind to the IL-13R1 chain. 230,231 In all of these
cases, the JAKs are activated by phosphorylation, which then leads to
phosphorylation of STAT6. 232,233 This activation is necessary for IL-4 and
IL-13 to mediate their eects by transcription of a plethora of inammatory
mediators and matrix proteins. 234
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As there are some known dierences between IL-4 and IL-13 responses
it has been postulated that these may be due to the ability of the type I
receptor, which can only bind IL-4, to induce a dierential signalling pathway.
Knockout studies have found several IL-4 mediated eects which are either
not STAT6 or only partially STAT6-dependent, such as antigen-induced
eosinophilia and VCAM-1 expression in mice. 235 More recently another study
in mice found antigen-induced expression of both STAT6-dependent and
-independent genes. 236 An alternative intracellular signalling pathway has
therefore been proposed, although this has been less thoroughly investigated
than the JAK/STAT system and remains relatively poorly understood.
This alternative pathway involves phosphorylation of one the homologous
insulin receptor substrate (IRS) proteins, IRS 1 or 2, which are able to bind
the IL-4R subunit. 237 This activation of IRS is thought to occur specically
due to IL-4 and not IL-13. 238 Experiments on cells containing the mutation
Y497F of IL-4R, which prevents phosphorylation of IRS 1, demonstrate
diminished ability to proliferate in response to IL-4. 239
The phosphorylation of IRS 1/2 is thought to activate the p85 sub-
unit of phosphoinositide 3-kinase (PI3K) leading to activation of the ser-
ine/threonine kinase Akt and potentially mitogen activated protein kinase
(MAPK) pathways. 239 The IRS activation of the PI3K pathway has been
linked to the proliferation of Th2 cells and induction of gene expression in
alternatively activated macrophages. 238 Blockade of the PI3K pathway in
haematopoetic cells has been shown to suppress IL-4-mediated protection
from apoptosis, although the mechanism for this remains unclear. 240 Much
of this research, however, has been performed in animal models or shown
by indirect mechanisms and the role of this pathway in primary human cells
remains unclear.
1.11 IL-13R2
As well as IL-4R/IL-13R1, IL-13 also binds to IL-13R2, originally
thought to be a \decoy receptor" (Figure 1.6). 241{243 IL-13R2 contains a
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short intracellular tail, is unable to initiate a signal through STAT6, 242,244
and its regulatory mechanism remains poorly understood.
IL-13 binding to IL-13R2 occurs very rapidly, with high anity and
does not dissociate easily. 243 This is commonly seen with negative regulators
supporting the idea of IL-13R2 being a \decoy receptor". A knockout mouse
for IL-13R2 has been shown to exhibit similar traits to mice overexpressing
IL-13, again substantiating the notion that IL-13R2 limits the eects of
IL-13 in vivo. 245,246 However, recently it has been shown that IL-13R2 also
acts as a negative regulator for IL-4 and was found to physically associate
with IL-4R (but not IL-4) in the presence of IL-4, attenuating the eects
of both IL-4 and IL-13 in an auto-regulatory manner, and therefore is not
solely acting as a \decoy". 165,224,247{250
1.11.1 Intracellular Pools of IL-13R2
Intracellular stores of IL-13R2 have been detected in epithelial cells, with
evidence that this receptor is mainly localised to the cytoplasm until Inter-
feron (IFN)  induces rapid mobilisation to the cell membrane. 251,252 As
IL-13R2 is able to modulate Th2 cytokine responses it has been postulated
that the presence of these pools enables rapid regulation of these cytokines,
which would not be possible if de novo synthesis was required. Previous
work has also demonstrated the upregulation of surface IL-13R2 by IL-13
pretreatment. 165,253 The fact that both IL-13 and IFN can upregulate
IL-13R2 supports the idea that IL-13R2 acts to negatively regulate the
Th2 response.
1.11.2 Soluble IL-13R2
In mice, soluble IL-13R2 (sIL-13R2) is released from the cell surface to
regulate the eects of IL-13. This is thought to be formed by alternative splic-
ing of the wild-type IL-13R2, 254,255 although enzyme (MMP8) and allergen
(house dust mite) dependent cleavage has also been observed. 256,257 This
form, however, has not been detected in either bronchoalveolar lavage uid
or serum from humans, 255,258 suggesting that Th2 cytokine regulation diers
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in mice and humans. sIL-13R2 does not contain the short intracellular tail
and whilst it can regulate IL-13, by sequestration, it is unable to bind IL-4
and the truncation of the tail prevents binding to IL-4R, 165,259 hindering
suppression of this cytokine. This especially highlights the importance of the
intracellular tail of IL-13R2 in the regulation of IL-4.
1.11.3 The Role of IL-13R2 in Other Diseases
IL-13R2 has been found to play an important role in various brotic
diseases, such as colitis, as well as cancers, including glioma. 249,260{266
Fibrosis
IL-4 and IL-13 are key cytokines in the immune response to helminth
infections. However in severe infections, such as schistosomiasis, where eggs
laid in the hepatic portal vein become trapped in the liver and intestine,
production of large quantities of these cytokines in an attempt to ght the
infection can lead to tissue destruction and brosis. 179 As both IL-4 and IL-
13 are important in the pathogenesis of schistosomiasis, much research has
been focussed on the role of IL-13R2, which is able to suppress the actions
of both of these cytokines. In mice treated with sIL-13R2 a signicant
reduction in tissue brosis and collagen deposition was observed, however
without regulation of IL-4, this is still not completely suppressed. 47,267
Cancer
Whilst IL-4 is normally associated with dierentiation and growth of B
and T cells, in the brain under normal conditions this cytokine inhibits the
proliferation of astrocytes. 268{270 However, whilst IL-4 decreases proliferation
in normal cortex, this is not the case in high grade glioma, where aberrant
growth is observed. 271 IL-4 has been found to exhibit pro-tumour activities
in rodent experimental glioma, with knockdown of this cytokine acting as an
eective therapy in animal models. 272 Interestingly though, this appears to
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be specic to higher-grade forms of this cancer as treatment with IL4 gene
transfer appears to actually have therapeutic benets in low grade glioma. 273
Astrocytic tumours (gliomas) are the most common brain tumours found
in adults and are almost always genetic in aetiology. 274 Glioblastoma multi-
forme (GBM) is a highly malignant, aggressive form of brain tumour, which
arises from astrocytes or their precursors. 274 Astrocytes exhibit many func-
tions in the central nervous system including coordination of inammation
and immune responses in the brain, 275,276 however in GBM these functions
are suppressed. IL-13R2 is highly expressed in glioblastoma cells but is
generally absent in normal astrocytes and lower grade gliomas. 248,277,278 Due
to this high expression, IL-13R2 has recently been proposed as a biomarker
for GBM. 277 This glioblastoma specic expression of IL-13R2 has been
postulated to prevent the growth arrest normally associated with IL-4 in
astrocytes.
1.11.4 Potential Signalling Pathways for IL-13R2
Despite previously being considered to only act as a \decoy receptor" due
to the short intracellular tail lacking any obvious signalling motifs, in recent
years there has been research suggesting that IL-13R2 may actually be able
to instigate a signal.
Two groups in particular have dominated this research, one proposing
an IL-13 induced Activator Protein 1 (AP-1) signal leading to brosis, and
another suggesting a STAT3 signal in response to IL-4 in GBM.
Signalling Via AP-1
Recent studies in macrophages, as well as animal models of colitis and
airway brosis by Fichtner-Feigl et al. have suggested that IL-13R2 is
able to transduce a signal, through an AP-1 variant containing c-Jun and
Fra-2, which in turn activates the TGFB1 promotor, leading to brosis
(Figure 1.7). 261{265
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Figure 1.7: Proposed mechanism for IL-13-induced activation of AP-1 via IL-
13R2. In experimental models of colitis it has been suggested that IL-13-
mediated signalling via IL-13R2 induced brosis. This occurs via activation of
AP-1, which drives increased TGFB1 transcription and induction of a brogenic
pathway involving insulin-like growth factor 1 (IGF-1) and early growth-response
gene product 1 (EGR-1). TGF1 induces the transition of these cells to become
myobroblasts, as well as collagen deposition by both broblasts and myobrob-
lasts. Myobroblast apoptosis is also observed. As proposed in Fichtner Feigl,
Young et al. 264
In oxazolone-induced colitis and bleomycin-induced lung brosis mouse
models, combined treatment with IL-13 and TNF was found to induce
activation of the TGFB1 promotor. In both THP-1 cells, which naturally
express IL-13R2, and an IL-13R2 overexpression model in monomac6 cells,
AP-1 was required for activation of the TGFB1 promotor. The authors have
proposed that this IL-13 induced activation of AP-1 initiates a brogenic
pathway, with increased expression of TGF1, insulin-like growth factor 1
(IGF-1) and early growth-response gene product 1 (EGR-1). These are
key factors involved in brogenic processes, which in turn leads to increased
production of collagen by myobroblasts. 264 Somewhat unexpectedly, apop-
tosis of myobroblasts is also observed in response to activation of EGR-1.
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However, it has been suggested that myobroblast function varies throughout
the cell life-cycle as a self-regulatory mechanism and that this may aid
removal of pre-existing myobroblasts, which can act to inhibit collagen
production by younger myobroblasts. 279
Blockade of IL-13R2 expression reduced TGF1 and collagen production
and prevented bleomycin-induced lung brosis. Therefore Fichtner-Feigl
et al. hypothesised that IL-13 induced brosis occurs via IL-13R2. 261{265
As airway remodelling, in the form of subepithelial brosis, is a hallmark
of asthma, activation of the TGFB1 promotor via IL-13R2 could be an
important mechanism in this disease.
Signalling Via STAT3
Whilst the work by Fichtner-Feigl et al. 261{265 has examined the possibility
of an IL-13-mediated signal via IL-13R2, other studies by Rahaman et al.
have investigated a potential IL-4-mediated signal in glioblastoma. 249,280
Unlike normal astrocytes and low grade gioma where IL-4 exhibits anti-
tumour eects, glioblastoma cells are considered refractory to IL-4 and IL-
13 as no STAT6 activation occurs after treatment with these cytokines. 249
Recent studies by Rahaman, Sharma et al. conrmed that this is due
to the high levels of IL-13R2 present in these cells. 249 They have since
demonstrated that in these cells STAT3 is aberrantly activated by IL-4,
which is partially mediated by IL-13R2, as demonstrated by knock-down
experiments. 280 The exact mechanism by which this occurs is unknown as
no physical contact is required between STAT3 and IL-13R2. 280
Ramahan, Vogelbaum et al. propose that IL-4 upregulates the BCL2
family of anti-apoptotic proteins, including Bcl-2. Bcl-XL, Mcl-1, in GBM
mainly via STAT3 (Figure 1.8), although the PI3K/AKT pathway may also
be involved. 280 In this proposed mechanism the IL-13R2 subunit appears
to bind to the IL-4R subunit, which has previously been shown to occur
in the presence of IL-4. 165,249 Rahaman, Vogelbaum et al. suggest that this
may induce a conformational change allowing the recruitment and activation
of STAT3, which is not normally observed. 280
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Figure 1.8: Proposed mechanism for IL-4-induced activation of STAT3 via IL-
13R2. Under normal conditions, stimulation of cells with either IL-4 or IL-13
results in signalling via the type II receptor, IL-4R:IL-13R1. This leads to
activation of the JAK/STAT pathway, with dimerisation of phosphorylated STAT6
inducing transcription of IL-4 and IL-13 responsive genes. However, it has recently
been suggested that in high-grade glioma the IL-13R2 subunit, which is able to
bind to IL-4R, interferes with either STAT6 phosphorylation or dimerisation and
instead alternative activation of STAT3 occurs. Upon entering the nucleus, this
dimerised STAT3 acts as a transcription factor leading to upregulation of Bcl-2.
Bcl-XL and Mcl-1. As proposed by Rahaman, Vogelbaum et al. 280
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Whilst previous studies have shown that IL-4 signalling is regulated
by IL-13R2, 165 the mechanism for this remains unclear. The proposal
by Rahaman, Vogelbaum et al. that IL-13R2 may actually induce a
signal in response to IL-4 could provide an explanation for this regulatory
mechanism. 280
1.11.5 The Eect of SNPs on IL-13R2 Regulation
Genetics have been found to aect the regulation of IL-13 by IL-13R2.
At least one polymorphism of IL-13, associated with asthma, demonstrates
diering regulation by IL-13R2 than the wildtype form. The rs20541 variant
of IL-13 is found in 20% of Caucasians and is more prominent in asthmatics
than healthy controls. 147 IL-13R2 is unable to regulate this variant form
of IL-13 as eectively as wildtype IL-13. This isoform demonstrates slower
association with IL-13R2 and mediates increased eotaxin production and
STAT6 activation in a low IL-13R2 environment in comparison to the
wildtype IL-13. 281
1.11.6 IL-13R2 in Asthma
Previous work has shown substantial variation in the responsiveness of both
bronchial broblasts and epithelial cells to IL-4 and IL-13 and that this
inversely correlates with IL-13R2 levels in the cells, which varies between
donors. 165,250,281 It is unclear at present whether this dierential expression
of IL-13R2 accounts for any dierences in the asthma phenotype, such as
the \Th2 high" and \Th2 low" groups which have been noted in recent
years. With IL-13R2 able to regulate the eects of both IL-13 and IL-4,
this receptor is important in the modulation of Th2 responses.
Therefore, as previous studies have shown that IL-4 signalling is regulated
by IL-13R2, 165 which could be related to the recent suggestion that this
\decoy receptor" may actually induce a signal in response to IL-4, this project
will attempt to address the mechanism by which this regulation occurs, to
provide greater understanding of the pathogenesis of asthma.
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1.12 Objectives & Hypothesis
The hypothesis I wish to test is that IL-13R2 is responsible for the regulation
of IL-4 mediated signalling in human bronchial broblasts and that regulation
by IL-13R2 is altered in asthma.
The aim of this study is to investigate the mechanism by which IL-13R2
regulates IL-4 mediated signalling. This could lead to the opportunity to
develop a therapy for asthma. IL-13R2 is a tempting therapeutic target
not only because it a naturally occurring protein, but it is also able to
attenuate both IL-4 and IL-13, which are key cytokines in the instigation
of inammation in the lung. Previous attempts to attenuate either IL-4 or
IL-13 individually have been largely unsuccessful due to their overlapping
responses and their importance in the maintenance of the immune response
in other areas of the body.
Determining the mechanism by which IL-13R2 inhibits IL-4 signalling
would have therapeutic value as this knowledge could be used to develop
small molecule inhibitors.
1.12.1 Objectives:
1. Is the surface expression of IL-4 and IL-13 receptors modulated?
i Characterise the levels of IL-13R2 and the IL-4 and IL-13 signalling
receptors in human bronchial broblasts (HBFs) from healthy and asth-
matic subjects.
ii Determine whether receptor expression is modulated by treatment with
Th2 or Th1 cytokines.
iii Conrm whether diering levels of IL-13R2 or the IL-4/13 signalling
receptors observed between subjects aect the responsiveness of the HBFs
to IL-4 and IL-13.
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2. Can the levels of IL-13R2 be modulated?
i Develop a model to modulate the levels of IL-13R2 in HBFs using siRNA
against IL-13R2 in high expressing cells and overexpression of IL-13R2
in low expressing cells.
ii Conrm that modication of the surface expression of IL-13R2 aects
the responsiveness of cells to both IL-13 and IL-4.
3. Does IL-13R2 signal?
i Establish whether IL-4 or IL-13 are able to instigate a STAT3 signal in
HBFs.
ii Ascertain whether this STAT3 signal is mediated by IL-13R2.
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Materials & Methods
2.1 Materials
The Interleukin (IL)-13 used in these studies was a gift from Novartis,
Horsham, UK. All other reagents were obtained from suppliers as detailed
below.
2.1.1 Cell Culture
Advanced BioMatrix, Tuscon, USA Bovine Collagen Type I (5005-B).
Becton Dickinson, Oxford, UK Matrigel (356231).
Greiner, Gloucestershire, UK Cryovials (126278).
Invitrogen, Paisley, UK Dulbecco's Modied Eagles Medium (DMEM)
(11960044), Heat-Inactivated Foetal Bovine Serum (FBS) (10108165), Peni-
cillin Streptomycin (25030-024), L-Glutamine (25030-024), Sodium Pyruvate
(11360-039), Minimum Essential Medium Non Essential Amino Acids (11140-
035), Trypsin-EDTA (15400054), Hank's balanced salt solution (HBSS)
without Ca2+Mg2+(14170-0880).
Lonza, Wokingham, UK BEBM Basal Medium (CC-3171), BEGM Single-
Quot Kit Supplements & Growth Factors (CC-4175) UltraCulture (12-725F).
45Chapter 2. Materials & Methods
Nutacon, Leimuiden, The Netherlands PureColl rat tail Collagen I
(5005-B).
Sigma-Aldrich, Poole, UK Bovine insulin, human transferrin, and
sodium selenite (ITS) liquid media supplement 100 stock solution (I3146),
Dimethylsulphoxide (DMSO) (D2650), Trypan Blue (T8154).
ThermoFisher Scientic, Loughborough, UK Nunc Cell Culture Flasks
and Plates.
2.1.2 Cell Treatments
Invivogen, Nottingham, UK Polyinosinic-Polycytidylic acid (Poly I:C)
(tlrl-pic).
National Institute for Biological Standards and Control (Health
Protection Agency), Potters Bar, UK IFN (00/572).
PeproTech, London UK IL-4 (200-04), IL-6 (200-06), IFN (300-02).
R&D Systems, Abingdon, UK Monoclonal Anti-Human IL-6 Receptor
(MAB227), Anti-Human IL-13R2 antibody (AF146).
Sigma-Aldrich, Poole, UK Cycloheximide (C4859), Dexamethasone
(D2915).
Stratech, Newmarket, UK Monoclonal Antibody to Human Interferon
/ R2 (IFNAR2) (21385-1).
2.1.3 siRNA Transfection
Dharmacon, ThermoFisher Scientic, Loughborough, UK Pool of
small interfering RNA (siRNA) against IL-13R2 (L-004598-00) and Control
siRNA (D-001810-10-05), 1 siRNA buer (B002000-UB-100).
Invitrogen, Paisley, UK OptiMEM (11058-021).
Roche Applied Science, Burgess Hill, UK X-treme Gene siRNA Trans-
fection Reagent (04 476 093 001).
46Chapter 2. Materials & Methods
2.1.4 Vector Transfection
American Type Culture Collection (ATCC), Manassas, USA BEAS-
2B cell line (CRL-9609).
Cell Signaling Technology, New England BioLabs, Hertfordshire,
UK HindIII Restriction Endonuclease (R0104), SalI Restriction Endo-
nuclease (R0138).
Invivogen, Nottingham, UK F-12 + GlutaMAX-1 Nutrient Mixture
(Hams) (31765), Geneticin (10131-019), pcDNA3.1 ({) vector.
Origene, Cambridge, UK IL13RA2 cDNA NM 00640 (SC125642).
Qiagen, Crawley, UK Eectene Transfection Reagent (301425).
2.1.5 RNA Extraction, Reverse Transcription &
Quantitative Polymerase Chain Reaction (PCR)
Ambion Applied Biosciences, Warrington, UK DNase Kit including
10 DNase Buer (AM1906).
BioRad, Hertfordshire, UK Plate seals (MSB-1001), Thin Walled 96-
Well PCR plates (MLL-9651).
Invitrogen, Paisley, UK Trizol (15596018).
PrimerDesign, Southampton, UK Precision MasterMix (Precision-ic),
Primers (PP-hu-900) for IL-6, IL-4R, IL-13R1, IL-13R2, c and Ubiq-
uitin C/Phospholipase A2 housekeeping genes (HK-PP-hu-900), Reverse
Transcription Kit (RT-Std).
Sigma-Aldrich, Poole, UK Chloroform (C2432), Ethanol (32221), Iso-
propanol (I9516).
2.1.6 Flow Cytometry
BD Biosciences, Oxford, UK Allophycocyanin (APC)-conjugated mouse
IgG2B negative control (555745), FACSAria, FACSDiva software v5.0.3.
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Dako, Cambridgeshire, UK Polyclonal rabbit anti-mouse immuno-
globulins/FITC Rabbit F(ab')2 (F031302).
GenProbe, Cedex, France Unconjugated mouse anti-human IL-13R2
(852.120.000), PE-conjugated mouse anti-human IL-13R2 (852.122.010),
mouse IgG1 (857.070.000), mouse IgG2A (857.080.000).
Invitrogen, Paisley, UK Heat-Inactivated FBS (10108165).
Promokine, Heidelberg, Germany Alexauor-405 (PK-PF-LK-405-05)
and Alexauor-488 (PK-PF-LK-488-05) antibody dye conjugation kits.
R&D Systems, Abingdon, UK APC-conjugated mouse anti-human
IL-13R1 (FAB1462A), APC-conjugated mouse anti-human IL-4R
(FAB230A), Carboxyuorescein (CFS)-conjugated mouse anti-human IL-
13R1 (FAB1462F), unconjugated mouse anti-human c (MAB2841),
CFS-conjugated mouse IgG2B (IC0041F) and APC-conjugated mouse IgG2A
(IC003A).
Sigma-Aldrich, Poole, UK Bovine Serum Albumin (BSA) Fraction V
(A3059), Dulbecco's Phosphate Buered Saline (PBS) without Ca2+Mg2+
(D8537), Ethylenediaminetetraacetic acid (EDTA) (03690).
2.1.7 SDS-PAGE & Western Blotting
BioRad, Hertfordshire, UK 30% Acrylamide/Bis-Acrylamide (37:1)
(161-0157), lter paper (1704085), Tris-Glycine-SDS (161-0772), Pre-cast
SDS-PAGE gels (Criterion) (345-0112), Precision Plus kaleidoscope colour
protein standard (161-0395), Mini-Protean Tetra Cell, Mini Trans-Blot Cell,
MOPS buer (161-0788), GS800 densitometer and QuantityOne software.
Cell Signaling Technology, New England BioLabs, Hertfordshire,
UK Rabbit anti-human Phospho-STAT3 (Tyr705) (#9131), Rabbit anti-
human STAT3 (#9132), Rabbit anti-human Phospho-STAT6 (Tyr641)
(#9361), Rabbit anti-human STAT6 (#9362).
Dako, Cambridgeshire, UK Swine Anti-Rabbit Secondary (P0217),
Rabbit Anti-Mouse Secondary (E0464).
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Fotospeed, Corsham, UK Print Developer (FX20), Rapid Fixer (PD5).
GE Life Sciences, Buckinghamshire, UK Enhanced Chemiluminescence
(ECL) Plus (RPN2132), Hybond-P Polyvinylidine uoride (PVDF) Transfer
Membrane (RPN303F), HyperlmTM ECL X-Ray Film (28906837).
Marvel, Dublin, ROI Skimmed Dried Milk.
Roche Applied Science, Burgess Hill, UK Complete Protease Inhibitor
Cocktail Tablets (11697498001), PhosStop Phosphatase Inhibitor Cocktail
Tablets (04906837001).
Sigma-Aldrich, Poole, UK Ammonium persulphate (APS) (A9164), -
mercaptoethanol (B-8026), Bromophenol Blue (M7522), Bovine Serum Albu-
min (BSA) Fraction V (A3059), Coomassie Brilliant Blue R (B0149), Glacial
Acetic Acid (27221), Glycine (G7126), Hydrochloric Acid (HCl) (07102), Iso-
propanol (24137), Methanol (24229), N,N,N',N'-tetramethylethylenediamine
(TEMED) (T7024), Ponceau Red Stain (P7170), Sodium Chloride (NaCl)
(S9625), Sodium Dodecyl Sulphate (SDS) (L6026), Tris base (T1503),
Tween-20 (P1379).
2.1.8 Enzyme-Linked ImmunoSorbant Assay (ELISA)
R&D Systems, Abingdon, UK Eotaxin DuoSet ELISA Kit (DY320),
Eotaxin Quantikine ELISA Kit (DTX00) IL-6 Quantikine ELISA Kit
(D6050).
2.1.9 Methylene Blue Assay
Sigma-Aldrich, Poole, UK Borate disodium tetraborate (Borax) (B9876),
Ethanol (32221), Formaldehyde (F8775), Hydrochloric Acid (HCl) (07102),
Methylene Blue (M-9140), NaCl (S9625).
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2.2 Patient History
A panel of 23 patients was used for this study, which includes 15 asthmatics
and 8 non-asthmatics. Cells were obtained from the Synairgen Research
Ltd. Biobank of Primary Cells and were provided under MTA to the Uni-
versity of Southampton. The cells were used under ethics approval granted
by the Southampton and Southwest Hampshire Research Ethics Committee
(ethics number: 05/Q1702/165 Investigation of pathophysiological mecha-
nisms in airways diseases such as asthma and COPD). Samples were assigned
a patient number to protect patient identity and collected from Southampton
General Hospital by Synairgen Research Ltd.
Age and sex matched patients were categorised based on GINA guidelines
(Tables 2.1 & 2.2). 14 No dierences were found in FEV1 or % predicted
FEV1 between the groups. PC20 data were not collected for healthy controls,
who had no previous history of asthma. Some healthy control patients were
atopic, but this was more frequently observed in the asthmatics (p < 0:01).
2.2.1 Healthy Control Subjects
Code Age Sex Atopy FEV1 %FEV1 SMA
A55 27 M No 4.64 94.6 10
A56 60 M No 3.63 114.5 5-10
A57 31 M No 4.41 98.7 20
A60 23 M Yes 4.75 97.4 20
A63 24 F No 3.73 115.1 15-20
A67 35 M Yes 5.14 120.0 20
A72 24 M Yes 4.77 115.9 10-15
A75 32 F No 3.16 132.9 20
Mean 32.0 2/6 a 5/3 b 4.28 111.1 16
SE 4.3 0.24 4.67 1.8
Table 2.1: Healthy control subject patient history. Healthy controls with no
previous history of asthma were given code A+number. a = Female/Male, b
= No/Yes, PC20 data were not collected for healthy control volunteers. SMA =
%  smooth muscle actin, %FEV1 = % predicted FEV1 , SE = Standard Error.
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2.2.2 Asthmatic Subjects
Code Age Sex Atopy FEV1 %FEV1 PC20 Medication SMA
B11 22 M Yes 5.02 107.0 7.0 SABA 20
B12 54 M Yes 3.21 104.0 1.2 SABA 25
B22 21 F Yes 3.87 104.3 11.8 SABA, ICS 10-15
B24 34 M Yes 4.30 101.8 2.5 None 5-10
B25 20 M Yes 5.16 114.7 8.0 SABA 20
B28 26 F No 2.93 88.5 0.0 SABA, ICS 20
B29 22 F Yes 3.95 105.0 1.1 SABA, ICS 10
B32 51 F Yes 2.68 132.4 15.5 SABA 30
B33 23 M Yes 4.79 102.5 6.1 SABA 30
B35 21 M Yes 4.87 110.7 >16 SABA, ICS 5
C11 34 M Yes 3.58 97.0 1.0 SABA, ICS
200 g BD
10-15
C22 26 M Yes 4.57 99.0 0.0 ICS+LABA
200 g BD
<5
C23 29 M Yes 3.87 93.0 4.0 ICS+LABA
100 g BD,
SABA, NICS
10-15
C30 36 F Yes 2.85 87.0 2.6 SABA, ICS
100 g BD,
NICS BD
10
C32 24 M Yes 4.81 95.0 16 ICS+LABA
100 g BD,
SABA
20
Mean 29.5 5/10 a 1/14 b 4.03 102.8 6.2 16
SE 2.8 0.22 2.90 1.5 2.2
Table 2.2: Asthmatic patient history. Mild-intermittent (B) or mild-moderate
asthmatics (C) grouped based on GINA guidelines. 14 A PC20 of 0 mg/ml indicates
a decrease with normal saline in the absence of methacholine. ICS presented as
Beclometasone dipropionate equivalent dose. All medication taken as required
unless dose stated. a = Female/Male, b = No/Yes, BD = 2 daily, %FEV1 = %
predicted FEV1 , ICS = Inhaled Corticosteroid, ICS+LABA = Combined therapy
of ICS and LABA, LABA = Long Acting 2 Agonist, NICS = Nasal ICS, SABA
= Short Acting 2 Agonist, SE = Standard Error.
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2.3 Methods
2.3.1 Cell Culture
Primary human broblasts (HBFs) were obtained by outgrowth from
bronchial biopsies of either healthy or known asthmatic patients, as pre-
viously described. 250 Cells were used between passage number 3 and 7.
Primary bronchial epithelial cells (PBECs) were obtained from bronchial
brushings from three healthy control subjects with no previous history of
asthma or atopy, as previously described. 250 These cells were kindly provided
at passage 2 on collagen I coated 12 well plates by Drs Emily Swindle and
Cornelia Blume.
All culture reagents were pre-warmed before addition to the cells
to prevent heat-shock. Primary broblasts were routinely cultured in
Dulbecco's Modied Eagles Medium (DMEM), supplemented with 10%
(v/v) heat-inactivated foetal bovine serum (FBS), 50 IU/ml penicillin,
50 g/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and
1 mM nonessential amino acids (DMEM Complete). Epithelial cells were
cultured in Bronchial Epithelial Growth Medium (BEGM). Both broblasts
and epithelial cells were incubated in a humidied Heraeus incubator at 37C,
5% CO2. All cell culture work was undertaken in a Class II biological safety
laminar ow hood.
2.3.2 Trypsinisation of Conuent Cell Monolayers
Fibroblasts were grown as monolayers on tissue culture plastic to 90%
conuency before passaging.
Trypsin-EDTA concentrate (10) was diluted before use to a 1 working
solution using Hank's balanced salt solution (HBSS) without Ca2+Mg2+. The
cell monolayer was washed twice with HBSS to remove all traces of serum,
Ca2+ and Mg2+, which can inhibit the action of trypsin. The monolayer was
washed with 1 ml of trypsin for a 75 cm2 ask and the cells were incubated
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for 1 minute (or until the majority of the cells had become loose, as visible
under the microscope) at 37C, 5% CO2. The asks were tapped sharply
to detach the cells and the trypsin was inactivated by addition of DMEM
Complete.
Cells were either frozen as stocks, or seeded into 75 cm2 asks at a seeding
density of 0:75106 cells/ask. For experiments cells were seeded in 6 or 12
well plates at a density of 5  104 and 1  105 cells/well respectively.
Where indicated (in Chapter 5) some cells were seeded onto a Matrigel-
coated well (200 l/well of a 12 well plate) or within Matrigel (500 l/well)
for 3-dimensional culture. Matrigel is liquid at 4C, but forms a gel at 37C.
The Matrigel-coated wells were prepared in advance by adding Matrigel to
the well and incubating at 37C prior to addition of the broblasts. When
the cells were grown in 3D culture, however, the cells were premixed with
chilled Matrigel prior to seeding. In this instance media was added to the
culture after 10 minutes incubation at 37C to allow gel polymerisation.
2.3.3 Viable Cell Counting
The Trypan Blue exclusion method was used to count the number of viable,
live cells. Non-viable cells stain blue, whilst viable cells with intact cell
membranes exclude the dye. Before counting, 20 l of cell suspension was
diluted into 20 l HBSS and 10 l of 0.4% (w/v) Trypan Blue.
An Improved Neubauer haemocytometer (depth 0.1 mm; 1/400 mm2)
was used to count the number of viable cells present within the 1 mm2
central square. This was repeated for both the top and bottom chambers
for accuracy. The viable cell count per millilitre was then calculated using
the following equation:
Viable cells=ml = (viable cell number)  (dilution factor used)  10
4:
Cells were diluted in DMEM Complete, to the appropriate concentration
and plated into wells or culture asks, as required.
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2.3.4 Cryogenic Storage & Regeneration of Cell Stocks
Post-trypsinisation, the cell suspension was pelleted at 300 g for 5 minutes
at 4C. The cells (approximately 1  106 cells per vial) were resuspended in
1 ml of chilled DMEM Complete containing 10% (v/v) dimethylsulphoxide
(DMSO), to act as a cryoprotectant and frozen in 2 ml cryovials at a rate of
-1C per minute to -80C overnight in a cryogenic freezing container, before
being transferred to liquid nitrogen vapour at -150C, for long-term cryogenic
storage.
For regeneration, cell stocks were warmed rapidly by the addition of
pre-warmed DMEM Complete. Once defrosted, the cells were pelleted and
resuspended in 15 ml DMEM Complete to remove all traces of DMSO and
transferred into a 75 cm2 ask for routine culture.
2.3.5 Treatments
Before treatment, broblasts were grown to 95% conuence and serum
starved using UltraCulture supplemented with 50 IU/ml penicillin, 50 g/ml
streptomycin and 2 mM L-glutamine (SFM) for 24 hours to make the cells
quiescent. In some instances broblasts were pre-treated with 10 ng/ml
IL-4 or IL-13 during this initial 24 hour period. The medium was replaced
with fresh UltraCulture in the presence or absence of recombinant human
Interleukin (IL)-13, IL-4, IL-6, Interferon (IFN) , IFN or Poly I:C at
varying concentrations (see Chapters 3{5 for details). Where indicated these
challenges were supplemented with dexamethasone treatment.
For PBECs the media were exchanged for BEBM containing 10 g/ml
bovine insulin, 5.5 g/ml human transferrin, 5 g/ml sodium selenite and
0.1% bovine serum albumin (BSA) (starvation media) for 24 hours prior
to treatment. Subsequently the media were exchanged for fresh starvation
media in the absence or presence of IL-13 or IFN for up to 24 hours.
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For experiments analysing de novo protein synthesis a 30 minute pre-
treatment step of 50 l cycloheximide (CHX) was included after the 24 hour
starvation period.
2.3.6 siRNA Against IL-13R2
Fibroblasts were seeded at 2104 cells per well of a 12 well plate in DMEM
supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS),
2 mM L-glutamine, 1 mM sodium pyruvate and 1 mM nonessential amino
acids but without antibiotics (siRNA Media) and used once they reached
30-40% conuence. A pool of siRNA against IL-13R2 or control siRNA
(varying concentrations from 0 to 50 nM) was diluted in OptiMEM (up
to 100 l total) in one eppendorf, and XtremeGene transfection reagent
(2 l) was combined with OptiMEM (98 l) in a separate eppendorf. The
XtremeGene and siRNA were mixed and incubated for 15 minutes at room
temperature. During this incubation the existing media on the cells was ex-
changed with 800 l fresh siRNA media before addition of the siRNA:Xtreme
Gene drop-wise onto the cells in duplicate.
Twenty-four to 96 hours after addition of the siRNA the cells were
homogenised in Trizol and analysed by RT-qPCR or trypsinised and analysed
by ow cytometry.
2.3.7 Overexpression of IL-13R2
BEAS2B cells overexpressing IL-13R2 were provided by Dr Allison-Lynn
Andrews and Dr Ali Tavassoli (School of Chemistry). Briey, IL-13R2 was
amplied by PCR from cloned cDNA using the following primers:
Forward SalI GTTGTTCTCGAGATGGCTTTCGTTTGCTTGGC
Reverse HindIII GTTGTTAAGCTTTCATGTATCACAGAAAAATTCTGG
The PCR product was digested with SalI and HindIII restriction endo-
nucleases, and cloned into pcDNA3.1 (-) vector between the SalI and HindIII
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restriction sites (Figure 2.1). The delity of the cloned sequence was
conrmed by sequencing. The cytomegalovirus (CMV) promotor in this
vector drives high levels of expression without the need for doxycycline
regulation. This system allows the establishment of stable cell lines by
Geneticin selection.
pcDNA3.1 (+/-)
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Figure 2.1: Vector map. The IL-13R2 cDNA was inserted at the EcoR I site.
Transcription was driven by a CMV promotor. Vector contains an ampicillin
resistance gene and a neomycin (Geneticin) resistance gene, which are used for
selection. PCMV = Cytomegalovirus promotor, Ori = origin of replication. SV40
ori = SV40 early promotor & origin, SV40 pA = SV40 early polyadenylation signal
BEAS2B cells were transfected with either a pcDNA3.1 vector containing
IL-13R2 (B2B-FL) or an empty vector (B2B) by lipofection. Stably trans-
fected cells (i.e. cells which had accepted the DNA into their genome) were
selected using Geneticin (600 g/ml). This was reduced to a maintenance
dose of 200 g/ml for routine cell culture. Levels of IL-13R2 surface
expression were determined by ow cytometry.
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2.3.8 Reverse Transcription Quantitative Polymerase
Chain Reaction (RT-qPCR)
For gene expression studies, broblasts were serum starved for 24 hours before
treatment with various stimuli for up to 48 hours. The cells were washed and
the RNA was extracted from the cells using the Trizol method. The RNA
was subsequently reverse transcribed to cDNA before analysis by RT-qPCR.
RNA Extraction
Trizol is a mono-phasic solution of phenol and guanidine isothiocyanate,
which enables single-step RNA isolation from cells by maintaining the in-
tegrity of the RNA during cell homogenisation. 282 The expected yield of
RNA from 1  106 broblasts is between 5 and 7 g.
The cell monolayer was washed with HBSS and then incubated with
Trizol for 5 minutes at room temperature to allow cellular lysis, as well as
dissociation of soluble protein factors from the RNA. This was followed by
disruption by pipetting, prior to transfer to an RNase and DNase free sterile
1.5 ml eppendorf. The samples were stored at -20C until required.
The samples were thawed on ice and 200 l of chloroform was added
per ml of Trizol used. The samples were mixed vigorously by hand and
incubated for 10 minutes before centrifugation at 12,000 g for 15 minutes
at 4C. The top aqueous layer containing the RNA was then transferred to
a fresh eppendorf and the remaining interphase and organic phase layers
were left intact and stored at -20C, to allow future extraction of DNA via
ethanol precipitation. Protein could be recovered from the organic phenol
phase using isopropanol precipitation. Isopropanol (500 l, equivalent to the
volume of the aqueous layer) was then added and the samples were mixed
thoroughly by shaking and stored overnight at -80C to improve the RNA
yield. The samples were incubated on ice for 15 minutes, thoroughly mixed
by vortexing for 5 to 10 seconds and centrifuged at 12,000 g for 30 minutes
at 4C. The supernatant was discarded, and the pellet containing the RNA
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was washed with 1 ml 75% ethanol. The pellet was re-centrifuged at 7,500 g
4C for 5 minutes, the ethanol was removed and the pellet was allowed to air
dry for 10 minutes before DNase treatment.
DNase Treatment
To remove trace amounts of genomic DNA present within Trizol extracted
RNA, the samples were treated with DNase. The DNase (1 l of 2 U/l
stock) was diluted in distilled water (17 l) containing 10 DNase buer
(2 l) before use. Each RNA pellet was resuspended in 20 l and incubated
at 37C for 1 hour, before addition of 5 l neutralisation buer to prevent
degradation of the RNA. After a 2 minute incubation at room temperature
the samples were spun at 12,000 g for 2 minutes to separate the slurry from
the RNA.
RNA Quantication
A NanoDrop ND-1000 Spectrophotometer was used to determine both the
quantity and quality of the RNA in each sample, by measuring absorbance
at the 230, 260 and 280 nm wavelengths.
The scanning area was wiped clean with a distilled water soaked tissue
before injection of 1 l of distilled H2O to act as the blank. Following this,
1l of sample was added to the scanning area and detected. The quality of
the RNA was analysed by the ratio between the wavelengths 260 and 280 nm
(a value of between 1.8 and 2 is desired). As 1 g RNA was used for each
reverse transcription reaction the volume of RNA required per sample was
determined by dividing 1,000 by the ng/l value provided.
Reverse Transcription
Reverse transcription was performed on all Trizol-extracted RNA samples
to obtain cDNA, for analysis using quantitative polymerase chain reaction
(qPCR).
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The RNA (1 g) was added in the initial, annealing step of reverse
transcription along with 2 l Oligo dT primer dTNP mix and 1 l Random
hexamer primer. This was then made up to 10 l using RNase/DNase free
H2O. This reaction was carried out within a thin-walled 200 l tube to allow
rapid heating and cooling. The samples were heated to 65C for 5 minutes,
followed by immediate cooling in an ice water bath. For the extension step, a
master mix containing 4 l 5 MMLV buer, 0.2 l RNase/DNase free H2O
and 0.8 l MMLV enzyme was added to each of the tubes. The samples were
then mixed by icking the tubes, and incubated at 42C in a water bath for
1 hour. After incubation, the cDNA was diluted 1:10 in DNase/RNase free
water and stored at -20C.
Quantitative PCR
Real time quantitative polymerase chain reaction (RT-qPCR) 283 was per-
formed using the BioRad CFX system. 2.5 l of cDNA template was
transferred to a well of a thin walled 96 well plate, together with 1 l
primer and probe (see Appendix A for sequences) and 12.5 l (22.5 l
for housekeeping genes, where two uorophores were multiplexed) Precision
Master Mix. Each sample was measured in duplicate, and all changes in gene
expression were compared to two previously determined housekeeping genes
(Ubiquitin C and Phospholipase A2 (UBC/A2)). All primers and probes
were pre-labelled with FAM (6-carboxyuoroscein), except Phospholipase
A2 which is labelled with Cy5.5 to enable multiplexing of the housekeeping
genes. Controls for the reverse transcription reaction (water used during the
reaction, no-RNA and no-enzyme reactions) and the PCR were included in
each run.
Data obtained from the RT-qPCR were analysed using the 2CT
method. 284 During amplication of cDNA the uorescent dye is released,
resulting in increased uorescent intensity in samples with more of the gene
of interest. The number of cycles of amplication required for the level
of uorescent intensity to reach a threshold (the CT value) is related to
the amount of target gene cDNA present, with a lower CT value indicating
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greater gene expression (a decrease of 1 CT is equal to a doubling of the
target gene). The CT values for the gene of interest were normalised to
the geometric mean of two housekeeping genes (UBC/A2). These data were
subsequently normalised to the baseline control value of one subject. 285
2.3.9 Flow Cytometric Analysis of IL-4 & IL-13
Receptor Subunits
Cells were characterised for the surface expression levels of IL-4R, IL-
13R1, IL-13R2 and c by ow cytometry. Fibroblasts were seeded into 12
well plates at a density of approximately 2  104 cells per well, and grown
until 95% conuent, as previously described. The cells were serum starved
for 24 hours and treated with either IFN, IFN, IL-4, IL-13, or Poly I:C for
up to 24 hours prior to analysis, as described in the results section. Where
appropriate a washout period was also included, consisting of the media being
exchanged for fresh ultraculture for 3 hours when indicated.
The cells were trypsinised, and the trypsin was inactivated by addition of
1 ml DMEM complete. The cell suspension was then washed in 2 ml FACS
buer (1 PBS, 0.5% BSA, 2 mM EDTA) and centrifuged at 300 g for 5
minutes at 4C. Samples were incubated on ice in the dark for 45 minutes
with an appropriate antibody or isotype control (Table 2.3) in 100 l FACS
buer containing 10% human serum.
Antibody Fluorophore Dilution Isotype Manufacturer
IL-4R APC 1:10 Mouse IgG1 R&D Systems
IL-13R1 APC 1:10 Mouse IgG2B BD Pharmingen
IL-13R1 CFS 1:10 Mouse IgG2B R&D Systems
IL-13R2 FITC 2 1:200 Mouse IgG1 GenProbe
IL-13R2 PE 1:10 Mouse IgG1 GenProbe
c AF-405 1:20 Mouse IgG2A GenProbe
Table 2.3: Flow cytometry antibody dilutions. 2 = Secondary antibody, AF =
Alexauor, APC = Allophycocyanin, CFS = Carboxyuoroscein, FITC = Fluo-
roscein Isothiocyanate, PE = Phycoetherin
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Prior to use the c and mouse IgG2A isotype controls were labelled with a
Promokine Alexauor-405 dye, according to the manufacturers instructions.
In initial experiments the IL-13R2 antibody and mouse IgG1 isotype control
were obtained in an unconjugated format and used with a rabbit anti-
mouse Fluorescein isothiocyanate (FITC) labelled secondary antibody. In
later experiments the uorophore used for the IL-13R1 and isotype control
was changed from allophycocyanin (APC) to carboxyuoroscein (CFS) and
the IL-13R2 antibody and isotype controls were purchased with a directly
conjugated uorophore (phycoetherin (PE)) in order to use all the uorescent
antibodies together in one reaction. In both cases the original antibody clone
from the same company was used.
Cells were washed with 2 ml FACS buer to remove any excess antibody,
centrifuged at 300 g for 5 minutes and resuspended in 250 l FACS buer.
Flow cytometric analysis was performed on a FACSAria using FACSDiva
software v5.0.3. Mean uorescent intensities (MFI) were normalised to
isotype controls giving specic MFI (SMFI).
2.3.10 SDS-PAGE & Western Blotting
Sample Preparation
Fibroblast monolayers were washed after treatment with ice cold phosphate
buered saline (PBS) and lysed in boiling sample buer (62.5 mM Tris-HCl
pH 6.8, 10% glycerol, 5% -mercaptoethanol, 2% SDS, 0.01% Bromophenol
blue), which contains a blue dye, enabling visualisation of the running front
as it moves through the gel. The samples were scraped from the base of
the well using a cell scraper and stored in eppendorf tubes at -20C until
required. Before western blotting, the DNA within the samples was sheared
by sonication using a probe sonicator for 15 seconds at an amplitude of 2.5 M
and the samples were boiled at 95C for 5 minutes to denature the proteins.
The samples were pulse spun and cooled to room temperature before loading
into an sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE).
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SDS-PAGE
SDS-PAGE was performed using a 10% polyacrylamide resolving-gel with
a 4% stacking gel, cast to a 1 mm thickness (see Appendix A) using the
Tetra Cell system. The 10% concentration was chosen to provide the best
resolution of proteins between 40 and 100 kiloDaltons (kDa). The resolving
layer was overlaid with water-saturated isopropanol to exclude oxygen, an
inhibitor of polymerisation. After allowing at least 45 minutes for the gel
to polymerise, the isopropanol was removed and the gel surface was washed
with water before addition of a 4% polyacrylamide stacking layer, and a
10-well comb was inserted. Twenty-ve microlitres of sample was loaded per
lane and 5 l of PrecisionPlus kaleidoscope protein standard was added to
enable a molecular weight comparison of the sample protein bands. The gels
were run in at a constant 100 V (up to 300 mA) in Tris-Glycine-SDS (TGS)
buer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 0.1% SDS) until the dye
front reached the bottom of the gel.
Where indicated, the SDS-PAGE gel was immersed in Coomassie Brilliant
Blue stain for 1 hour and destained in 25% methanol, 10% glacial acetic acid
overnight.
Western Blotting
The gels were preshrunk in Transfer buer (TGS buer containing 20%
methanol) for 15 minutes, before western blotting. A polyvinylidene di-
uoride (PVDF) membrane was prepared by pre-wetting with methanol for
3 minutes, followed by transfer buer for 10 minutes.
The gel and PVDF were sandwiched between blotting paper and
ScotchbriteTM pads, and inserted into a transfer chamber lled with transfer
buer with the PVDF closest to the anode. The protein bands within the
gel were transferred to PVDF at a constant 90 V (up to 350 mA) on ice,
with constant stirring to ensure heat dissipation, for 2 hours to allow for
complete transfer of high molecular weight proteins.
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Ponceau Staining
Ponceau stain was used to conrm transfer of the proteins from the gel
to the membrane. This stain binds reversibly to the protein bands on a
PVDF membrane, and can be easily removed by washing with water without
aecting the protein bound to the membrane.
After electrophoretic transfer, the membrane was washed for 15 minutes
in Tris-buered saline containing 0.05% Tween 20 (TBS-Tween) to remove
any excess salts. The membrane was then fully immersed in ponceau stain
(0.1 % (w/v) Ponceau S in 5% acetic acid (w/v)) for 5 minutes. Excess stain
was removed by rinsing in distilled water, until the background was clear.
The presence of protein on the membrane was indicated by red bands.
Antibody Incubation
After ponceau staining the membrane was washed in TBS-Tween for 10
minutes to remove any remaining red stain before incubating in 5% low-
fat milk powder in TBS-Tween (blocking buer) for 30 minutes at room
temperature with rocking to block non-specic binding sites.
The primary antibody was diluted in TBS-Tween containing 5% (w/v)
bovine serum albumin fraction V (BSA), as directed by the manufacturer,
(see Table 2.4 for details) and incubated overnight, with rocking at 4C.
The membrane was then washed in TBS-Tween for 30 minutes with three
changes in buer to remove any excess antibody. An appropriate horseradish
peroxidase (HRP) conjugated secondary antibody was selected and diluted
in blocking buer (see Table 2.4 for details) and incubated for one hour at
room temperature, followed by four, 10 minute washes in TBS-Tween.
Protein Detection
Enhanced Chemiluminescence (ECL) plus was used for detection of the
protein bands. The ECL plus reagents were equilibrated to room temperature
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Antibody Species Concentration Dilution
Phospho-STAT3 (Tyr705) Rabbit 43 g/ml 1:1000
Pan-STAT3 Rabbit 89 g/ml 1:1000
Phospho-STAT6 (Tyr641) Rabbit 42.6 g/ml 1:1000
Pan-STAT6 Rabbit 100 g/ml 1:1000
HRP Conjugated Anti-Rabbit 2 Swine 1300 g/ml 1:2000
Table 2.4: Western blotting antibody dilutions. 2 = Secondary antibody, HRP =
Horseradish Peroxidase
before use and used according to the manufacturers instructions. The
membrane was incubated in ECL plus for ve minutes, before draining the
excess reagent by dabbing the corner of the membrane against a tissue.
The membrane was carefully placed protein side up between two sheets
of transparent OHP lm, ensuring no air bubbles were present and the
sheets were sealed shut in an X-ray lm cassette and taped in place to
prevent movement during exposure. In a dark room autoradiography lm
was exposed to the membrane for 1 minute. The X-ray lm was developed
in Print Developer for 1 minute with rocking, and xed in Rapid Fixer for
one minute with rocking before immersion in water. If necessary, this initial
exposure was used to determine the subsequent exposure times, which varied
from generally between 5 seconds and 5 minutes.
Protein bands were quantied using a densitometer and normalised to
the pan-protein using QuantityOne software.
2.3.11 Enzyme-Linked ImmunoSorbant Assay (ELISA)
Conditioned media from cells were analysed for levels of eotaxin or IL-6 by
ELISA. The principals of this assay are summarised in Figure 2.2.
Sample Preparation
Fibroblasts were seeded at 5  104 cells per well in 12 well plates and grown
to 95% conuence. For analysis of eotaxin production, cells were serum
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Figure 2.2: The principals of an enzyme-linked immunosorbant assay (ELISA).
A sandwich ELISA detects a specic protein of interest from conditioned media.
The wells are initially coated with a capture antibody and blocked for non-specic
binding before addition of the conditioned media containing the analyte, which is
specically retained by the capture antibody. After washing, a biotinylated detec-
tion antibody, which also detects the desired protein, is then added. Streptavidin-
HRP binds to this biotin and turns the chromagen blue. Acid stops the reaction,
resulting in a yellow colour proportional to the amount of the protein of interest
present. Protein quantitation can be determined by measuring the absorbance
and normalising to a standard curve. HRP = Horseradish Peroxidase, TMB =
3,30,5,50-tetramethylbenzidine, H2SO4 = Sulphuric Acid.
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starved in the presence or absence of 10 ng/ml IL-4 or IL-13 or 10 g/ml
Poly I:C for 24 hours. The cells were incubated for 3 hours with fresh medium
before further treatment (as described in Chapters 3 & 4). In some cases cells
were also pretreated during this 3 hour washout step with a blocking antibody
against IL-13R2. For analysis of IL-6, conditioned medium was collected
at baseline after 24 hours serum starvation.
In both instances media were claried by centrifugation (300 g for 5 min-
utes) before analysis.
Eotaxin ELISA
Conditioned media was analysed for levels of Eotaxin using a DuoSet ELISA
Kit. The eotaxin capture antibody was reconstituted in 1 ml Dulbecco's
phosphate buered saline (DPBS) to a concentration of 360 mg/ml and the
eotaxin detection antibody was diluted in DPBS containing 1% BSA Fraction
V (reagent diluent) to a concentration of 18 mg/ml. The antibodies were
frozen at -20C in aliquots for up to 6 months and reconstituted by a 1:180
dilution in their respective reconstitution buers before use. During each
incubation the plate was covered with a fresh plate seal.
Maxisorp 96 well ELISA plates were incubated with 100 l/well 2 mg/ml
eotaxin capture antibody overnight at room temperature before aspirating
each well and addition of 300 l/well wash buer (0.05% Tween-20 in DPBS)
by multichannel pipette. To remove the buer the plate was inverted and
impacted against clean paper towels ensuring complete removal of the liquid
at each step. This process was repeated three times for every wash cycle.
To prevent non-specic binding the wells were incubated with 300 l/well
reagent diluent for one hour at room temperature with rocking, before
repeating the washing step.
The conditioned media samples were diluted 1:10 before use and 100 l
of sample was added per well. A standard curve using recombinant human
eotaxin was created by reconstituting a 120 ng stock in 0.5 ml reagent
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diluent and further diluting 1:60 to form a 7 point standard curve with 2-
fold dilutions ranging from 1000 to 15.6 pg/ml eotaxin (Figure 2.3). Each
sample or standard was added in duplicate and incubated for 2 hours at room
temperature, before washing 3 times as before.
Figure 2.3: A typical eotaxin standard curve.
An eotaxin detection antibody was diluted 1:180 with reagent diluent to
100 ng/ml and 100 l was added to each well and incubated for 2 hours at
room temperature. The wells were subsequently washed as before. Strep-
tavidin conjugated horseradish peroxidase (HRP) was diluted 1:200 with
reagent diluent and 100 l was incubated per well for 20 minutes before
washing as previously described.
To enable colorimetric quantication of the eotaxin present in each well,
100 l of single solution TMB was added per well and incubated in the dark,
resulting in the development of a blue colour correlating to the concentration.
After 20 minutes the reaction was stopped by the addition of 50 l stop
solution (1 M H2SO4), converting the chromagen to yellow. The optical
density at 450 nm was immediately determined using a MultiScan plate
reader, with wavelength () correction at 570 nm.
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The detection limit of this assay is 15.6 pg/ml. The manufacturer tested
this assay for specicity using a panel of 82 cytokines and growth factors,
including IL-4, IL-6, IL-13 and TGF, and no signicant cross-reactivity or
interference was observed. Inter-assay variation was determined to be less
than 11.6%. 286
IL-6 ELISA
Media obtained from broblasts at baseline (post 24 hours of serum star-
vation) were analysed for levels of IL-6 using a Quantikine ELISA kit
according to the manufacturers instructions. The plates were pre-blocked
to prevent non-specic binding and pre-coated with a mouse monoclonal
primary antibody against IL-6. Conditioned media samples (diluted 1:6)
and IL-6 standards (reconstituted to 300 pg/ml and serial diluted to 3.12
pg/ml providing a 7 point standard curve as directed by the manufacturer
(Figure 2.4) were diluted in Calibrator Diluent RD5T (specic for cell
culture supernatant samples) and incubated in duplicate for 2 hours at room
temperature with rocking.
Figure 2.4: A typical IL-6 standard curve.
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The wells were washed 4 times with 300 l wash buer (provided as
a 25 buered surfactant with preservatives, diluted 1:25 immediately be-
fore use with distilled water) per well using a multichannel pipette before
addition of 200 l/well of the IL-6 conjugate (polyclonal antibody against
IL-6 conjugated to horseradish peroxidase). After 2 hours of incubation at
room temperature, the wells were again rinsed 4 times with washed buer
and incubated with 200 l substrate solution (equal parts Colour Reagent A
(stabilised hydrogen peroxide) and Colour Reagent B (stabilised tetramethyl-
benzidine (TMB) chromagen)) for 20 minutes at room temperature in the
dark before addition of 50 l stop solution (1 M H2SO4), which converts the
blue chromagen to yellow. The plates were tapped gently to ensure even
colour development and read at 450 nm with  correction at 570 nm, using
a MultiSkan plate reader.
The minimum detectable concentration for this assay is 3.12 pg/ml. No
cross-reactivity or interference was observed by the manufacturer with a panel
of 25 cytokines, growth factors and receptors including TGF, IL-4 and IL-6
soluble receptor. Inter-assay variation was determined to have a coecient
of variance of less than 3.7%. 287
2.3.12 Methylene Blue Growth Assay
Methylene blue is a cationic dye, which binds to negatively charged cell
constituents and can be used to determine cell number after treatment based
on measurement of cell biomass. 288 When conditioned media was collected
for assaying by ELISA the cells were xed in Formal Saline (4% (v/v)
formaldehyde in 0.9% (v/v) saline solution) for at least 30 minutes. Cells
were subsequently stained with methylene blue dye (see Appendix A for
details) for 30 minutes, and excess dye was carefully washed o with tap
water. The dye was eluted using 1:1 ethanol:HCl (see Appendix A for details)
and allowed to sit for 30 minutes to ensure full elution of the dye. The eluted
dye was read at 630 nm using a MultiSkan plate reader.
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To determine the number of cells present a standard curve was prepared
(Figure 2.5). Cells were serial diluted when seeded in triplicate in a 96 well
plate from 5105 cells/well in doubling dilutions to form a 12 point standard
curve. The cells were allowed at least 6 hours to attach to the plate before
being xed in formal saline and stained with methylene blue as above.
Figure 2.5: Methylene blue standard curve.
2.3.13 Statistics
Data collected were initially analysed by ANOVA, or a Kruskal-Wallis test
if data were non-parametric, to determine if there was any statistical signif-
icance. When appropriate Bonferroni or Dunn's post tests were included.
Statistical analyses on single comparisons were performed using a paired
Student's t-test or Wilcoxon Matched Pairs test if data were not normally
distributed. (GraphPad Prism v5.0c, GraphPad Software Inc., San Diego,
USA).
Results were considered signicant if p < 0:05 (? = p < 0:05, ?? = p <
0:01, ? ? ? = p < 0:001).
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Characterisation of the
IL-4 & IL-13 Receptors
3.1 Introduction & Objectives
Previous studies have demonstrated natural variation in the responsiveness
of HBFs from dierent subjects to IL-4 and IL-13. 281,289 It has been sug-
gested that this may be due to dierential expression of IL-13R2, which
has previously been shown to be upregulated in response to IL-13 treat-
ment. 165,245,253 However, the expression levels of the signalling receptors,
IL-4R, c and IL-13R1, may also play an important role in the regulation
of these cytokines. 290
Whilst these receptors have been studied individually there has been little
work investigating the expression and regulation of IL-4R, c, IL-13R1 and
IL-13R2 together. Where co-expression of more than one of these receptors
has been investigated, only limited numbers of subjects have been studied,
and thus it has not been possible to undertake comprehensive analysis of the
involvement of each of these receptors in the regulation of IL-4 and IL-13.
Therefore this chapter will undertake a systematic review of the dynamics
of each of the dierent IL-4 and IL-13 receptor subunits to determine if
it is upregulation of IL-13R2 expression alone that is responsible for the
dierences in responsiveness to IL-4 and IL-13 in bronchial broblasts, or in
combination with downregulation of the signalling receptors.
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The objectives of this study were to:
i) characterise the levels of each IL-4 and IL-13 receptor subunit expressed
by broblasts from healthy and asthmatic subjects,
ii) determine if the expression is aected by treatment with various cy-
tokines and
iii) establish whether dierences between subjects correlate with functional
responsiveness of HBFs to IL-4 or IL-13.
3.2 Results
3.2.1 Characterisation of the Responsiveness of Fibro-
blasts to IL-4 & IL-13
Fibroblasts are known to produce eotaxin, a chemoattractant for eosinophils
in response to both IL-4 and IL-13. 161,184,185 This can therefore be used as
a functional readout for the responsiveness of HBFs to these cytokines. To
conrm this, bronchial broblasts obtained by outgrowth of bronchial biop-
sies from healthy and asthmatic volunteers (for clinical details see Tables 2.1
and 2.2) were initially treated with varying concentrations of IL-4 or IL-
13 for 24 hours. The conditioned media was collected and analysed for
levels of eotaxin production by ELISA. The cells were xed and the level
of eotaxin production was normalised to cell number, which was determined
by methylene blue assay.
In the case of both IL-4 (Figure 3.1a) and IL-13 (Figure 3.1b), a dose
dependant increase was observed in eotaxin production, with 10 ng/ml of
either treatment resulting in the largest induction of eotaxin (p < 0:001).
Although statistical signicance was also observed at 1 ng/ml (p < 0:01),
after challenge with 10 ng/ml of either IL-4 or IL-13 a greater dierence
was observed between subjects, where some produced much larger quantities
of eotaxin than others. Whilst there was considerable variation in eotaxin
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Figure 3.1: Induction of eotaxin by broblasts in response to IL-4 or IL-13
treatment. HBFs were grown until 95% conuent, before 24 hours serum
starvation. Cells were subsequently incubated in the presence of between 0 and
10 ng/ml IL-4 or IL-13 for 24 hours and eotaxin production was analysed by
ELISA of the conditioned media. Eotaxin levels were normalised to cell number,
determined by methylene blue assay. n = 6 healthy and 5 asthmatic subjects.
? ? = p < 0:01 ? ? ? = p < 0:001.
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production by the dierent subjects, there was no dierence observed between
broblasts obtained from asthmatics versus healthy controls.
Previous work by Andrews, Nasir et al. has also demonstrated that
addition of a pretreatment step with IL-13 during the initial serum starvation
stage, causes desensitisation of the HBFs to both IL-13 and IL-4 and results in
a decrease in the production of eotaxin and STAT6 phosphorylation normally
observed in response to both cytokines. 165 To conrm this, and to see if this
also occurs if the cells are pretreated with IL-4, HBFs were serum starved in
the presence or absence of 10 ng/ml IL-4 or IL-13 for 24 hours. The media
were then exchanged for 3 hours to ensure all traces of the pretreatment
were removed (washout period), before the subsequent treatment with either
IL-4 or IL-13 for 24 hours. The supernatant was collected and analysed for
changes in eotaxin production by ELISA and the cell number was determined
by methylene blue as previously described.
As observed in Figure 3.1, treatment with either IL-4 or IL-13 resulted
in a signicant increase in production of eotaxin (p < 0:01). However, if the
cells were exposed to a pretreatment step using either IL-13 or IL-4 during
the initial serum starvation period eotaxin production was signicantly
attenuated (p < 0:05) (Figure 3.2). This suggests that longer term exposure
with either cytokine results in the implementation of a regulatory pathway,
which desensitises the cells to the ligand preventing an uncontrolled response.
It has previously been suggested that both the variation observed between
subjects at baseline and this phenomenon of reduced responsiveness after
pretreatment is linked to the IL-13R2 expression levels on the cells. 165
3.2.2 The Role of IL-13R2 in Reducing Responsive-
ness to IL-4 & IL-13
To determine if the levels of this receptor could be responsible for these eects
the cells were initially characterised for baseline levels of IL-13R2 by ow
cytometry (representative FACS plots for high and low expressers, compared
to a relevant isotype control shown in Figure 3.3a). HBFs from these known
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Figure 3.2: The eect of IL-4 or IL-13 pretreatment on broblast responsiveness.
HBFs were seeded in 12 well plates at a density of 5  104 cells/well and grown
until 95% conuent, before 24 hours serum starvation in the presence or absence
of 10 ng/ml IL-4 or IL-13. Cells were subsequently exposed to a 3 hour washout
period with fresh media before a further 24 hour incubation in the presence or
absence of 10 ng/ml IL-4 or IL-13 for 24 hours. Eotaxin production was analysed
by ELISA of the conditioned media and levels were normalised to cell number,
determined by methylene blue assay. n = 4 healthy and 3 asthmatic subjects.
Statistical signicance was determined using a Friedman test, with Dunns post-
test. ? = p < 0:05 ? ? = p < 0:01.
high or low basal expressers of IL-13R2 were serum starved for 24 hours in
the presence or absence of 10 ng/ml IL-4 or IL-13. The cells were, as before,
exposed to a 3 hour washout period prior to treatment for a further 24 hours
with fresh media containing either IL-4, IL-13 or no cytokine. Eotaxin levels
and cell number were determined as previously described.
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Figure 3.3: The eect of basal IL-13R2 expression on eotaxin production.
Baseline levels of IL-13R2 surface expression were determined by ow cytometry.
Low and high basal expressers of IL-13R2 were selected and grown until 95%
conuent, before serum starvation for 24 hours in the presence or absence of
10 ng/ml IL-4 or IL-13. The media was exchanged for 3 hours and cells were
subsequently incubated with 10 ng/ml IL-4, IL-13 or media for 24 hours. Eotaxin
production was analysed by ELISA and was normalised to cell number using a
methylene blue assay. a) A typical FACS plot (of at least 4 subjects) showing
IL-13R2 staining of untreated cells from a high or low expresser of IL-13R2
in comparison to a FITC-labelled isotype control. b) Eotaxin release by low
expressers of IL-13R2 in response to IL-4 or IL-13 was greater than release by
high expressers and was suppressed by pretreatment with either cytokine. n = 4
high and 4 low expressers of IL-13R2. Data expressed as median +=  IQR.
? ? ? = p < 0:001.
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In this instance the variation in responsiveness to IL-4 or IL-13 was
negatively related to the surface expression levels of IL-13R2 (Figure 3.3b),
where low expressers of IL-13R2 produced high levels of eotaxin in response
to treatment, whilst high basal expressers of IL-13R2 only released marginal
amounts of eotaxin into the media (Figure 3.3b). The low basal expressers of
IL-13R2 demonstrated approximately a 65 to 75 fold increase in eotaxin
production in response to IL-13 and IL-4 respectively in the absence of
any pretreatment, compared with 9 to 13 fold increase observed from cells
naturally expressing high baseline levels of IL-13R2. This appears to
suggest a functional response to IL-13R2 surface expression levels.
When the broblasts were pretreated with either IL-4 or IL-13, the
production of eotaxin signicantly decreased in the low basal expressers
(p < 0:001). The high basal expressers of IL-13R2, on the other hand,
demonstrated a trend towards a decrease in the levels of eotaxin produced
after pretreatment in comparison to those without this pretreatment step,
however this did not achieve statistical signicance. In this instance it may be
that, if IL-13R2 levels are responsible for these dierences, the existing high
expression of surface IL-13R2 is already suppressing eotaxin production and
therefore the addition of a pretreatment step to desensitise the HBFs to these
cytokines has little impact. Both IL-4 and IL-13 had similar eects, both in
the level of induction of eotaxin, and the degree of attenuation of this due to
pretreatment.
As the desensitisation of the cells to IL-4 or IL-13 appeared to be related
to IL-13R2 it was necessary to conrm that this eect was due to the
regulatory activity of this receptor.
3.2.3 Characterisation of the Levels of IL-13R2
Expression in Dierent Subjects
Kinetic experiments were consequently undertaken to determine whether
the receptor levels were aected by IL-4 or IL-13 treatment. As previous
data have demonstrated that 24 hours of treatment with IL-13 resulted in
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increased surface IL-13R2 levels, which, in turn, was able to inhibit both
IL-4 and IL-13 induced eotaxin production by HBFs, 165 initial experiments
focussed on IL-13R2. HBFs were serum starved for 24 hours prior to
treatment with 10 ng/ml IL-4 or IL-13 for 0, 4, 8, 24 and 48 hours before
assessment of IL-13R2 mRNA levels by RT-qPCR.
All the subjects studied demonstrated more than a 2-fold increase in
IL-13R2 mRNA in response to both IL-4 and IL-13 treatment after 4 hours
(Figure 3.4). This increase became signicant in response to either treatment
after 8 hours (p < 0:001) and continued to rise over a 48 hour period. Whilst
the levels of IL-13R2 mRNA produced increased in all subjects, at the later
timepoints the increase observed was markedly variable between subjects,
which could be due to dierences in regulation of IL-13R2 gene expression
between subjects aecting the levels of mRNA produced, and may aect the
amount of protein subsequently produced.
These initial analyses, however, only determined changes in the level of
mRNA expression due to treatment and not dierences in surface expression
of IL-13R2 between subjects. It is this surface expression level that is
important as the increase in mRNA observed may not translate to a change
at the protein level. Therefore, to establish whether the surface expression
levels of IL-13R2 are aected by treatment, HBFs obtained from healthy
and asthmatic volunteers were serum starved for 24 hours in the presence or
absence of 10 ng/ml IL-4 or IL-13 before characterisation of surface receptor
levels by ow cytometry.
A signicant shift in uorescence was observed due to the specic detec-
tion of surface IL-13R2 at baseline on the HBFs in comparison to a matched
isotype control (Figure 3.5a and b). As with the mRNA, IL-13R2 surface
expression signicantly increased when HBFs were treated with either IL-4
(Figure 3.5a and c) or IL-13 (Figure 3.5b and d) (p < 0:001). There was no
overall dierence observed between HBFs obtained from asthmatic or healthy
volunteers (Figure 3.5c and d), either at baseline or with treatment.
Whilst all subjects exhibited specic staining at baseline, the degree of
staining varied greatly between subjects. There was also substantial variation
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Figure 3.4: Induction of IL-13R2 mRNA by IL-4 and IL-13. HBFs were grown
to 95% conuence and were serum starved for 24 hours prior to treatment
with 10 ng/ml a) IL-4 or b) IL-13 for between 0 (T0) and 48 hours. RNA
was extracted using the Trizol method. RT-qPCR analysis compared IL-13R2
mRNA levels to the geometric mean of two housekeeping genes (Ubiquitin C and
Phospholipase A2). Data have been normalised to the average CT of IL-13R2
in the unstimulated controls. Symbols represent individual volunteers (7 healthy
and 7 asthmatic subjects) and are expressed as median, interquartile range and
standard Tukey whiskers. Statistical signicance was determined using a Friedman
test, with Dunns post-test. ? ? ? = p < 0:001.
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Figure 3.5: The eect of IL-4 or IL-13 treatment on IL-13R2 surface expression
on broblasts from healthy and asthmatic subjects. HBFs were serum starved for
24 hours in the presence or absence of 10 ng/ml IL-4 or IL-13. 1105 cells/subject
were incubated with either an antibody against IL-13R2 or an appropriate isotype
control before incubation with a FITC conjugated secondary antibody and analysis
on a FACSAria. A typical FACS plot (of at least 18 subjects) showing the staining
of untreated cells (black), in comparison to an isotype (grey) and the shift caused
by (a) IL-4 or (b) IL-13 pretreatment. Challenge with (c) IL-4 or (d) IL-13 caused
a signicant increase in IL-13R2 surface expression. The magnitude of increase
varied between subjects but no dierence was found between healthy controls
compared with asthmatic subjects. Data were normalised to an isotype control
and expressed as specic mean uorescent intensity (SMFI). n = 8 healthy and
10 asthmatic subjects. Statistical analysis was determined using Friedman test,
with Dunns post-test. ? ? ? = p < 0:001.
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between subjects in the level of increase of IL-13R2 surface expression in
response to IL-4 or IL-13 treatment (Figure 3.5c and d), with HBFs from
some subjects expressing more than twice as much IL-13R2 as at baseline,
whilst others only marginally increased their surface expression levels. The
level of increase in surface IL-13R2 expression was generally consistent for
each subject in response to both IL-4 and IL-13. These data are also in line
with the mRNA expression level of IL-13R2 as an increase in mRNA at
8 hours could lead to an increase in surface expression by 24 hours.
The dierential response by subjects with similar baseline levels of
IL-13R2 to both IL-4/13 cytokine stimulation, suggests that high IL-13R2
at baseline may not be sucient to prevent a response. This could be due to
a number of factors, such as the degree of signalling receptor expression or
their intracellular signalling components, or the storage of diering quantities
of IL-13R2 in intracellular pools.
Intracellular Pools of IL-13R2
It has previously been observed that in epithelial cells IL-13R2 is mainly
intracellular and that this can be mobilised to the surface by IFN. 251 It was
therefore of interest to conrm whether broblasts also increase their surface
expression of IL-13R2 in response to IFN and subsequently if this is due to
the presence of intracellular pools or if de novo protein synthesis is required.
Fibroblasts were serum starved for 24 hours before treatment with varying
concentrations of IFN for up to 24 hours. Primary bronchial epithelial cells
provided by Drs Swindle and Blume were also included as a positive control.
The surface expression of IL-13R2 was determined by ow cytometry as
previously described.
Treatment of broblasts with 1 or 10 ng/ml IFN for either 2 or 8 hours
was insucient to increase the expression of IL-13R2 on the cell surface
(Figure 3.6a). Fibroblast IL-13R2 surface expression did however increase
in response to IFN after 24 hours of stimulation. At this timepoint both
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1 ng/ml and 10 ng/ml IFN treatment resulted in a signicant increase in
surface expression of IL-13R2 (p < 0:01 and p < 0:001 respectively).
In comparison, the PBECs IL-13R2 surface expression increased after
2 hours (Figure 3.6b), reaching signicance after 8 hours with both doses
of IFN tested (p < 0:001 and p < 0:01 respectively). The fact that the
epithelial cells demonstrated much faster kinetics than the HBFs with regard
to upregulation of surface IL-13R2 suggests that the regulation of expression
of IL-13R2 may dier between these cells.
Experiments were therefore undertaken to characterise the presence of
intracellular pools of IL-13R2 in these dierent cell types. Initial attempts
to study the presence of pools of IL-13R2 using cell permeabilisation were
unsuccessful due to extremely high levels of non-specic staining observed
with both the IL-13R2 antibody and the isotype control. Instead, an
alternative approach for determining whether intracellular stores of IL-13R2
existed in broblasts was required. To this end cycloheximide (CHX) was
used as this suppresses de novo protein synthesis, 291 and can thus indicate
if pools of IL-13R2 exist within the cell.
Fibroblasts were treated with either IFN or IL-13 for up to 24 hours,
with some of the cells also pretreated with 50 g/ml CHX for 30 minutes
immediately prior to addition of IFN or IL-13. Primary bronchial epithelial
cells were again included as a positive control for the presence of intracellular
pools of IL-13R2 in this assay. The surface expression of IL-13R2 was
determined by ow cytometry.
When the cells were pretreated with CHX (Figure 3.6c) the increase
in surface expression of IL-13R2 previously observed in response to both
IFN and IL-13 was attenuated, suggesting that in broblasts de novo
protein synthesis is required for this increased expression. In comparison
the epithelial cells included as a positive control (Figure 3.6d) were able to
upregulate surface expression levels of IL-13R2 in response to IFN and
IL-13 both in the presence and absence of CHX pretreatment, indicating
the existence of intracellular pools of IL-13R2 in these cells, which are not
found in broblasts.
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Figure 3.6: Characterisation of IL-13R2 intracellular pools in bronchial brob-
lasts and epithelial cells. Fibroblasts were serum starved for 24 hours before
treatment with a) 1 or 10 ng/ml IFN for up to 24 hours or c) 10 ng/ml IFN
or IL-13. Some cells were also treated with 50 g/ml cycloheximide (CHX) for 30
minutes prior to cytokine stimulation to block de novo protein synthesis. Epithelial
cells were included as a positive control (b) and d)). Cells were incubated with
an antibody against IL-13R2 or an isotype control and analysed on a FACSAria.
Data were normalised to the isotype and the specic mean uorescent intensity
(SMFI). Fibroblasts n = 4 healthy and 5 asthmatic subjects. Epithelial cells n =
3 healthy subjects. Data are presented as median with standard Tukey whiskers.
? ? = p < 0:01 and ? ? ? = p < 0:001.
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3.2.4 Expression of IL-4R, IL-13R1 & c by HBFs
As intracellular pools of IL-13R2 were not found in primary human
bronchial broblasts, it was thought that the variation in responsiveness
by subjects expressing similar baseline surface levels of IL-13R2 observed
in Figure 3.5 may instead be due to dierential expression of the IL-4 and
IL-13 signalling receptor subunits.
IL-4R is an essential component of both the type I and type II receptors.
Whilst the c subunit of the type I receptor can only bind IL-4, both IL-4R
and IL-13R1, which constitute the type II signalling receptor, are able to
bind both IL-4 and IL-13 respectively. A recent paper investigating human
and mouse monocytes has suggested that levels of IL-4R and IL-13R1 may
also be involved in regulating sensitivity to IL-4 and IL-13. 290 Therefore, the
mRNA samples obtained earlier from HBFs treated with IL-4 or IL-13 for
up to 48 hours were analysed by RT-qPCR for levels of IL-13R1, IL-4R
and c, to determine if these also varied between patients with IL-4 or IL-13
treatment.
Both IL-13R1 and IL-4R mRNA were detected in every subject,
however the expression levels of neither IL-13R1 (Figure 3.7a and b) nor
IL-4R (Figure 3.8a and b) were aected by either IL-4 or IL-13 treatment.
c mRNA, on the other hand, was undetected in any of the samples,
regardless of IL-4 or IL-13 treatment (data not shown). In this case the
validity of the assay was conrmed using a positive control (BAL cell cDNA
from healthy and asthmatic subjects provided by Dr Karl Staples), where
mRNA expression was observed.
As with the IL-13R2 data, it was important to see how these obser-
vations made at the mRNA level compared to the surface expression of
the receptor subunits. Therefore, the surface expression levels of the IL-4
and IL-13 signalling receptors on primary human bronchial broblasts were
analysed by ow cytometry, following the same methods as before.
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Figure 3.7: The impact of IL-4 and IL-13 on IL-13R1 mRNA expression by
bronchial broblasts. HBFs were serum starved for 24 hours before treatment
with 10 ng/ml a) IL-4 or b) IL-13 for 0 (T0), 4, 8, 24 or 48 hours. RNA was
extracted using the Trizol method. PCR analysis compared IL-13R1 mRNA
levels to the geometric mean of two housekeeping genes (UBC/A2). Data have
been normalised to the average CT of IL-13R1 in the unstimulated controls.
n = 4 healthy and 3 asthmatic subjects. Data are presented as median with
standard Tukey whiskers.
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Figure 3.8: Characterisation of IL-4R mRNA levels in response to treatment
with IL-4 or IL-13. HBFs were serum starved for 24 hours prior to challenge with
10 ng/ml a) IL-4 or b) IL-13 for 0 (T0) to 48 hours. RNA was extracted using
the Trizol method. PCR analysis compared IL-4R mRNA levels to the geometric
mean of two housekeeping genes (UBC/A2). Data have been normalised to the
average CT of IL-4R in the unstimulated controls. n = 7 healthy and 7
asthmatic subjects. Data are presented as median with standard Tukey whiskers.
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Substantial surface expression of IL-13R1 was detected in HBFs from
every subject and, as with the mRNA, was unaected by treatment with
IL-13 (Figure 3.9). The levels of the receptor were not signicantly dierent
between healthy or asthmatic subjects, however one subject demonstrated
expression levels approximately 2 4-fold higher than any other. This result
was conrmed by repeating the experiment with the same end-result. This
subject did not demonstrate signicantly dierent levels of the other IL-4 or
IL-13 receptors in comparison to other subjects and responded to IL-4 and
IL-13 in a similar manner to cells from subjects with similar levels of the
other IL-4 and IL-13 receptors suggesting that this high surface expression
of IL-13R1 did not elicit a signicant eect on the responsiveness of this
subject to either IL-4 or IL-13.
Similarly to the mRNA data, no surface expression of c was detected
by ow cytometry (Figure 3.10). These data were conrmed to ensure
there was not a problem with the antibody by analysing surface expression
of PBECs, which are known to express this subunit. 80 In this instance
5 g of the antibody demonstrated signicant surface expression. For the
HBFs up to 10 g of antibody was tested on cells from 8 subjects with no
expression detected at any concentration. These data imply that there is no
c expression by broblasts, correlating with previous data suggesting c is
only expressed by haematopoietic cells. 233
IL-4R surface expression was observed in every subject at baseline,
however, this was found to signicantly decrease by approximately 50 60%
after 24 hours of treatment with either IL-4 (Figure 3.11a) (p < 0:001)
or IL-13 (Figure 3.11b) (p < 0:001). To determine if this decrease was
specic, HBFs were also treated with IFN before analysis of IL-4R levels.
In this instance no signicant dierence in surface expression was observed
between the treated and the untreated cells (Figure 3.11c). There was also
no dierence observed between disease phenotypes, either at baseline or in
response to treatment, although expression levels did vary between subjects.
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Figure 3.9: Determination of IL-13R1 surface expression on broblasts and the
eects of IL-13 treatment. HBFs were seeded in 12 well plates and grown until
95% conuent, before 24 hours serum starvation in the presence or absence or
10 ng/ml IL-13. 1105 cells/subject were incubated with either an APC labelled
antibody against IL-13R1 or an APC-IgG2B isotype control before analysis on
a FACSAria. a) Histogram (typical of 8 subjects) demonstrating specic staining
with no shift due to IL-13 treatment compared with unstained and isotype controls.
b) No variation was observed due to treatment with IL-13. Data were normalised
to an isotype control and expressed as specic mean uorescent intensity (SMFI)
n = 5 healthy and 4 asthmatic subjects. Data are median, interquartile range
with standard Tukey whiskers.
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Figure 3.10: c surface expression on broblasts from healthy and asthmatic
subjects. HBFs were grown in 12 well plates until 95% conuent, before 24 hours
serum starvation in the presence or absence of 10 ng/ml IL-13. 1105 cells/subject
were incubated with an antibody against c or IgG2A isotype control conjugated
to Alexauor-405 and analysed on a FACSAria. No specic staining for c was
observed in any of the 8 subjects analysed.
The expression levels of IL-4R were found to vary between patients,
however this was not found to correlate with either the baseline IL-13R2
expression, or the level of increased expression previously observed.
To further characterise this eect, HBFs were treated for 24 hours with
varying doses of IL-4, before analysis of IL-4R levels by ow cytometry.
The reduction in IL-4R surface expression due to challenge with IL-4 was
found to behave in a dose dependent manner (Figure 3.12a), although this
appeared to plateau after 1 ng/ml IL-4 treatment (p < 0:01), which had a
similar eect to 10 ng/ml IL-4 (p < 0:01).
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Figure 3.12: Dose and kinetic characterisation of IL-4R internalisation by HBFs.
HBFs were grown until 95% conuent, before 24 hours serum starvation. Cells
were treated with a) 0 to 10 ng/ml IL-4 for 24 hours or b) 10 ng/ml IL-4, IL-13
or serum-free media for up to 48 hours. 1 105 cells/subject were incubated with
either an APC labelled antibody against IL-4R or an APC-IgG2A isotype control
before analysis on a FACSAria. Data were normalised to an isotype control and
expressed as a) specic mean uorescent intensity (SMFI) b) % change in SMFI
n = 4 healthy and 2 asthmatic subjects. Data are median with interquartile
range. ?? = p < 0:01 and ? ? ? = p < 0:001.
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Downregulation of receptors following ligand stimulation is a well char-
acterised phenomenon. To determine the kinetics of the reduction of IL-4R
surface expression the cells were treated with 10 ng/ml IL-4 or IL-13 for
between 1 and 48 hours and analysed by ow cytometry as before. In the
case of both IL-4 and IL-13 treatment, a signicant decrease occurred within
1 hour (p < 0:01 and p < 0:001 respectively), and the surface expression levels
remained low over a 48 hour period (Figure 3.12b). At every timepoint, IL-4
appeared to cause a greater reduction (a 50   60% decrease) in the surface
expression of IL-4R in comparison to IL-13 (a 40 50% reduction), however
this dierence was not found to be statistically signicant.
In the experiments undertaken previously in this chapter HBFs were
sometimes exposed to a pretreatment step with either IL-4 or IL-13 with
a consequent desensitisation of the cells to these ligands. As challenge with
either cytokine signicantly decreased expression of IL-4R, it was necessary
to determine if this diminished responsiveness observed after pretreatment
could be attributed to the reduction in IL-4R surface expression as well as
the increase in IL-13R2 levels. In the instances where a pretreatment step
was included, the cells were always given a 3 hour washout period between
treatments to ensure removal of any excess pretreatment that may have been
left behind. Therefore, at the 24 hour timepoint, half of the cells were also
exposed to a 3 hour washout period to determine if this decrease in surface
expression of IL-4R could be reversed by exchanging the media.
As before, after either IL-4 or IL-13 treatment, IL-4R surface expression
was reduced by approximately 50% (Figure 3.13a), with the IL-4 treatment
appearing to cause a greater reduction than the IL-13. When the washout
step was included, however, the IL-13 treated HBFs were able to fully recover
their surface expression levels of IL-4R to their untreated state. Whilst
a similar response was observed for IL-4 (p < 0:001), the levels were still
signicantly lower than those observed on cells that had not been exposed
to any cytokine treatment (p < 0:001). The dierences observed here may
be due to the diering binding anities that these cytokines have for the
IL-4R subunit, which may aect the internalisation of this receptor.
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Figure 3.13: The eect of ligand removal on IL-4R and IL-13R2 surface expres-
sion. HBFs were grown until 95% conuent, before 24 hours serum starvation
in the presence or absence or 10 ng/ml IL-4 or IL-13. Half of the cells were
subsequently incubated with fresh media for 3 hours. 1  105 cells/subject were
incubated with either antibodies against IL-4R and IL-13R2 or relevant isotype
controls before analysis on a FACSAria. IL-4R levels signicantly decreased in
response to IL-4 or IL-13 treatment for 24 hours, whilst IL-13R2 levels signi-
cantly increased. Levels of IL-4R were restored during the 3 hour washout period
after IL-4 or IL-13 treatment respectively but IL-13R2 levels were unaected.
Data were normalised to an isotype control and expressed as percentage change
of specic mean uorescent intensity (SMFI) n = 8 healthy and 8 asthmatic
subjects. Data are median +=  IQR. ? ? ? = p < 0:001.
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As the expression of IL-4R mostly recovers within this washout period
these data suggest that the downregulation of IL-4R is unlikely to be the
cause of the dierences in responsiveness to IL-4 and IL-13 observed after
pretreatment with either cytokine.
As the levels of IL-13R2 have previously been shown to increase in
response to IL-4 or IL-13 challenge, the broblasts were also analysed for
changes in levels of IL-13R2 surface expression with and without a washout
period. As demonstrated in Figure 3.5, when treated with either IL-4 or
IL-13 the surface expression levels of IL-13R2 signicantly increased (Fig-
ure 3.13b). In contrast to the changes observed with the IL-4R expression,
the washout period did not signicantly aect either the baseline surface
expression of IL-13R2 or the level of increase observed in response to either
IL-4 or IL-13 challenge, with IL-13R2 expression remaining high in both
instances.
3.2.5 Conrmation of IL-13R2 Involvement in the
Attenuation of Responsiveness to Both IL-4 &
IL-13
At this stage, the attenuation of responsiveness observed after HBFs were
pretreated with either IL-4 or IL-13 could not be linked directly to IL-13R2.
Although a link has been observed between IL-13R2 surface expression and
eotaxin production, and pretreatment with either IL-4 or IL-13 was found
to increase the levels of IL-13R2 it may be that pretreatment also induces
other eects, such as an increase in Suppressor of Cytokine Signalling (SOCS)
protein production. It was therefore necessary to undertake an experiment to
determine whether this was a specic consequence of the IL-13R2 expression
level, as previously suggested by Andrews, Nasir et al.. 165
To investigate the involvement of IL-13R2 in the regulation of both IL-13
and IL-4, HBFs were serum starved for 24 hours in the presence or absence of
IL-4 or IL-13 followed by a 3 hour washout period and treatment for 24 hours
in the presence or absence of the two cytokines. In this experiment some of
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the cells were exposed to either a neutralising antibody against the receptor
(IL-13Ra2 NAb) or a relevant isotype control. The conditioned media were
collected for analysis of eotaxin production by ELISA, which was normalised
to the cell number determined by methylene blue assay.
As before, HBFs produced eotaxin in response to both IL-4 and IL-13 (p <
0:001) (Figure 3.14a and d) and, as previously reported this was signicantly
reduced with the addition or either IL-13 or IL-4 pretreatment (p < 0:05)
(Figure 3.14a and d). Addition of an IL-13R2 NAb to cells restored both
the IL-13 and IL-4 responses (Figure 3.14b and e), demonstrating that IL-
13R2 negatively regulates IL-13, as previously described. 165 The fact that
this was also observed with IL-4 challenge (Figure 3.14e), indicates that
although IL-13R2 is unable to bind IL-4 directly, 165 it is able to negatively
regulate this cytokine's actions. In both instances the isotype control had
no eect on eotaxin production (Figure 3.14c and f ) and no dierence was
observed between using either IL-4 or IL-13 in the pretreatment step.
Fibroblasts have also previously been shown to produce Interleukin 6
(IL-6) in response to IL-13, 292 and this could be used as another measure
of responsiveness to conrm these results. It was therefore of interest to
determine initially if both IL-4 and IL-13 could induce HBFs from asthmatic
and healthy patients to release IL-6, and subsequently establish whether
pretreatment with IL-13 and the use of an IL-13R2 NAb caused the same
eects as observed with eotaxin production in Figure 3.14.
All the HBFs analysed produced IL-6 at baseline and this production was
signicantly increased by stimulation with either IL-4 or IL-13 for 24 hours
(p < 0:001), with both cytokines inducing similar eects (Figure 3.15).
Mirroring what was observed with eotaxin, pretreatment of the cells with
IL-13 did not signicantly aect the baseline production of IL-6 by the
broblasts but did reduce the responsiveness of the cells to both IL-4 and
IL-13. Again, as previously shown in Figure 3.14, addition of a neutralising
antibody against IL-13R2 was able to restore the responsiveness of the cells
to both IL-4 and IL-13.
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Figure 3.15: The eect of an IL-4 or IL-13 pretreatment step on IL-6 production,
and the consequences of treatment with an IL-13R2 NAb. HBFs were grown
in 12 well plates until 95% conuent and serum starved for 24 hours in the
presence or absence of 10 ng/ml IL-4 or IL-13. Cells were washed out with fresh
media for 3 hours during which half the cells were incubated with an IL-13R2
NAb or relevant isotype control. HBFs were incubated for a further 24 hours in the
presence or absence of 10 ng/ml IL-4 or IL-13  IL-13R2 NAb where indicated.
IL-6 production was analysed by ELISA of the conditioned media. n = 3 healthy
and 4 asthmatic subjects. Data expressed as median with IQR and Tukey whiskers.
? ? ? = p < 0:001.
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3.2.6 The Eect of Neutralising IL-13R2 at Baseline
Whist these experiments had focussed on the eects of pretreatment with
IL-4 or IL-13 to upregulate the surface expression levels of IL-13R2, it was
also important to determine the eect the IL-13R2 NAb at baseline. In
particular it was of interest to establish whether a naturally high expresser
of IL-13R2 could be made to behave like a naturally low expresser using this
antibody to neutralising the receptor. To study this, HBFs from naturally
low or high expressers of IL-13R2 were selected. The cells were serum
starved for 24 hours in the absence of either cytokine and pretreated for
3 hours with either the IL-13R2 NAb or an isotype control before subsequent
treatment with IL-4 or IL-13. The conditioned media were analysed for
changes in eotaxin production, which was again normalised to cell number
as determined by methylene blue assay.
As observed in Figure 3.3, in the absence of the IL-13R2 NAb the
naturally low expressers of IL-13R2 produced signicantly more eotaxin
in response to both IL-4 and IL-13 than the naturally high expressers
(Figure 3.16a) (p < 0:001). However, addition of the IL-13R2 NAb
increased the cells responsiveness to both cytokines (p < 0:001). This eect
was observed with both the low and high expressers of IL-13R2, although
the NAb appeared to have a greater eect in the naturally higher baseline
expressers.
As the dose initially studied did not completely restore the responsiveness
to IL-4 and IL-13 to the levels observed in the naturally low expressers,
a subsequent dose response of the antibody was performed. Here it was
found that the higher concentrations of antibody were able to further reduce
the ecacy of the IL-13R2 on the surface of the naturally high IL-13R2
expressers, resulting in greater release of eotaxin in response to treatment
with IL-4 and IL-13, which was similar to that observed with naturally low
expressers of IL-13R2.
These data therefore demonstrate a specic role for IL-13R2 in the
regulation of both IL-4 and IL-13.
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Figure 3.16: The eect of an IL-13R2 NAb on the responsiveness of HBFs to
IL-4 and IL-13 at baseline. HBFs from known high or low expressers of IL-
13R2 were seeded in 12 well plates and grown until 95% conuent, before
24 hours serum starvation. Cells were treated with 1 g/ml IL-13R2 NAb for
3 hours before subsequent treatment with 10 ng/ml of either IL-4 or IL-13 for
24 hours. Conditioned media were collected and cells were xed for quantitation
of cell number by methylene blue assay. Eotaxin production was determined by
ELISA and normalised to cell number. n = 4 low basal expressers and 4 high basal
expressers of IL-13R2. Data are median with interquartile range. ?? = p < 0:01
and ? ? ? = p < 0:001.
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3.3 Discussion
Dierent subjects have previously been shown to vary in their responsiveness
to IL-4 and IL-13. 289 This has been suggested to be related to the surface
expression levels of IL-13R2, which acts as a negative regulator of these cy-
tokines. 165,281,289 It was, therefore, hypothesised that the variation in surface
expression levels of IL-13R2 would lead to dierences in responsiveness to
IL-4 and IL-13 in human bronchial broblasts. It was also hypothesised that
the surface expression levels of IL-13R2 would increase in response to IL-4
and IL-13, and that this may be due to a regulatory loop.
Initial experiments investigated the production of eotaxin by HBFs from
healthy and asthmatic subjects. All of the broblasts studied produced
eotaxin in a dose dependent manner in response to challenge with either
IL-4 or IL-13 (Figure 3.1). The amount of eotaxin produced in response
to either IL-4 or IL-13 signicantly varied between subjects, although was
not found to be related to disease phenotype, and was most noticeable when
treated with 10 ng/ml of either cytokine.
The responsiveness of the cells to both IL-4 and IL-13 was reduced
when a pretreatment step with either cytokine was added, demonstrating
the presence of a regulatory mechanism to prevent uncontrolled signalling
(Figure 3.2). The mechanism previously proposed for this is the expression
of IL-13R2, 165,281,289 and it was found that eotaxin production in response
to IL-4 and IL-13 was related to the surface expression levels of this receptor,
with high expressers of IL-13R2 producing less eotaxin than low expressers
(Figure 3.3). The eect of pretreatment was also most noticeable with
subjects which naturally expressed lower levels of IL-13R2 at baseline,
where a signicant attenuation was observed, which was not the case in
the high baseline expressers.
Experiments were subsequently undertaken to determine the eect that
IL-13 and IL-4 had on IL-13R2 expression levels to determine whether
this was the only mechanism by which the pretreatment step reduced
the sensitivity of these cells to both IL-4 and IL-13. IL-13R2 mRNA
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signicantly increased in response to both IL-4 and IL-13 treatment over
time (Figure 3.4). A corresponding signicant increase in IL-13R2 surface
protein levels was also observed after 24 hours of treatment with either IL-
4 or IL-13 (Figure 3.5). However, the basal expression and the extent of
increase in IL-13R2 levels due to treatment varied dramatically between
subjects. This is consistent with the variation observed in the eotaxin
produced in response to IL-4 and IL-13, as well as previous reports of
varied responsiveness to these cytokines by dierent subjects. 289 There was
no variation due to disease phenotype, with no signicant dierence found
between cells obtained from healthy controls or asthmatic patients. As IL-
13 is also implicated in atopy 137{139,147 it is also important to note that
the asthmatic patients used in these studies were atopic, whilst the healthy
controls were non-atopic. Whilst it is not possible to rule out dierences
due to atopic status without studying atopic non-asthmatics, as the asthma
phenotype may be having other underlying eects, it appears as if the levels
of IL-13R2 at baseline do not correlate to an atopic phenotype.
The presence of intracellular pools of IL-13R2 have been observed in
various cell types, in particular in epithelial cells, 251,293,294 with reports
showing that these can be mobilised in response to challenge with IFN. 251
In this study whilst IFN was able to upregulate the surface expression levels
of IL-13R2 in both HBFs and PBECs, it was only in the latter that this
was found to be due to the presence of intracellular stores of IL-13R2.
Whilst there have been some reports of intracellular staining of IL-13R2
in broblasts these data are not conclusive. One study by Konstantinidis,
Puddicombe et al. 252 looked at a range of cell types, including primary
bronchial epithelial cells and broblasts, and, contrary to other reports, were
unable to detect any extracellular IL-13R2. However, they did observe
intracellular staining in each of the dierent cell types analysed. These data
however contradict other existing publications, which have demonstrated
extracellular staining on many of these cell types including epithelial cells and
broblasts, which has also been observed in this chapter. In this study the
localisation of IL-13R2 was determined by immunohistochemistry and ow
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cytometry, however the only comparative staining showing the extracellular
as well as intracellular IL-13R2 included in this study was for epithelial cells,
where it is widely agreed that intracellular pools of IL-13R2 are present.
This study also only analysed a small patient group (n = 3 asthmatic
patients), rather than the systematic analysis of cells obtained from both
healthy controls and asthmatic subjects presented herein, so the lack of
extracellular staining on the epithelial cells could simply be due to these
subjects being low expressers of IL-13R2. In the work presented within this
chapter broblasts from a total of 9 subjects were analysed for the ability
to rapidly mobilise IL-13R2 from intracellular stores after treatment with
IFN. No increase in surface expression was observed in the broblasts until
after 24 hours of treatment, which is slower than might be expected if there
were intracellular pools of IL-13R2 present, and provides sucient time
for de novo protein synthesis of this receptor. This was also conrmed by
treatment with CHX which prevented the increase in surface expression of
IL-13R2 in the broblasts but not the epithelial cells.
The fact that both IL-4 and IL-13 can induce upregulation of IL-13R2
surface expression over 24 hours suggests that the surface expression levels
of IL-13R2 may have been articially raised by the addition of the pre-
treatment step used in Figures 3.2 and 3.3, and that this might be the cause
of the abrogation of eotaxin production observed in response to challenge
with IL-4 or IL-13, as has previously been suggested. 165 However it was
necessary to consider that the regulation may not be solely due to IL-13R2.
Both IL-4R and IL-13R1 are key components of IL-4 and 13 signalling
in human cells, although IL-4 can also signal via IL-4R and c. Whilst
many cells express both the type I (IL-4R:c) and type II (IL-4R:IL-
13R1) receptors this is not the case for all cells. The expression of IL-4R
and IL-13R1 has previously been reported in primary human bronchial
broblasts, however the presence of c has been debated. The ability of HBFs
to respond to IL-4 and IL-13 is dependent on the presence of the dierent
receptor subunits, and it has been suggested that the overall prole of these
receptors may be responsible for the dierences in responsiveness observed
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between subjects, rather than just IL-13R2 surface expression levels. 290 It
was therefore, important to consider the roles of the other receptor subunits
in the regulation of IL-4 and IL-13.
To address this, systematic characterisation of these receptor subunits
was undertaken. The mRNA and surface expression levels of IL-4R, IL-
13R1 and c were analysed to establish whether the expression levels varied
between subjects and if they were aected by IL-4 or IL-13 treatment.
It was hypothesised that, in contrast to what was observed with the IL-
13R2 expression, the levels of the signalling receptors would not increase
in response to either IL-4 or IL-13 as otherwise the level of signalling could
rapidly become uncontrollable. If a change did occur in response to either
cytokine it would be more likely that, as these are signalling receptors, their
expression would be downregulated with treatment.
Whilst both IL-13R1 (Figure 3.7) and IL-4R (Figure 3.8) mRNA were
detected in all subjects, the levels of expression were not aected by IL-4 or
IL-13 treatment. c mRNA expression, on the other hand, was not detected
in any of the subjects studied. To conrm the accuracy of these data, positive
controls were used in this assay. The stable production of IL-4R and IL-
13R1 mRNA, regardless of treatment, was expected because if these levels
were to increase in response to IL-4 or IL-13 treatment this could result
in uncontrolled responses to these cytokines, which would have a damaging
eect on the body.
As the expression of mRNA does not always correlate with changes in
protein expression, the cells were also analysed for surface expression levels
of each IL-4 or IL-13 receptor subunit by ow cytometry. Similarly to the
mRNA, IL-13R1 was detected in every subject and was not aected by
IL-13 treatment (Figure 3.9). This is consistent with previous reports and
detection of IL-13R1 in these cells was expected as without this subunit the
cells would not be able to respond to IL-13.
Surface expression of c (Figure 3.10), analogous to that which was ob-
served at the mRNA level, was not detectable in any of the subjects studied.
Previous studies investigating expression of the IL-4 and IL-13 receptors have
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demonstrated diering results with regards to c, with several suggesting c
is not present on non-haematopoietic cells 233 or skin broblasts, 295 whilst
another group 27 has demonstrated the presence of c in bronchial broblasts.
Whilst the former two studies corroborate with my data it is important to
note that in the latter the c mRNA was only detectable in either foetal
or adult broblast cell lines, rather than primary cells, in the presence of
cycloheximide, an inhibitor of protein synthesis. When these experiments
were performed with primary cells obtained from cancer patients, constitutive
mRNA expression, which was not dependent on cycloheximide, was observed;
however, in this instance it was in human lung myobroblasts rather than
broblasts and this was reported to be in contrast to observations in normal
cells. 27 These cancerous myobroblasts may exhibit many disease-specic
phenotypic dierences to the primary human bronchial broblasts obtained
from healthy or asthmatic volunteers that were used in this study, which
could explain the presence of c in these cells.
There were, however, dierences observed at the surface expression level
of IL-4R in response to both IL-4 and IL-13 stimulation. In this instance,
whilst the mRNA levels remained unchanged, the surface expression of IL-
4R was downregulated by treatment with either IL-4 or IL-13, whilst
Interferon  had no eect (Figure 3.11). This reduction in IL-4R expression
occurred in a dose-dependent manner in response to IL-4 (Figure 3.12a),
with 10 ng/ml reducing the expression by approximately 50   60% after
24 hours. The surface expression of IL-4R decreased rapidly and plateaued
within 1 hour of treatment with either IL-4 or IL-13 and was sustained over
a 48 hour period (Figure 3.12b). No correlation was observed between the
surface expression levels of IL-4R to the responsiveness of the HBFs to IL-4
or IL-13 either at baseline or after treatment with either cytokine.
The phenomenon of IL-4R internalisation with IL-4 or IL-13 stimulation
has been debated in the literature. Some previous studies have seen IL-4R
internalisation in the presence of IL-4 or IL-13 in both foetal lung broblast
cell lines and T cells. This was found to occur very rapidly (within 15 minutes
for IL-4, but slower for IL-13). In the experiments by Doucet, Brouty-Boy e et
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al. 296 IL-4R was found in the early endosomes and they postulated that it
might be either recycled back to the cell surface or degraded. In the washout
experiments undertaken in this chapter the surface IL-4R is repopulated
within three hours with fresh media, suggesting that the majority of the IL-
4R is recycled back to the surface.
A study by Friedrich, Kammer et al. 297 found that IL-4R internalised
with IL-4 but that this was not necessary for IL-4 signalling. They found
that c was needed for this to occur, despite the fact that the two receptor
subunits internalised with dierent kinetics. Whilst c was not found on
the cell surface of the broblasts studied, IL-13R1 was observed, and it
may be that this subunit is required for internalisation. IL-13R1 surface
expression did not change after 24 hours of treatment with IL-13, however
it may be that they are both internalised together and that IL-13R1 is
recycled more rapidly to the surface. Alternatively the IL-13R1 subunit
may be expressed in such high abundance that the dierence observed due
to internalisation with IL-4R does not cause a noticeable reduction in IL-
13R1 surface expression.
It might also be that the IL-13R1 subunit is not needed here, as another
study, which investigated an IL-4 toxin demonstrated that  60% of the
receptor internalised if only IL-4R was present and that this did not change
if either IL-13R1 or c were present. 298 These experiments were undertaken
with CHO-KI cells, which do not normally express IL-4 or IL-13 receptors
so the IL-4R, IL-13R1 and c were incorporated by transfection. Whilst
using CHO-KI cells provides the advantage of studying the eects of the
individual receptor subunits independently, articially adding these receptors
may also lead to diering kinetics than those which would be observed in cells
naturally expressing these receptors. Further experiments would therefore
be needed in primary human bronchial broblasts, which naturally express
high levels of IL-4R and IL-13R1, to determine the exact kinetics of
internalisation and whether IL-13R1 is necessary for internalisation of IL-
4R to occur.
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It has also been reported that the expression of IL-4R increases in
response to treatment with IFN. 299 This study, however, used an epithelial
cell line, BEAS-2B, rather than broblasts and a very high dose (100 ng/ml)
of IFN over a 48 hour period was required to see this eect. As IFN
is involved in the switch to a Th1 phenotype it would be unexpected for
treatment with this cytokine to result in upregulation of a Th2 receptor,
unless this occurred only in an already Th1 polarised environment, where it
may be involved in a feedback loop. A study by Huang, Xin et al., 300 on the
other hand, demonstrated in mice that IFN reduces the phosphorylation
of STAT6, whilst no change was observed in levels of IL-4R, although in a
previous study the same group found levels of IL-4R increased in response to
IL-4 treatment in spleen and lymph cells from C57Bl/6 mice. 301 The diering
results found in these studies may be due to the cell types analysed or the
methods used. In the broblast studies reported in this chapter investigating
the eect of IFN on IL-4R surface expression a standard dose of 10 ng/ml
was used, and previous results from within our laboratory have found that
treating broblasts with a higher dose of IFN results in signicant cell death
of both broblasts and epithelial cells (Andrews, unpublished observations).
A pretreatment step with IL-4 or IL-13 had been included in some
experiments to modulate the responsiveness of these cells to IL-4 and IL-
13. As treatment with IL-4 or IL-13 for more than 1 hour results in down-
regulation of IL-4R, it was important to establish whether this reduction
in surface expression of IL-4R could be responsible for the regulation of
these cytokines. When a pretreatment step was included in an experiment,
the cells were washed for 3 hours with fresh media before the addition of
the subsequent treatment. The data presented herein, demonstrate that this
three hour period is long enough for cells pretreated with IL-13 to repopulate
their surface expression to similar levels observed on untreated cells. Whilst
the surface expression levels did not completely recover within this time
after IL-4 pretreatment, the responses to IL-4 or IL-13 treatment by HBFs
were similar regardless of which pretreatment was used. If minor changes
in the surface expression levels of IL-4R were important for regulating the
106Chapter 3. Characterisation of the IL-4 & IL-13 Receptors
responsiveness to either cytokine it would be likely that dierences would be
observed here.
In contrast the levels of IL-13R2 were raised during treatment with
both IL-13 and IL-4 and were unaected by the washout step, suggesting
that this is the mechanism of regulation of both IL-4 and IL-13 in HBFs.
This, however, needed to be conrmed by the use of a neutralising antibody
against IL-13R2.
Cells incubated with an IL-13R2 NAb after pretreatment with either
cytokine and subsequently challenged with IL-4 or IL-13 for a further 24 hours
produced similar levels of eotaxin (Figure 3.14) and IL-6 (Figure 3.15) to
those which did not undergo the pretreatment step, whilst an isotype control
had no eect. This demonstrates the specic involvement of IL-13R2 in this
regulatory mechanism. This also highlights that IL-13R2 is able to regulate
IL-4, even though IL-4 is not able to bind directly to this receptor. These
data are consistent with work by Andrews, Nasir et al., where the importance
of IL-13R2 in the regulation of IL-4 in human bronchial broblasts was rst
noted. 165
The neutralising antibody experiment, also demonstrates that the de-
crease in IL-4R surface expression does not aect the cells responsiveness
to IL-4 or IL-13. The pretreatment step would have caused not only
upregulation of IL-13R2 but also signicant downregulation of IL-4R on
the surface. A washout step was included, however as shown in Figure 3.12,
the IL-4 pretreated cells would not have fully recovered their surface pools
of IL-4R within this time, therefore if IL-4R was critical in the regulation
of IL-4 or IL-13 signalling the IL-4 pretreated cells would have responded
dierently to the IL-13 pretreated cells, which was not the case.
However to conrm that the eect of the pretreatment step was the same
as observed in naturally high and low expressers of IL-13R2 it was also
necessary to test this at baseline. When the IL-13R2 NAb was added to
the cells which were naturally high expressers their ability to produce eotaxin
in response to IL-4 or IL-13 increased and was found to be similar to the
naturally low expressers of IL-13R2.
107Chapter 3. Characterisation of the IL-4 & IL-13 Receptors
3.4 Summary
In summary this work has highlighted the importance of IL-13R2 in the
regulation of IL-4 and IL-13 mediated signalling in human bronchial bro-
blasts. Whilst the IL-13R1 subunit is essential for IL-13 and IL-4 signalling
in broblasts the expression levels appear to have little regulatory eect on
these cells. Although rapid reduction in surface expression levels of IL-4R
may have short-term regulatory eects, it is the IL-13R2 surface expression
levels that appear to be most important for regulation of both IL-13 and IL-4
signalling.
As the importance of IL-13R2 as a regulator of IL-4 and IL-13 signalling
has been demonstrated in this chapter, the next chapter will investigate the
eects of modulating the levels of IL-13R2 in order to provide a model
that can be used to determine how IL-13R2 aects the responsiveness of
cells to IL-4 and IL-13. Whilst a pretreatment step was used to regulate the
responsiveness of the HBFs to IL-13 and IL-4, by upregulating the surface
expression levels of IL-13R2, this is not a clean system as it may have
other unintended eects, such as upregulation of SOCS proteins, as well as
the observed eects on IL-4R. Therefore the next chapter will attempt to
establish a clean model whereby IL-13R2 levels can be specically knocked
down in HBFs using specic siRNA against IL-13R2.
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Development of a Model to
Modulate Levels of IL-13R2
4.1 Introduction & Objectives
The importance of IL-13R2 for the regulation of both IL-4- and IL-13-
mediated signalling in human bronchial broblasts was established in Chap-
ter 3 and it was, therefore, of interest to understand more about this receptor.
In the previous chapter a neutralising antibody against IL-13R2 was
exploited to reduce the levels of this receptor. However large quantities of
the IL-13R2 NAb were required, making it quite expensive to use. This
prompted further studies to develop a more eective model whereby IL-
13R2 can be knocked down at the gene expression level in primary human
bronchial broblasts to enable further characterisation of its actions. An
alternative method of knocking down gene expression in cells is through the
use of small interfering RNAs (siRNAs), which disrupt the expression of a
specic gene of interest. 302{305
siRNAs are 20-30 nucleotide sections of double stranded RNA (dsRNA),
which have highly specic, generally inhibitory functions in a wide range
of organisms and cell types, 302{305 including human bronchial broblasts.
These are routinely used in vitro and have allowed targeted studying of gene
knockdown in primary human cells after development.
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The objectives of this study were to:
i) develop a model to modulate the levels of IL-13R2 in HBFs using
siRNA against IL-13R2 in high expressing cells,
ii) conrm that modication of the surface expression of IL-13R2 aects
the responsiveness of cells to both IL-13 and IL-4.
4.2 Results
4.2.1 siRNA Knockdown of IL-13R2
To study the knockdown eciency of the siRNA broblasts from a subject
previously shown to be a high expresser of IL-13R2 were selected. HBFs
were seeded at 2104 cells per well in 12 well plates and grown in the absence
of antibiotics until  30   40% conuence. The cells were subsequently
incubated with either scrambled siRNA, as a control, or a pool of four siRNAs
against IL-13R2 for 24 hours. Specic knockdown of IL-13R2 was analysed
by RT-qPCR.
This initial experiment demonstrated approximately a 50% reduction
in IL-13R2 mRNA due to treatment with specic siRNA (p < 0:05), in
comparison to the control after 24 hours (Figure 4.1). Interestingly though,
it was only the lower of the doses used which appeared to have an eect,
with higher doses actually increasing expression of IL-13R2 mRNA. This
was noted with both the IL-13R2 siRNA, as well as the scrambled control.
In addition, it was important to determine whether a knockdown of IL-
13R2 surface expression was also observed, as expression on the surface of
the cells is required for regulation of both IL-13 and IL-4. To this end, HBFs
were seeded and treated with siRNA as previously described and IL-13R2
expression was analysed by ow cytometry after 48 hours.
Treatment with the siRNA did not cause a knockdown of IL-13R2
protein expression on the surface of the cells. In fact, a signicant increase
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Figure 4.1: The eect of siRNA on IL-13R2 mRNA levels. Fibroblasts from
a known high-expresser of IL-13R2 were treated with with fresh media (NT)
or siRNA against IL-13R2 or a scrambled control for 24 hours in the absence
of antibiotics. RNA was extracted using the Trizol method. PCR analysis
compared IL-13R2 mRNA levels to the geometric mean of two housekeeping
genes (UBC/A2). Data have been normalised to the average dCT of IL-13R2 in
the unstimulated controls. n = 3 independent experiments. ? = p < 0:05
in IL-13R2 surface expression was observed after treatment with 15 nM
scrambled siRNA compared to the no siRNA control (Figure 4.2). As this
was the exact opposite eect to that which was anticipated, this implied
that the cells were eliciting an alternative response to the presence of siRNA,
resulting in an increase in IL-13R2 expression.
As higher concentrations of siRNA appeared to increase the levels of IL-
13R2 in a dose dependent manner it was considered that lower doses of
siRNA may actually be more useful.
To this end, HBFs were treated with siRNA as before, with doses ranging
from 0.625 to 5 nM. A high dose of 30 nM siRNA was also included for
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Figure 4.2: The eect of IL-13R2 siRNA on the surface expression of IL-13R2.
Fibroblasts known to express high levels of IL-13R2 were grown in the absence of
antibiotics for 24 hours before treatment with various doses of siRNA as indicated
for 48 hours. A no transfection reagent control (NT) was also included. 1  105
cells/subject were incubated with an antibody against phycoerythrin-conjugated
IL-13R2 or relevant isotype control before analysis on a FACSAria. Data were
normalised to an isotype control and expressed as percentage change of specic
mean uorescent intensity (SMFI) n = 5 independent experiments. Data are mean
+=  standard error. ?? = p < 0:01 and ? ? ? = p < 0:001
comparison with the previous experiment. In this instance no decrease in
surface expression of IL-13R2 was observed with the lower doses of IL-
13R2 siRNA studied, but a signicant increase in IL-13R2 expression was
still seen with the higher dose of siRNA (Figure 4.3). No dierence was
observed between the scrambled and specic IL-13R2 siRNA added.
Although no decrease in surface expression level was observed with IL-
13R2 siRNA treatment, it was of interest to establish whether this could
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Figure 4.3: Characterisation of IL-13R2 surface expression in response to lower
doses of siRNA. Human bronchial broblasts from a high expresser of IL-13R2
grown in the absence of antibiotics were treated with fresh media (NT) or varying
concentrations of siRNA against either IL-13R2 or a scrambled control for
48 hours. The cells were trypsinised and incubated with an antibody against
IL-13R2 or a matched IgG1 isotype control. Surface expression of IL-13R2
was determined by ow cytometry. Data were normalised to an isotype control
and expressed as percentage change of specic mean uorescent intensity (SMFI)
+=  standard error n = 5 independent experiments. ?? = p < 0:01 and
? ? ? = p < 0:001
prevent an increase in IL-13R2 by treatment with IL-13. In Chapter 3, IL-
13 was shown to increase the surface expression of IL-13R2 by broblasts
over a 24 hour period. Therefore, a range of siRNA doses were studied with
IL-13 treatment included.
Addition of specic siRNA against IL-13R2 did not prevent the increase
in surface expression levels due to IL-13 treatment (Figure 4.4), which was
signicant in every instance (p < 0:001). The surface expression levels of IL-
113Chapter 4. Development of a Model to Modulate Levels of IL-13R2
13R2 in fact increased even higher with the top doses of siRNA in the
presence of IL-13 (purple bars). This seemed to be the case more with
scrambled siRNA than the specic IL-13R2 siRNA, although there was
no signicant dierence between matched pairs.
Figure 4.4: The inuence of siRNA against IL-13R2 on IL-13-induced upregula-
tion of IL-13R2. Fibroblasts were treated with various doses of siRNA against
IL-13R2 or a scrambled control in the absence of antibiotics for 24 hours before
dropwise addition of 10 ng/ml IL-13 to half of the wells for a further 24 hours. A
no transfection reagent control was also included (NT). Cells were trypsinised and
incubated with either an antibody against IL-13R2 or a relevant isotype control
before analysis on a FACSAria. Data were normalised to an isotype and expressed
as % change of specic mean uorescent intensity (SMFI) +=  standard error.
n = 5 independent experiments. ? ? ? = p < 0:001
4.2.2 siRNA Induced Interferon Response
One of the known pitfalls of using siRNA to knock down gene expression is
the potential induction of an Interferon response due to the cells detecting
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the siRNA as double stranded RNA (dsRNA). This is a well documented
complication of siRNA treatment 306 that could be having an eect in these
cells and may be aecting the ability of the cells to knock down IL-13R2.
In Chapter 3 a type II Interferon, IFN, was found to upregulate surface
expression levels of IL-13R2, therefore it was hypothesised that the cells
were detecting the siRNA as dsRNA resulting in the production of Interferon,
which caused the cells to increase their expression of IL-13R2.
To test this hypothesis, cells were treated with polyinosinic:polycytidylic
acid (Poly I:C), a strand of poly (inosine) annealed to a strand of poly
(cytidine), which is frequently used in vitro as a synthetic analogue of dsRNA.
Poly I:C has previously been shown to induce an Interferon response in
human bronchial broblasts. 307 Therefore, to establish whether IL-13R2
mRNA levels were aected by dsRNA, broblast cDNA samples (kindly
provided by Dr Nicole Bedke) from healthy and asthmatic patients treated
for dierent times and dierent doses of Poly I:C and were then analysed for
IL-13R2 mRNA expression by RT-qPCR.
IL-13R2 mRNA increased after 24 hours in both healthy and asthmatic
subjects in response to Poly I:C in a dose dependent manner (Figure 4.5).
This increase reached signicance with 1 g/ml Poly I:C in both the healthy
and asthmatic subjects (p < 0:05 and p < 0:001 respectively) but the
greatest increase was observed with 10 g/ml Poly I:C (p < 0:01 and
p < 0:001 respectively). This increase in IL-13R2 mRNA appeared to
be time-dependent, reaching signicance after 24 hours.
HBFs from healthy and asthmatic patients were subsequently treated
with Poly I:C for 24 hours for analysis of changes in surface expression of
IL-13R2 as previously described. In this instance, challenge with IL-13 was
also included as a positive control.
Treatment with either Poly I:C or IL-13 resulted in a signicant increase
in IL-13R2 expression on the surface of the cells after 24 hours (Figure 4.6).
This was the case with both healthy and asthmatic subjects and no dierence
was observed between the two.
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Figure 4.5: Dose and kinetic characterisation of IL-13R2 mRNA expression in
response to Poly I:C treatment. HBFs were seeded at 1  105 cells/well on
6 well plates and grown until 95% conuent. Cells were serum starved for
24 hours before treatment with varying concentrations of Poly I:C for 24 hours.
RNA was extracted using the Trizol method. PCR analysis compared IL-13R2
mRNA levels to the geometric mean of two housekeeping genes (Ubiquitin C
and Phospholipase A2). Data have been normalised to the average dCT of IL-
13R2 in the unstimulated controls. n = 11 healthy and 11 asthmatic subjects.
Data are presented as median with standard Tukey whiskers. ? = p < 0:05 and
? ? ? = p < 0:001.
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Figure 4.6: The eect of Poly I:C on IL-13R2 surface expression. Fibroblasts
from healthy and asthmatic subjects were grown until 95% conuent and serum
starved for 24 hours before stimulation with either 10 g/ml Poly I:C or 10 ng/ml
IL-13 for 24 hours. Cells were trypsinised and incubated with either an antibody
against IL-13R2 or a relevant isotype control before analysis on a FACSAria.
Data were normalised to an isotype and expressed as % change of specic mean
uorescent intensity (SMFI). n = 5 healthy and 6 asthmatic subjects. Data are
median +=  IQR with Tukey whiskers. ? ? ? = p < 0:001.
117Chapter 4. Development of a Model to Modulate Levels of IL-13R2
In the previous chapter, IL-13R2 surface expression levels were shown to
regulate the cells responsiveness to IL-13 and IL-4. To conrm whether this
Poly I:C induction of IL-13R2 surface expression translated to a functional
response, the cells were pretreated with Poly I:C in a similar manner to the
the IL-4 and IL-13 pretreatments used in the previous chapter. To this end,
HBFs from healthy and asthmatic subjects were grown in 12 well plates until
95% conuent. The cells were serum starved in the presence or absence of
10 g/ml Poly I:C. As with previous pretreatment experiments, the cells were
exposed to a 3 hour wash period, before subsequent treatment with IL-13.
A neutralising antibody against IL-13R2 was also included in some of the
treatments, where indicated. Conditioned media was collected after 24 hours
for analysis of eotaxin production and the cells were xed and stained with
methylene blue for cell number determination.
As previously observed in Chapter 3, broblasts from all of the subjects
produced eotaxin in response to IL-13 (Figure 4.7), however when the cells
were pretreated with Poly I:C this production was signicantly reduced
(p < 0:05). This eect could be reversed by the addition of an IL-13R2
neutralising antibody, matching what was previously observed with IL-4 or
IL-13 pretreatments.
As Poly I:C is known to induce production of Interferon (IFN)  in
broblasts 307 it was therefore postulated that it is the IFN production in
response to Poly I:C that induces increased IL-13R2 surface expression. To
conrm this, the cDNA samples provided by Dr Bedke were also analysed
for changes in IFN production in response to Poly I:C treatment.
The induction of IFN mRNA was found to occur very rapidly with the
largest increase observed after 2 hours (Figure 4.8). This increase was found
to be dose dependent, reaching signicance after 1 g/ml Poly I:C (p <
0:01) although a greater increase was observed with 10 g/ml (p < 0:001).
However, this production of IFN mRNA was diminished over time and after
24 hours was greatly reduced.
This rapid increase in IFN mRNA again indicated that this Interferon
production by the broblasts may be the driving force behind the increased
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Figure 4.7: The eect of Poly I:C pretreatment on eotaxin production, and the
consequences of treatment with an IL-13R2 NAb. Conuent HBFs were serum
starved in the presence or absence of 10 g/ml Poly I:C. The cells were washed
for 3 hours before subsequent challenge with 10 ng/ml IL-13 for 24 hours. In some
cases an IL-13R2 neutralising antibody (NAb) was added during the washout
period and subsequent challenge as indicated. Eotaxin production was measured
by ELISA of conditioned media and levels were normalised to cell number, deter-
mined by methylene blue assay. n = 3 healthy and 3 asthmatic subjects. Data
expressed as median with standard Tukey whiskers. ? ? = p < 0:01.
expression of IL-13R2. To test this, HBFs were treated with various doses
of IFN for 24 hours before analysis of IL-13R2 surface expression by ow
cytometry as previously described. Again, IL-13 was included as a positive
control.
IFN (as previously observed with IFN, Figure 3.6) was found to
increase the surface expression of IL-13R2 in a dose dependent manner
(Figure 4.9).
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Figure 4.8: The impact of Poly I:C treatment on Interferon  mRNA production
by bronchial broblasts. Fibroblasts from healthy and asthmatic patients were
serum starved for 24 hours before exposure to 0-10 g/ml Poly I:C for up to
24 hours. Total RNA was extracted using the Trizol method. RT-qPCR compared
Interferon (IFN)  expression with the geometric mean of two housekeeping genes
(Ubiquitin C and Phospholipase A2). Data were normalised to the average dCT
of IFN in unstimulated controls. n = 6 healthy and 6 asthmatic subjects. Data
are mean +=  SEM. ? ? p < 0:01 ? ? ? = p < 0:001.
The largest increase in surface expression occurred with the highest doses
used, 50 and 100 IU IFN (p < 0:001), with 50 IU having a similar eect
as 10 ng/ml IL-13. As expected, the increase in surface expression occurred
later than the mRNA expression. The highest dose of IFN analysed did
induce a statistically signicant increase in surface expression of IL-13R2
after 8 hours, which is earlier to what has previously been observed with
either IL-13, IFN or Poly I:C treatment, although the greatest increase was
observed after 24 hours.
To further establish the role of IFN in the upregulation of IL-13R2 a
neutralising antibody against the Interferon / receptor (IFN / R NAb)
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Figure 4.9: Dose and kinetic characterisation of IL-13R2 surface expression in
response to IFN in human bronchial broblasts. Fibroblasts were seeded in
12 well plates and grown until 95% conuent. Cells were serum starved for
24 hours before treatment with 1 - 100 IU IFN, 10 ng/ml IL-13 or no treatment
(NT). Cells were trypsinsed and incubated with an isotype control or antibodies
against IL-13R2 and analysed for surface expression by ow cytometry. Data
were normalised to an isotype control and expressed as specic mean uorescent
intensity (SMFI). n = 5 healthy and 7 asthmatic subjects Data are median += 
standard Tukey whiskers. ? = p < 0:05 ? ? = p < 0:01 ? ? ? = p < 0:001.
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was utilised. Both IFN and IFN share a receptor consisting of IFNAR1
and IFNAR2, and this antibody is able to block access to the active site,
preventing signalling.
HBFs were serum starved for 24 hours before a 3 hour pretreatment step
with either the IFN / R NAb or a relevant isotype control. The cells were
subsequently challenged with 10 g/ml Poly I:C for 24 hours before analysis
of IL-13R2 surface expression by ow cytometry.
The broblasts demonstrated a signicant increase in surface expression
of IL-13R2 in response to Poly I:C both in the presence and absence of
the isotype control at a range of doses, with no dierence observed when
the isotype was included (Figure 4.10). However, when the IFN / R NAb
was added a dose dependent attenuation of this increase in IL-13R2 surface
expression was observed (p < 0:001). The highest dose used (10 g/ml) had
the greatest aect and it appeared as if this had not yet plateaued, however
due to the cost implications higher concentrations were not tested.
When this experiment was repeated with IFN treatment, rather than
Poly I:C, again a signicant attenuation was observed in the presence of the
IFN / R NAb, whilst the isotype control had no eect (Figure 4.11).
So, as these experiments demonstrated that challenge with dsRNA
induces an IFN-mediated increase in IL-13R2 expression this may be the
cause of the problems with the siRNA model.
Steroid Sensitivity
Steroids are regularly used in the treatment of the moderate to severe forms
of asthma due to their immuno-suppressive and anti-inammatory actions,
which occur via suppression of inammatory gene expression. Dexamethsone
(Dex) is a synthetic glucocorticosteriod, which is often used in a laboratory
setting.
It has previously been observed that dexamethasone treatment can sup-
press the IFN gene expression caused by challenge with Poly I:C. 308 It was
therefore hypothesised that cells treated with both Dex and Poly I:C would
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Figure 4.10: The eect of a neutralising antibody against IFN / R on Poly I:C
induced upregulation of IL-13R2. HBFs grown in 12 well plates until 95%
conuent before 24 hours serum starvation. The cells were incubated in the
presence or absence of either a neutralising antibody against the IFN / receptor
(IFN / R NAb) or a relevant isotype control for 3 hours before subsequent
challenge with 10 g/ml Poly I:C for 24 hours. Surface expression of IL-13R2
was analysed by ow cytometry. Data were normalised to an isotype control and
expressed as percentage change specic mean uorescent intensity (SMFI) n = 4.
Data presented as median with standard Tukey whiskers. ? ? ? = p < 0:001.
not increase surface expression of IL-13R2, but that the expression of IL-
13R2 on cells treated with dexamethasone and IFN would still increase,
demonstrating that direct stimulation with IFN, rather than IFN-induced
gene expression, is required for this upregulation.
HBFs were treated with Poly I:C or IFN for 24 hours in the presence
or absence of Dex and surface expression of IL-13R2 was analysed by ow
cytometry.
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Figure 4.11: The impact of an IFN / R NAb on IFN-induced IL-13R2
upregulation. Fibroblasts were grown until 95% conuent before being serum
starved for 24 hours. A neutralising antibody (NAb) against the IFN / receptor
(10 g/ml) or a relevant isotype control (10 g/ml) was added for 3 hours where
indicated before challenge with 100 IU IFN for a further 24 hours. Surface
expression of IL-13R2 was analysed by ow cytometry. Data were normalised to
an isotype control and expressed as percentage change specic mean uorescent
intensity (SMFI) n = 4. Data presented as median with standard Tukey whiskers.
? ? ? = p < 0:001.
As before, cells treated with either Poly I:C or IFN demonstrated
signicantly higher levels of expression of IL-13R2 than those which were
not exposed to any treatment (p < 0:01 in both instances) (Figure 4.12).
Addition of Dex in the absence of any other treatment resulted in a slight
reduction in IL-13R2 levels. When cells were treated with Poly I:C in the
presence of Dex the increase in IL-13R2 expression previously observed
was suppressed. With IFN treatment in the presence of Dex, a signicant
increase in surface expression was observed in comparison to cells treated with
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Dex alone (p < 0:05), however this was still much reduced in comparison to
IFN treatment alone.
Whilst this small increase was observed with IFN in the presence of Dex,
compared with Dex treatment alone, it is clear that the addition of steroids
has a suppressive eect on IL-13R2 expression.
Figure 4.12: Attenuation of Poly I:C and IFN induced IL-13R2 upregulation by
dexamethasone. Fibroblasts were seeded in 12 well plates and grown until conuent
before being serum starved for 24 hours. Cells were challenged with 10 g/ml
Poly I:C or 50 IU IFN in the presence or absence of 50 nM dexamethasone
for a further 24 hours. Surface expression of IL-13R2 was analysed by ow
cytometry. Data were normalised to an isotype control and expressed as percentage
change specic mean uorescent intensity (SMFI) n = 4 healthy and 6 asthmatic
subjects. Data presented as median with standard Tukey whiskers. ? = p < 0:05
? ? = p < 0:01.
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4.3 Discussion
As the mechanism by which IL-13R2 regulates IL-4 is unclear, because it is
unable bind directly, it was therefore of interest to establish a model whereby
levels of IL-13R2 could be specically modulated. To this end this chapter
aimed to develop a knockdown model using specic siRNA against IL-13R2.
Initial experiments were undertaken to characterise an siRNA knockdown
model to selectively regulate the surface levels IL-13R2. Whilst this
appeared to have some eect at the mRNA level (Figure 4.1) there was
no decrease in surface expression of IL-13R2 (Figure 4.2 and 4.3).
The IL-13R2 siRNA not only failed to induce a specic knockdown
of surface IL-13R2 but it was also unable to prevent an IL-13-mediated
increase in IL-13R2 surface expression, regardless of the dose used (Fig-
ure 4.4). This was therefore found not to be a satisfactory model.
The lack of knockdown in response to siRNA and the fact that higher
doses actually increased expression of IL-13R2 mRNA and surface expres-
sion suggested that the cells may be eliciting an Interferon response to the
siRNA.
Interferon production is a potential side eect of treating cells with siRNA
as it can be detected by pattern recognition receptors, such as Toll-Like
Receptor (TLR) 3, which detects double stranded RNA. In Chapter 3 IFN
was found to upregulate IL-13R2 surface expression, and it was therefore
hypothesised that any Interferon production in response to siRNA treatment
may have actually upregulated IL-13R2 levels.
To test this, broblasts were treated with a synthetic analogue of dsRNA,
Poly I:C. IL-13R2 surface expression was upregulated in a time and dose
dependent manner in response to Poly I:C. There was a similar increase in
IL-13R2 in response to IL-13, with no dierence found between healthy and
asthmatic subjects with either treatment, corresponding to that which was
observed in Chapter 3. This upregulation was shown to have a functional
consequence on the cells, in a similar manner to IL-4 or IL-13 pretreatment,
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where cells pretreated with Poly I:C demonstrated a reduced responsiveness
to IL-13.
Fibroblasts have previously been shown to produce IFN in response
to Poly I:C 307 and this was conrmed initially by measuring IFN mRNA,
which was found to signicantly increase within 2 hours of Poly I:C treat-
ment. Challenging broblasts with IFN directly also signicantly increased
surface expression levels of IL-13R2 in a dose-dependent manner, over
24 hours.
When a neutralising antibody against IFN / R was added both the
Poly I:C and IFN-mediated increase in IL-13R2 surface expression could
be attenuated, conrming that the Poly I:C induction of IL-13R2 is IFN-
mediated.
This was not a complete attenuation, as there was still an increase in
surface expression compared to the baseline, although when a range of doses
of the NAb were used prior to Poly I:C pretreatment, it was found that
higher doses could elicit a greater eect. Unfortunately it was not possible
to test greater doses as it was cost prohibitive but it would be of interest to
determine whether this could be further attenuated or if another mediator is
involved in the upregulation of IL-13R2. The fact that a similar response
was found with both the Poly I:C and IFN treatment suggests that it is
simply ineciency of the antibody, but this would need to be conrmed.
Neither IFN nor IFN can signal through the IFN / R, so it may be
that the broblasts also produce one of these Interferons in response to the
Poly I:C treatment, and that this is able to upregulate surface expression of
IL-13R2. Further research would be required to establish the full range of
mediators produced by these cells in response to dsRNA stimulation.
As will be discussed further in Chapter 6 these results have implications
in respiratory viruses, which are one of the leading causes of asthma exacer-
bations. 118
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Subsequent experiments investigated the eect of steroids on IL-13R2.
Here it was found that the addition of Dex was able to attenuate the Poly I:C-
mediated induction of IL-13R2 surface expression, however challenge with
IFN could partially overcome the Dex treatment. This suggests that whilst
Poly I:C treatment could normally induce IFN production, which could
in turn increase the IL-13R2 surface expression, this was prevented with
by the addition of steroids. Whilst direct treatment with IFN was still
able to increase surface expression of IL-13R2 in the presence of Dex, this
was substantially reduced in comparison to cells treated in the absence of
steroids. However, in these experiments only one dose of Dex was tested and
it would be important to further characterise this steroid suppressive eect
by investigating multiple concentrations of this drug.
The fact that the baseline levels of IL-13R2 decreased in response to
Dex suggests that the regulation of this receptor is steroid-sensitive. Whilst
there was insucient time to study this further it would be of interest to
greater understand the regulation mechanisms controlling IL-13R2 surface
expression. This is especially true for understanding the role of steroids
as these are regularly used as a therapy for moderate and severe forms of
asthma. These drugs elicit anti-inammatory eects and have been found to
reduce levels of IL-13 production. 309,310 Therefore, if these also downregulate
the levels of IL-13R2 any IL-4 or IL-13 produced could have a greater eect
than in the absence of steroids. It would also be of interest to determine
whether Dex can suppress IL-13 induced IL-13R2 surface expression.
4.4 Summary
In the current chapter attempts were made to develop a model to study the
eects of IL-13R2. When siRNA knockdown was tested it was found that
the cells detected siRNA as dsRNA, which induced an Interferon response.
Whilst not ideal, this work has highlighted an increase in IL-13R2 ex-
pression due to this Interferon response, which occurred when the broblasts
were stimulated with dsRNA.
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Unfortunately, it was therefore not possible to develop a model for knock-
ing down IL-13R2 in primary human bronchial broblasts using siRNA due
to this production of Interferon. However, as the importance of IL-13R2 as
a regulator of IL-4 and IL-13 signalling has been highlighted in Chapter 3
an alternative model is still required to determine how IL-13R2 is able to
regulate the eects of IL-4 despite being unable to bind to it directly.
As mentioned previously, it has been suggested that IL-13R2 may be
able to instigate an IL-4 mediated signal via STAT3 in glioblastoma cells,
however this has not yet been studied in non-malignant cells or asthma.
Therefore the next chapter will attempt to validate an overexpression
model of IL-13R2, which is already in use in our laboratory. This model
will then be used to establish whether IL-13R2 is able to instigate a signal
in response to IL-4.
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Regulation of IL-4 & IL-13 by
IL-13R2
5.1 Introduction & Objectives
Having established in Chapter 3 the importance of IL-13R2 in the regulation
of both IL-4 and IL-13 it was of interest to try to establish the mechanism
by which this occurs. In Chapter 4 attempts were made to develop a model
whereby IL-13R2 levels could be reduced by siRNA to complement experi-
ments using the IL-13R2 neutralising antibody. As this proved unsuccessful
due to the induction of an Interferon response by the broblasts in response
to the siRNA another model was required to investigate the mechanisms of
action of IL-13R2 in a clean system. An alternative method for studying a
receptor is overexpression in cells which normally only express very low levels.
An overexpression model of IL-13R2 in BEAS-2B cells has previously been
developed in our laboratory and the preliminary experiments of this Chapter
will look to validate this model.
IL-13R2 was originally considered a non-signalling decoy receptor due
to its short intracellular tail, which, unlike the IL-4 and IL-13 signalling
receptors, is unable to instigate a STAT6 signal. However, recent studies
have proposed several, as yet unconrmed signalling mechanisms, 261,264,280
one of which could explain how IL-13R2 is able to regulate IL-4, despite
being unable to bind to it directly. 243
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In studies investigating the dierences between glioblastoma cells and
normal astrocytes it has been suggested that IL-13R2 may instigate a signal
via activation of the transcription factor STAT3. 249,280 Glioblastoma cells
are unable to induce IL-4 or IL-13 mediated STAT6 signals and express high
levels of IL-13R2 in comparison to normal astrocytes which are IL-4 and
IL-13 responsive and do not express this regulatory receptor. 247,249,277 The
mechanism of STAT3 activation is currently undetermined and direct binding
of STAT3 to IL-4R does not appear to be required. 280
STAT3 signalling is classically associated with the IL-6-type family of
cytokines, which signal via the gp130 receptor. 311 However it has been shown
more recently to act as a signalling molecule for various Interferons and
growth factors. 312
Similarly to STAT6 signalling, STAT3 is activated by JAK, which causes
phosphorylation of tyrosine 705 near the carboxy-terminus, resulting in
homodimerisation. The STAT3 dimer translocates to the nucleus where it
binds to DNA and activates transcription of a range of genes. 313 The genes
activated by STAT3 vary by cell type and often have seemingly contradictory
eects. 312
STAT3 elicits anti-apoptotic and pro-proliferative actions, which are com-
monly observed with cytokines in the IL-6 family, in B and T lymphocytes.
However, the opposite eect is seen in monocytes, where STAT3 prevents
growth and activates terminal dierentiation. 312,313
STAT3 also exhibits pro- and anti-inammatory eects. Various models
of gastric inammation and cancers have observed constitutive STAT3
activation resulting in the release of pro-inammatory cytokines and
chemokines. 314 However, the reverse has also been observed with STAT3
seeming to negatively regulate inammation in macrophages, and knockout
studies have demonstrated chronic enterocolitis, an inammatory condition
of the bowel, in STAT3 decient mice. 315
The mechanism by which these diering responses to one signal trans-
ducer occur is currently unknown, although it is of particular interest in
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diseases such as cancer and autoimmune conditions where excessive prolifer-
ation and/or inammation occurs.
Many of the studies which have investigated STAT3, and in particular the
potential of this signal occurring via IL-13R2, have done so in a malignant
setting as STAT3 has been found to be constitutively activated in various
cancers, 316{318 however this has not yet been considered to have implications
in non-malignant conditions such as asthma.
As both inammation and brosis are hallmarks of asthma it would be of
great interest to determine whether IL-4 is able to induce STAT3 activation
via IL-13R2 in primary human bronchial broblasts.
The objectives of this study were to:
i) validate an overexpression model of IL-13R2,
ii) establish whether IL-4 or IL-13 induce STAT3 phosphorylation in HBFs,
iii) determine whether this STAT3 signal is mediated by IL-13R2.
5.2 Results
5.2.1 Validation of an IL-13R2 Overexpression Model
As the attempts to knockdown IL-13R2 surface expression in Chapter 4
were unsuccessful, an over expression model of IL-13R2 was instead vali-
dated. In this model, established by Dr Allison-Lynn Andrews, BEAS-2B
cells, which normally only express low levels of IL-13R2 on the surface were
stably transfected with a pcDNA3.1 vector containing cDNA for full length
IL-13R2 (B2B-FL) or a mock transfected sequence (B2B). The cells which
had accepted the plasmid were selected via a geneticin selection method.
BEAS-2B cells are a bronchial epithelial cell line which has been trans-
formed using an adenovirus12-SV40 virus hybrid. In Chapter 3, it was
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established that there are some key dierences in the regulation of IL-
13R2 in broblasts and epithelial cells, such as pooling of IL-13R2 within
intracellular stores in epithelial cells but not broblasts. Therefore this is
not an ideal model for studying the regulation of IL-4 by this receptor in
broblasts. However, previous attempts by Dr Andrews to establish similar
models in a variety of lung broblast cell lines, such as MRC-5 cells proved
unsuccessful. Therefore, as no alternative model was available, preliminary
experiments were undertaken using these cells as this provided a clean system
in which to study the regulation of IL-4 by IL-13R2.
Initially, expression of IL-13R2 was conrmed in B2B-FL cells. To this
end, surface expression levels of IL-13R2 on both B2B and B2B-FL cells
were analysed by ow cytometry at baseline. To determine the responsiveness
of the cells to IL-4 and IL-13 STAT6 phosphorylation was studied via western
blotting as these cells do not produce eotaxin in response to challenge with
these cytokines.
When surface expression levels of IL-13R2 were analysed by ow cytom-
etry, a clear shift in uorescence was observed in the B2B-FL cells compared
with the B2B cells, demonstrating substantial IL-13R2 expression on the
cell surface (Figure 5.1a).
B2B and B2B-FL cells which were treated with either IL-4 or IL-13 also
exhibited diering functional responses, with a strong phospho-STAT6 signal
visible in response to treatment with either cytokine in the B2B cells but
only very minimal STAT6 phosphorylation was observed in the B2B-FL cells
(Figure 5.1b). These data are consistent with previous reports that STAT6
phosphorylation is substantially reduced in the presence of high levels of IL-
13R2. 165
As this model has been shown to behave as we would functionally expect,
it can therefore be utilized to provide greater understanding of the regulatory
methods of IL-13R2.
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Figure 5.1: Validation of an IL-13R2 overexpression model in BEAS-2B cells.
BEAS-2B cells, which had previously been stably transfected with either full length
IL-13R2 (B2B-FL) or a mock control (B2B) were grown in 12 well plates until
95% conuent. The cells were serum starved for 24 hours before a) ow cytomet-
ric analysis of surface expression of IL-13R2 and b) treatment with either serum
free medium (NT), IL-4 or IL-13 for 1 hour and analysis of STAT6 phosphorylation
by western blotting. Representative of n = 3 independent experiments.
5.2.2 STAT3 Signalling in an Overexpression Model of
IL-13R2
IL-4 has been shown to induce an IL-13R2-mediated STAT3 signal in
glioblastoma cells, 249,280 therefore, to conrm this, initial experiments were
undertaken utilising the B2B model of IL-13R2 overexpression.
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B2B and B2B-FL cells were seeded in 6 well plates at a density of
5  105 cells per well and grown until 95% conuent. The cells were
serum starved for 24 hours before challenge with IL-4 or IL-13 for 1 hour
and analysis of STAT3 activation by western blotting.
The B2B-FL cells, expressing high levels of IL-13R2 on the cell surface,
demonstrated a marked increase in phosphorylation of STAT3 in response
to treatment with IL-4 (Figure 5.2), which was not found in the B2B cells
(p < 0:001). A smaller apparent increase was also observed after challenge
with IL-13, however this was not found to be signicant.
5.2.3 STAT3 Signalling in Primary Human Bronchial
Fibroblasts
Whilst the B2B data in Figure 5.2 corroborate the work in glioblastoma
cells by Rahaman et al., 249,280 it was important to determine whether this
could be replicated in primary human bronchial broblasts, which naturally
express IL-13R2.
Initial experiments were therefore undertaken to establish whether treat-
ment with either IL-4 or IL-13 resulted in an increase in STAT3 phosphoryla-
tion in HBFs. Fibroblasts were grown on 12 well plates until 95% conuent.
The cells were serum starved for 24 hours and either lysed immediately
(baseline) or treated either in the absence (T60) or presence of 10 ng/ml
IL-4 or IL-13 for 1 hour. As before, the cell lysates were analysed by western
blotting for phosphorylated STAT3, with total STAT3 protein acting as a
loading control.
In these cells, high basal activation of STAT3 was observed in the absence
of any stimulus (Figure 5.3), which was signicantly reduced by exchanging
the media (p < 0:001). Because the baseline STAT3 activation was so high,
a signicant decrease in STAT3 was observed in every treatment group.
Whilst there did appear to be a trend towards an increase with IL-4 or
IL-13 treatment when compared to T60, where basal phosphorylation was
still observed, this was not found to be signicant.
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Figure 5.2: STAT3 phosphorylation by BEAS-2B expressing IL-13R2. Phos-
phorylated STAT3 was detected in western blots of lysates from BEAS-2B cells
expressing full length IL-13R2 (B2B-FL) but not those which had been mock
transfected (B2B). STAT3 phosphorylation was normalised to the total STAT3
and presented as % change in peak optical density (OD). n = 4 independent
experiments. ? ? ? = p < 0:001
As experiments in glioblastoma cells have suggested that the STAT3
signal is initiated via IL-13R2 280 it was of interest to determine whether
increasing the surface expression of IL-13R2 resulted in a greater signal,
which would be more clearly visible above the background phosphorylation
that was observed in Figure 5.3, even when the medium was exchanged for
an hour.
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Figure 5.3: STAT3 phosphorylation by bronchial broblasts. Phosphorylated
STAT3 was detected in western blots of lysates from broblasts serum starved
for 24 hours and either lysed immediately (baseline) using Sample Buer, or the
media was exchanged for 1 hour in the absence (T60) or presence of 10 ng/ml
IL-4 or IL-13. Data were normalised to the pan STAT3 levels as a loading control,
quantied by densitometry and expressed as percentage change in peak optical
density (OD). n = 10 subjects +=  SEM. ? ? = p < 0:01 ? ? ? = p < 0:001.
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The experiments performed in Chapter 3 demonstrated substantial dier-
ential expression of IL-13R2 on the surface of bronchial broblasts obtained
from dierent subjects, with often only relatively low expression levels on the
surface of the cells at baseline (Figure 3.5). To study the link between IL-
13R2 and STAT3, subjects naturally expressing higher levels of IL-13R2
were selected and pretreated with IL-4 or IL-13 for 24 hours to further
increase the surface expression of this receptor. The cells were exposed to
a 3 hour washout period to remove any traces of the pretreatment before
challenge in the absence (T60) or presence of IL-4 or IL-13 for one hour and
analysed for changes in STAT3 phosphorylation by western blotting. In this
instance STAT6 phosphorylation was also analysed as an indirect measure of
the increase in the levels of IL-13R2. 165
As found in previous experiments, high levels of STAT3 phosphorylation
were observed at baseline, resulting in a signicant decrease in activation
in every instance when the media was exchanged (Figure 5.4a). When
comparing the STAT3 phosphorylation levels between T60 and cells treated
for 1 hour with either IL-4 or IL-13 there was again a trend towards an
increase but this was once more not found to be signicant.
In comparison, both IL-4 and 13 induced activation of STAT6 (Fig-
ure 5.4c) as anticipated, which was attenuated by the addition of the
pretreatment step (Figure 5.4d), suggesting that the pretreatment resulted
in increased expression of IL-13R2 as observed in Figure 5.1.
Whilst addition of the pretreatment with IL-4 or IL-13 for 24 hours
appeared to increase surface expression of IL-13R2, it did not result in
increased STAT3 activation and even appeared to attenuate the trend pre-
viously observed (Figure 5.4b).
Whilst neither of these initial experiments in HBFs demonstrated a
signicant increase in STAT3 phosphorylation, these studies into the poten-
tial role of IL-13R2 in STAT3 signalling were complicated by endogenous
activation of STAT3 observed in the absence of any treatment (Figure 5.3
and Figure 5.4) in this model. This high background phosphorylation sug-
gested an autocrine signalling molecule was activating STAT3 in these cells.
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Figure 5.4: The eect of IL-4 or IL-13 pretreatment on STAT3 and STAT6
phosphorylation. Fibroblasts were seeded on 12 well plates and when 95%
conuent were serum starved with UltraCulture in the absence (NT) or presence of
10 ng/ml IL-4 or IL-13 (pretreatment). After 24 hours the media was exchanged for
one hour with either 10 ng/ml IL-4, IL-13 or no treatment (T60). Cell lysates were
obtained from solubilisation in Sample Buer and analysed by Western blotting
for STAT3 and STAT6 phosphorylation, which were normalised to a pan-STAT3
control by densitometry. Data is expressed as percentage change in peak optical
density (OD). High baseline activation of STAT3 was observed, which showed a
trend towards an increase in response to IL-4 or IL-13 (a), however when a the
cells were pretreated with IL-4 or IL-13 this trend was no longer observed (b).
In the absence of any pretreatment, IL-4 and IL-13 induced phosphorylation of
STAT6 (c), which was attenuated by pretreatment with either cytokine (d). n = 5
subjects +=  SEM.
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Therefore, it was necessary to determine what might be driving this STAT3
phosphorylation, to see if background activation could be removed, enabling
us to determine whether IL-4 or IL-13 aect STAT3 phosphorylation.
Previous studies have shown that the IL-6 signalling pathway activates
STAT3. 319 IL-6 is a key pro-inammatory cytokine associated with airway
remodelling in asthma and is dysregulated in interstitial lung disease, where it
results in the associated downstream STAT3-mediated responses becoming
pro-survival, rather than pro-apoptotic as seen in healthy peripheral lung
broblasts. 58 Therefore, to determine if IL-6 could be the cause of this basal
activation of STAT3 it was necessary to determine if HBFs from both healthy
and asthmatic subjects endogenously produce IL-6, and if variation exists
between patient groups.
HBFs from healthy and asthmatic subjects seeded at 5104 cells per well
on 12 well plates, and when 95% conuent were serum starved for 24 hours
before collection of conditioned media. Levels of IL-6 production by HBFs
from healthy and asthmatic subjects were analysed by ELISA.
Although no dierence was found between HBFs from healthy and asth-
matic subjects, in the absence of any external stimuli high basal expression
of IL-6 was observed after 24 hours (Figure 5.5), which could account for the
basal STAT3 phosphorylation. However, to establish a causal relationship
between endogenous IL-6 and STAT3 phosphorylation, augmented activation
of STAT3 would need to be demonstrated by IL-6 treatment and endogenous
STAT3 phosphorylation would need to be knocked down with the use of a
specic inhibitor against IL-6.
To this end, an experiment to demonstrate STAT3 phosphorylation by
IL-6 was undertaken. HBFs grown from healthy or asthmatic subjects were
grown on 12 well plates (seeded at 5  104 cells per well) and once 95%
conuent were treated either in the absence (T60) or presence of IL-6 at 1 and
10 ng/ml for 1 hour. STAT3 phosphorylation was compared to basal STAT3
activation (baseline) by western blotting of cell lysates. Protein bands were
normalised to pan-STAT3 to act as a loading control.
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Figure 5.5: Basal IL-6 production by broblasts from healthy and asthmatic
patients. To determine whether HBFs derived from asthmatics dierentially
express IL-6, levels of this cytokine from unstimulated HBFs derived from 14
healthy and 15 asthmatic subjects were measured in conditioned media by ELISA.
Data are presented as median with standard tukey whiskers.
STAT3 activation due to IL-6 was shown to behave in a dose-dependent
manner (Figure 5.6). Treatment with 10 ng/ml IL-6 was sucient to induce
STAT3 phosphorylation to a greater extent than observed at baseline after
the initial 24 hour serum starvation period, whilst 1 ng/ml IL-6 instigated
STAT3 phosphorylation to approximately 87% of the baseline level (Fig-
ure 5.6).
A further experiment was subsequently undertaken to conrm that IL-6
was responsible for this observed baseline activation of STAT3. A neutral-
ising antibody which blocks the IL-6R (IL-6R NAb), and therefore prevents
IL-6 signalling, was added as indicated in Figure 5.7 to conuent broblasts
from healthy and asthmatic subjects.
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Figure 5.6: STAT3 Phosphorylation by IL-6. Conuent HBFs were serum starved
overnight and harvested directly (baseline) or the media changed and incubated
for a further hour in the absence (T60) or presence of IL-6. Cells were solubilised
in sample buer before western blotting and probing with a phospho-STAT3
antibody. Bands were analysed by densitometry (BioRad) and normalised for
loading using a pan STAT3 antibody. Data are mean +/- SEM. n = 6.
Addition of the IL-6R NAb resulted in the attenuation of the baseline
STAT3 activation by between 50 and 64% respectively at the lowest and
highest doses used, with all doses found to cause a statistically signicant
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Figure 5.7: The eect of IL-6R neutralising antibody on STAT3 phosphorylation.
To assess whether basal STAT3 phosphorylation was due to endogenous IL-6,
HBFs were treated as described in the schematic diagram and STAT3 phosphory-
lation was measured by western blotting (normalised to pan-STAT3 for loading).
In the presence of IL-6R NAb, STAT3 phosphorylation was signicantly reduced.
Data are mean +=  SEM. n = 6 healthy and 8 asthmatic subjects.
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reduction in STAT3 phosphorylation (p < 0:001 for every dose of IL-6R
NAb) (Figure 5.7).
As this IL-6R NAb was able to reduce the background phosphorylation,
the initial experiment studying the eects of IL-4 and IL-13 on STAT3
activation in HBFs (Figure 5.3) was repeated in the presence or absence
of the neutralising antibody as indicated (Figure 5.8a).
As before, in the absence of the IL-6R NAb the cells demonstrated
relatively high levels of basal activation of STAT3, which did not signicantly
increase with treatment (Figure 5.8b). When the IL-6R NAb was included
however, the basal phosphorylation was reduced and a signicant increase in
activation of STAT3 was then observed in response to IL-4 (p < 0:01). No
signicant change was seen in response to IL-13 treatment (Figure 5.8c).
Although addition of the IL-6R NAb highlighted a dierence in phospho-
rylation between IL-4 and IL-13 treatment, the question remains that if high
basal activation of this transcription factor is observed does a small increase
in phosphorylation have an eect? Whilst it is possible that it simply requires
a threshold be reached before activating further gene transcription, the fact
that the cells were producing high levels of IL-6 in the absence of any stimulus
it was considered that actually the cells may be in a more activated state
than would normally be observed in vivo.
Matrigel is a basement membrane matrix which is used to better emulate
the natural environment for broblasts within a tissue culture setting, and
can therefore be used to establish whether this high basal IL-6 production
is an artefact of standard tissue culture. This gel contains solubilised
extracellular matrix proteins, such as collagen IV, laminin and proteoglycans,
as well as various growth factors, and can be used either as a coating on which
the cells grow or a thick gel with cells embedded within.
Initial experiments were performed to characterise the eects of growing
broblasts either on (2D culture) or within (3D culture) Matrigel, in compar-
ison to tissue-culture coated plastic. HBFs were serum starved for 24 hours
prior to analysis of basal IL-6 production by ELISA of conditioned media.
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Figure 5.8: The eect of an IL-6R NAb on IL-4 and IL-13{mediated STAT3
phosphorylation. Fibroblasts were pretreated with or without an IL-6R neu-
tralising antibody (NAb) before stimulation with 10 ng/ml IL-4 or IL-13 for
1 hour as described in the schematic diagram (a). Phosphorylation of STAT3
was determined by western blotting and normalised to total STAT3 protein. Data
are mean +=  SEM. n = 14
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As found in Figure 5.5, at baseline the HBFs produced approximately
1000 pg/ml IL-6 over a 24 hour period (Figure 5.9), however the cells grown
either in 2D culture on Matrigel or 3D culture embedded within Matrigel
produced substantially less IL-6 than those on tissue-culture plastic. This
decrease was signicant when the cells were grown in 3D culture (p < 0:05).
In the 2D Matrigel system, only a trend towards signicance was observed,
which may be due to the limited number of subjects studied in this prelimi-
nary experiment.
Figure 5.9: Basal IL-6 production by broblasts in various culture conditions.
HBFs were grown either directly on tissue-culture plastic, on a well coated with
Matrigel or embedded within Matrigel. The cells were serum starved for 24 hours
before analysis of IL-6 production by ELISA of the conditioned media. Data are
mean +=  SEM. n = 3 healthy subjects.
The smaller reduction in IL-6 production observed with the cells grown on
Matrigel could also be related to the experimental design. One of the issues
found with the 2D Matrigel culture was the tendency of uneven coating of
146Chapter 5. Regulation of IL-4 & IL-13 by IL-13R2
the well by the gel, therefore some of the cells may still have been growing
either partially or fully on tissue-culture plastic.
The 3D culture of cells within Matrigel also provides complications as, to
date, no reliable method for extracting cells from the gel at the end of the
experiment has been established. Matrigel is a thermo-responsive matrix,
which forms a gel at 37C but liquies at colder temperatures (4C).
Therefore, it was considered that cooling the matrix could allow recovery of
the cells. Preliminary experiments were undertaken where cells were grown
in Matrigel or on tissue-culture plastic and treated for 1 hour with IL-4, IL-
13 or fresh media. At the end of the experiment, ice cold PBS containing
phosphatase and protease inhibitors was added to the cells to liquify the
Matrigel. The liquid Matrigel:PBS mix was transferred to a fresh tube and
stored on ice and this process was repeated until all of the Matrigel had
been collected. The cell:Matrigel:PBS solution was centrifuged at 300 g for
5 minutes to pellet the cells, before the addition of sample buer.
To conrm the presence of protein in samples obtained from each com-
partment an SDS-PAGE gel was run. Fairly consistent recovery of protein
was observed between the tissue-culture plastic and Matrigel-extracted sam-
ples (Figure 5.10), although there was more higher molecular weight protein
present in the latter. Presumably this protein is due to carry-over of the
matrix proteins, although no cell counting experiments have been performed
at this stage to ascertain if more cells were recovered in these samples.
Subsequently these samples were analysed for levels of STAT3 activation
by western blotting. When the cells were grown on tissue-culture plastic basal
phosphorylation of STAT3 was observed in both the presence and absence
of IL-4 and IL-13 (Figure 5.11). However, this endogenous activation of
STAT3 was markedly reduced in the cells which were embedded within the
Matrigel. As with the cells grown on tissue-culture plastic, no dierence
was observed with treatment, however this is possibly due to the inability of
the cytokine to penetrate into the gel, and therefore the mechanics of this
would need to be considered for future experiments. To overcome this, the
cells may need to be challenged for longer to allow the cytokine to penetrate.
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Figure 5.10: Protein extracted from broblasts grown within Matrigel. Fibroblasts
were grown either directly on tissue-culture plastic or embedded within Matrigel.
The cells were serum starved for 24 hours before treatment with IL-4, IL-13 or no
treatment (NT) for 1 hour. The cells grown on plastic were lysed by direct addition
of sample buer. The Matrigel-embedded cells were recovered by addition of chilled
PBS before pelleting and lysing the cells in sample buer. Protein content was
visualised by Coomassie blue stain. Mr = molecular weight marker. Representative
blot of n = 3 healthy subjects.
Alternatively, the cells could be grown embedded within Matrigel and then
extracted immediately prior to stimulation with IL-4 and IL-13, however the
cooling of the cells to extract them from the matrix could induce a response.
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Figure 5.11: STAT3 phosphoylation by broblasts in various culture conditions.
To assess whether basal STAT3 phosphorylation was observed in dierent culture
conditions, broblasts were grown either directly on tissue-culture plastic or
embedded within Matrigel. The cells were serum starved for 24 hours before media
exchange in the presence of IL-4, IL-13 or no treatment (NT) for 1 hour. STAT3
phosphorylation was measured by western blotting (normalised to pan-STAT3 for
loading). Representative blot of n = 3 healthy subjects.
5.3 Discussion
As IL-13R2, which has been classically considered to act as a \decoy
receptor", has recently been suggested to be able to initiate an intracellular
signal 249,280 this chapter focussed on attempting to elicit whether IL-13R2
can mediate STAT3 phosphorylation via IL-4.
In Chapter 4 attempts were made to develop a knockdown model of IL-
13R2. As these experiments using siRNA provided an unsatisfactory model
alternatives were sought. Another method of studying IL-13R2 is via an
overexpression model. As there was already such a model established within
our laboratories, initial experiments focused on validating this, and demon-
strated not only high levels of IL-13R2 on the surface of the transfected cells,
but also that these cells behaved as expected, with reduced responsiveness
to both IL-4 and IL-13.
The overexpression model of IL-13R2 validated in Section 5.2.1 was
subsequently used to investigate the role of IL-13R2 in STAT3 signalling to
determine whether IL-4 could mediate a STAT3 signal and establish if this
required IL-13R2 on the cell surface.
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Initial experiments demonstrated a signicant increase in STAT3 phos-
phorylation in the B2B-FL cells, which had been transfected with full length
IL-13R2. This was not observed in the B2B cells, which only contained a
mock sequence, suggesting that IL-13R2 is able to induce an IL-4-mediated
STAT3 signal in these cells.
Whilst these preliminary experiments showed similar results to that which
has been observed in glioblastoma by Rahaman et al. 249,280 these were
performed in an epithelial cell line. This is not an ideal model as in Chapter 3
broblasts were shown to behave dierently to epithelial cells with regards
to IL-13R2, however previous attempts by Dr Andrews to develop this
overexpression model in broblast cell lines have been unsuccessful.
Initial attempts to determine if IL-13R2 allows IL-4 signalling through
STAT3 activation in primary human bronchial broblasts were complicated
by the constitutive STAT3 phosphorylation by HBFs cultured for 24 hours in
serum free medium, with the removal of the conditioned medium leading to
a reduction in STAT3 phosphorylation, regardless of whether IL-4 or IL-13
treatment was included.
No signicant increase in STAT3 phosphorylation was observed in re-
sponse to either IL-4 and IL-13 compared with 1 hour of serum free medium.
This was even the case when the cells were pretreated with either cytokine
to upregulate the levels of IL-13R2, although this experiment may have
been complicated by also upregulating other genes such as SOCS proteins.
Therefore subsequent experiments set out to establish what caused the basal
STAT3 phosphorylation with the aim of minimising this artefact.
The reduction observed after exchanging the media suggested the pro-
duction of an autocrine mediator by the cells, released over a 24 hour period,
which constitutively activated STAT3. However, this mediator appeared
to be removed when the media was exchanged for one hour as the STAT3
phosphorylation decreased, regardless of whether IL-4 or IL-13 were present.
Therefore it was necessary to determine what this mediator was and what
was causing its production.
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As previous work has demonstrated that STAT3 is phosphorylated by
IL-6, experiments were performed to establish whether HBFs from healthy
and asthmatic patients release IL-6 at baseline. Substantial constitutive
release of IL-6 was observed in both patient groups in the absence of
any treatment, with no signicant dierence between HBFs obtained from
healthy or asthmatic subjects.
This phenomenon has previously been observed by Gomes, Mathur et
al. who demonstrated that IL-6 is endogenously secreted by a lung-derived
broblast cell line in their studies investigating the eects of eosinophil-
broblast co-cultures. 320
Whilst no dierence in basal IL-6 production was observed in this experi-
mental setting between healthy and asthmatic subjects, the cytokine milieux
within the lungs of subjects with and without asthma will vary greatly.
For instance, there is reported to be higher levels of TGF present in the
asthmatic lung. 135,321 TGF is a pro-brotic mediator associated with airway
remodelling, that is produced by broblasts, myobroblasts, epithelial and
inammatory cells in excess in asthma patients, in comparison to healthy
controls. 100,135,321{323 In the study by Gomes, Mathur et al. they observed
that the level of IL-6 produced by broblasts is augmented with TGF
treatment. 320 I have also undertaken preliminary experiments and found that
treatment of broblasts obtained from asthmatics but not healthy control
subjects with TGF results in a substantial increase in the production of IL-6
(data not shown), suggesting there may be dierences between the asthmatic
and healthy lung not readily demonstrated by the experiments presented
herein. Further work, however, would be required to fully characterise these
disease-related dierences.
Subsequent studies investigating the eects of adding IL-6 to the cells
found that 10 ng/ml IL-6 signicantly increased STAT3 phosphorylation, as
expected based on previous reports in various cell types. 319 However, this
was not sucient to conrm that IL-6 was the only cause of this endogenous
STAT3 phosphorylation so an IL-6R NAb was added, which resulted in
attenuation of STAT3 phosphorylation in a dose dependent manner. In this
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study four dierent concentrations of the IL-6R NAb were used, the highest
of which resulted in a 64% reduction in STAT3 phosphorylation. Whilst
this did not provide complete inhibition of the endogenous STAT3 activation
and addition of more antibody may have resulted in a greater reduction, the
scale of this diminution of phosphorylation compared with the cost was not
deemed viable.
Therefore, this dose was used in subsequent experiments to block the
endogenous STAT3 phosphorylation within these cells and it was found that
treatment of human bronchial broblasts with IL-4 in the presence of this
IL-6R NAb resulted in a signicant increase in STAT3 phosphorylation.
Interestingly, as with the B2B-FL cells, a smaller but non-signicant increase
was also observed with IL-13 treatment. It is unclear whether this increase
is sucient to aect downstream signalling and gene transcription.
There are several potential explanations for the dierences observed here
between the IL-4 and IL-13 treatment. One explanation could simply be that
as IL-13 is able to bind to IL-13R2 with high anity that it may just be
sequestered by this receptor, reducing the availability for signalling. As IL-4
is unable to bind to IL-13R2 directly this sequestration would not occur
for this cytokine. Alternatively if IL-4R is also required for the activation
of a STAT3 signal then the diering binding anities of IL-4 and IL-13 for
IL-4R may come into play.
Whilst in an overexpression system of IL-13R2 STAT3 phosphorylation
increased in response to challenge with IL-4, further work is required to
conrm if this is mediated by IL-13R2 in bronchial broblasts. Ideally
this would have been conrmed using an IL-13R2 knockout system in
primary human bronchial broblasts to see if this abrogated the STAT3
phosphorylation observed in response to IL-4 treatment, however due to
complications with the siRNA model this was not possible. In the absence of
this, an IL-13R2 NAb, which has previously been shown to have an eect on
anti-inammatory responses to IL-4 and IL-13, could be used to determine
if this IL-4-induced phosphorylation of STAT3 is mediated by IL-13R2.
152Chapter 5. Regulation of IL-4 & IL-13 by IL-13R2
Based on the assumption that this IL-4 induced STAT3 signal is IL-13R2
mediated the obvious question is what is the relevance of this phosphorylation
in vivo? Given the basal activation of STAT3 due to the endogenous produc-
tion of IL-6 observed in the early experiments it could have been assumed that
any changes in STAT3 phosphorylation would not be biologically signicant.
However, the basal IL-6 production appears to be an artefact from the in
vitro culture of these broblasts and although they were serum starved prior
to treatment they did not become completely quiescent. One method to
further quiesce the cells is by growing the cells in Matrigel, which better
mimics the in vivo environment where broblasts are not in an activated
state. Preliminary experiments found that under these conditions the basal
production of IL-6 by broblasts is substantially reduced in comparison to
broblasts grown on tissue culture plastic. Therefore, one might hypothesise
that within their normal environment, where the cells are not producing
substantial amounts of IL-6, and any that is produced does not persist in the
same manner as in a tissue culture well, much smaller increases in STAT3
are likely to be observed and that these will have an eect on the cells.
This experiment was expanded to analyse the STAT3 phosphorylation in
these dierent culture conditions. The retrieval of cells from Matrigel has
not been well characterised, therefore in this pilot experiment the gel was
cooled with ice-cold PBS in order to liquify the matrix. The ecacy of this
method was conrmed by running an SDS-PAGE gel, which was stained
with coomassie brilliant blue dye, before undertaking western blotting on
these samples.
In the cells obtained from within the Matrigel, a reduction in basal phos-
phorylation of STAT3 was observed, again suggesting that this endogenous
activation is likely to be an experimental artefact. However, the treatment
with either IL-4 or IL-13 failed to have an eect on these cells. This treatment
was added after the gel had already formed, and thus it is not clear whether
the cytokine was able to enter this matrix. Therefore, an essential next step
is to establish a method whereby cells can be stimulated with a cytokine
in this system. It may be that this is not possible, in which case the
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Matrigel coating may be the best available alternative. If IL-4-mediated
STAT3 phosphorylation was found in this system, this experiment could
then be expanded with studies of gene activation to determine the eects of
this STAT3-activation.
Another technical issue discovered during this experiment was the fact
that upon removal of the Matrigel, a layer of cells was also found attached
to the base of the well. Although all of the cells were seeded together with
the Matrigel, some of these broblasts migrated to the tissue-culture plastic
underneath. In future experiments, to prevent this from occurring, the base
of the well could be lined with a reagent such as agar or gelatin prior to
addition of the Matrigel:cells solution.
These Matrigel experiments have highlighted one of the issues of in vitro
experiments. Whilst this system allows us to investigate the eects of specic
cytokines in simplied systems, the eects of the culture conditioned must
also be considered. In this instance, the high basal production of IL-6 by
the broblasts grown on tissue-culture plastic, which was lost when the cells
were embedded within Matrigel and therefore quiesced, suggests that the
broblasts are receiving an activation signal by the tissue-culture plastic.
Similar responses have been observed with hepatic stellate cells, which
become myobroblastic on tissue-culture plastic but quiescent in Matrigel. 324
This has implications in not only these specic experiments, but also the
use of tissue-culture plastic as a growth support in broblast experiments.
Whilst collagen coating is also regularly used, experiments performed by Dr
Andrews found that similar levels of IL-6 were produced both at baseline and
after 24 hours serum starvation on collagen-coated and uncoated wells. This
suggests that a better model for broblast-based in vitro experiments might
be to use the Matrigel system. However, before this can be done routinely
the technical methodology would need to be improved to allow the current
range of experiments to be undertaken. In particular, methods of treating
cells within Matrigel, and extraction of cells embedded within this matrix
would need to be established.
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Previous work has suggested that the STAT3 mediated responses dier
in interstitial lung disease patients compared with healthy subjects. 58 Here
Moodley, Misso et al. demonstrate a switch to a pro-survival phenotype
resulting in brosis. 58 In idiopathic pulmonary brosis these dierences have
been attributed to IL-6 and in particular a shift in IL-6 signalling from
pro-apoptotic, as observed in healthy controls, to pro-survival has been
observed. 58 However, if IL-13R2 is able to instigate a STAT3 signal via
IL-4 it would be of great interest to determine whether this aects cell
proliferation in the asthmatic lung where remodelling in the form of brosis
is also observed.
It could be hypothesised that in healthy patients STAT3 prevents pro-
liferation, and that this is dysregulated in asthma, which may contribute to
the subepithelial brosis observed in asthmatic lung remodelling. This is
another interesting area for future work.
Several studies have also highlighted the role of STAT3 in the activation
of angiogenesis in cancer, however to date this has not been studied in
asthma. 325 As angiogenesis is often observed in asthmatic airway remodelling
the potential involvement of both IL-4 and STAT3 in this angiogenesis would
need to be investigated further.
As IL-6-mediated activation of STAT3 has also been found to elicit both
pro- and anti-inammatory eects it would also be of interest to investigate
this further. IL-4 is involved in Th2-mediated inammation, which is often
considered a hallmark of asthma. Therefore, if IL-4 is able to mediate
an erroneous STAT3 signal via IL-13R2 this could impact the chronic
inammation observed in asthma. 314
5.4 Summary
In summary, an overexpression model of IL-13R2 demonstrated the ability
of IL-4 to induce STAT3 phosphorylation and that this requires IL-13R2.
Initial experiments to conrm this in primary human bronchial broblasts
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were complicated by the presence of endogenous IL-6 production, but when
this was neutralised, IL-4-mediated activation of STAT3 was observed. Fur-
ther experiments using a neutralising antibody against IL-13R2 would be
required to conrm this is IL-13R2-mediated.
Whilst no dierence was found between healthy and asthmatic subjects,
further work is required to understand the signalling consequences of this
IL-4-mediated STAT3 activation. Initially this would involve conrmation
of nuclear localisation of the phosphorylated STAT3 by immunostaining,
followed by analysis of STAT3-induced gene expression using a focussed
micro-array.
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6.1 Overview
Both IL-4 and IL-13 can be regulated by IL-13R2, however very little is
known about this receptor. In particular the mechanism by which IL-13R2
can attenuate the eects of IL-4, when the two are unable to bind, and the
importance of the other IL-4 and IL-13 receptors in the regulation of these
cytokines has been uncertain.
The key ndings of this project are that long-term upregulation of IL-
13R2 surface expression occurs in response to stimulation by a range of both
Th2 and Th1 mediators, including IL-4, IL-13 and IFN. In broblasts this
requires de novo protein synthesis as these cells do not contain intracellular
stores of this receptor, a phenomenon previously observed in epithelial cells.
Whilst a transient reduction in IL-4R was found in response to IL-4 or
IL-13, thereby reducing the ability to bind ligand and transduce a signal, it
is the IL-13R2 subunit that appears to be responsible for the longer-term
regulation of these two, key Th2 cytokines.
Investigations into the mechanism by which IL-13R2 can regulate IL-4
in the absence of their direct association identied that IL-4 can induce a
STAT3 signal in the presence of IL-13R2, although further work is required
to establish the signalling consequences of this phosphorylation on gene
expression and cell function.
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6.2 Regulation of IL-4 & IL-13 Receptor
Surface Expression
The initial aim of this project was to characterise the expression and reg-
ulation of the dierent IL-4 and IL-13 receptors, and determine their roles
in the variation in responsiveness observed between subjects to IL-4 and IL-
13. To this end, in Chapter 3 IL-13R2, IL-4R, IL-13R1 and c were
systematically examined from gene to surface expression in HBFs from a
range of healthy and asthmatic subjects.
The Interleukin 4 and 13 receptor system appears to be dynamic, with
surface expression of IL-4R rapidly depleting in response to stimulation by
either ligand, whilst IL-13R2 surface expression increased much more slowly
and appears to be less dynamic once it reaches the cell surface. Whilst the
internalisation of the IL-4R receptor may help to regulate IL-4 and IL-13
in the short term, it appears that IL-13R2 is important for the longer term
regulation of these Th2 cytokines.
Interestingly though, the regulation of IL-13R2 does not appear to occur
simply in response to IL-4 and IL-13. Instead there appears to be much
broader regulation by other cytokines. Previously, upregulation of surface
IL-13R2 from intracellular stores has been observed in response to IFN in
epithelial cells. 251 In this project this work has been expanded and it was
found that not only IFN, but also IFN and dsRNA are able to upregulate
IL-13R2 surface expression on human bronchial broblasts, and that this
occurs despite the lack of intracellular pools in these cells. Instead, in these
cells addition of any one of these stimuli results in de novo protein synthesis.
In epithelial cells, where IL-13R2 can be upregulated from intracellular
pools, an increase in expression is observed hours before that of broblasts,
which require de novo synthesis. This slower upregulation in broblasts may
be part of the longer-term modulation of these cytokines, with a reduction
in IL-4R regulating short term eects.
158Chapter 6. Final Discussion
The internalisation of IL-4R in this system appears to be transient, with
restoration of surface expression occurring shortly after the ligand is removed,
suggesting that this receptor is not being degraded. This internalisation of
IL-4R in response to ligand binding is a common phenomenon observed
with receptors to prevent overstimulation. 326,327 In the IL-2 receptor system,
which shares a common c subunit with the type I IL-4 receptor, binding
of IL-2 leads to the endocytosis of IL-2R:c, which is then targeted for
degradation. 328 With the IL-4 receptor system neither IL-4R not IL-4
appear to be broken down after internalisation. 297 Both IL-2R and c
contain sequence elements in their cytoplasmic domains which target these
receptor subunits for degradation. 329 No such sequences, however, have been
found on IL-4R. 330{333
IL-4R internalisation also does not appear to be necessary for induction
of an IL-4 or IL-13 signal, 297 and therefore would be assumed to play a role in
the regulation of these ligands by reducing the amount of the receptor avail-
able on the surface. In this study the regulation of IL-4 and IL-13 was studied
after 24 hours where addition of an IL-13R2 NAb restored responsiveness
to IL-4 and IL-13, as measured by eotaxin production. However, whilst this
longer-term regulation appears to be dependent on IL-13R2, it is likely
that IL-4R internalisation is responsible for any short-term regulation of
responses to these cytokines.
The ability of broblasts to upregulate IL-13R2 in response to not only
Th2, but also Th1 cytokines and stimuli, and subsequently regulate Th2
responses suggests this receptor is important in the Th1/Th2 balance. How-
ever, whilst the role of IL-13R2 in regulating inammatory gene expression
has been demonstrated through suppression of both eotaxin and IL-6 produc-
tion, it is not clear whether this receptor is also involved in upregulating the
expression of other genes, or if this alternative gene activation is important
for the regulatory mechanism of IL-13R2.
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6.3 Can IL-13R2 Instigate a Signal?
One of the main questions regarding IL-13R2 has been how does IL-13R2
regulate IL-4, despite being unable to bind directly to it? Whilst IL-13
responsiveness could be regulated by IL-13R2-mediated sequestration of
the ligand, in recent years several groups have proposed that in fact both
IL-4 and IL-13 may induce a signal via IL-13R2, which may be involved in
this regulatory mechanism.
In Chapter 5, IL-4 was found to induce STAT3 phosphorylation in the
presence of IL-13R2 in both an overexpression model and primary human
bronchial broblasts. However, due to the time constraints of this project
further interrogation of this pathway is required to understand the role of
this STAT3 activation.
STAT3 is a transcription factor normally associated with anti-apoptotic,
pro-proliferative actions, although this appears to elicit pleiotropic eects
with the activation of both pro- and anti-inammatory genes depending on
the cell type. Whilst no disease-related dierences were observed in the
activation of STAT3, it is unclear whether greater activation of STAT3 would
be found in asthmatic subjects compared with healthy controls in vivo, due to
the increased levels of IL-6 in the asthmatic lung. 334 This endogenous IL-6
in the asthmatic lung could negate the requirement for an IL-4-mediated
STAT3 signal, or this may act in an additive manner. However, STAT3
signalling has been found to exhibit pleiotropic, and often opposing eects,
where sometimes dierent signalling consequences are observed depending
on the disease state. One such example is found with IL-6-mediated STAT3
signalling, which in the healthy lung is pro-apoptotic, however in idiopathic
pulmonary brosis (IPF) this switches to become pro-brotic. 58,335 As bro-
sis and remodelling are often observed in the asthmatic lung, it could be that
this is caused by an increase in anti-apoptotic, pro-brotic signals in response
to STAT3 activation.
In the brain, the role of IL-4 appears to be linked to reducing proliferation
and arresting growth. 268{273 However, in glioblastoma, the induction of
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STAT3 activation by IL-4 via IL-13R2 results in increased transcription
of anti-apoptotic genes, with IL-13R2 seeming to induce a survival signal
in these cells. 249,280 In the lung, proliferation of broblasts is a hallmark of
the remodelling observed in asthma. Therefore, it is hypothesised that the
IL-4-mediated induction of STAT3 in broblasts might lead to anti-apoptotic
eects in these cells by activation of the BCL2 family.
IL-13R2 has previously been found to regulate both IL-4 and IL-13,
however the data presented in this thesis suggest that the regulation mecha-
nism may be dierent for each of these cytokines, with IL-4 able to instigate
a strong STAT3 signal, which was not observed with IL-13. With IL-13, on
the other hand, it might be that IL-13R2 simply acts as a decoy receptor
for this cytokine. Alternatively, as has been recently suggested, AP-1 may
also be involved in at least part of the regulation of IL-13.
A variety of possible mechanisms have been proposed for the regulation
of IL-4 and IL-13 by IL-13R2 (Figure 6.1), each of which will be discussed
below.
IL-13R2 has previously been considered as a \decoy receptor" for IL-13
as it binds this ligand with high anity (Figure 6.1a). The consequence of
this may simply be sequestration of IL-13, thus reducing the amount of this
cytokine available for signalling. Alternatively, binding of IL-13 to IL-13R2
may be sucient to induce a signal. This latter option has been generally
considered unlikely due to IL-13R2 having short intracellular tail, contain-
ing only 17 amino acid residues and lacking any obvious signalling motifs, 241
suggesting that another protein would be required to allow signalling to
occur. However, it has been suggested recently that IL-13R2 may induce an
intracellular signal in response to IL-13. 261{265 These studies have identied
an alternative signalling molecule that may be involved, an AP-1 variant
consisting of c-Jun and Fra-1, which activates the TGFB1 promoter. 262,336
This appears to be specically in response to IL-13, and not IL-4, which is
unable to bind directly to this receptor. As IL-13R2 has a short intracellular
tail and is not known to bind to IL-13R1, it is not currently clear how this
activation might occur. The investigations by Fichtner Feigl et al. have
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Figure 6.1: The possible mechanisms of IL-13R2 signalling. IL-13R2 may
attenuate IL-4 and IL-13 in a variety of ways. a) Whilst previous studies have
suggested that IL-13R2 can block IL-13 signalling by acting as a decoy this is
an unlikely mechanism for controlling IL-4-mediated responses as it is unable to
bind to this receptor. 165 IL-13R2 can, however, bind to IL-4R, which could
b) prevent recruitment of IL-13R1 or c, which may allow activation of an
alternative signalling pathway. Binding of IL-13R2 to the type II receptor may
c) block activation of JAK-1 or STAT6 or d) could again form a unique scaold,
which might allow the docking of an alternative signalling molecule. IL-13R2
could also instigate a signal on its own via either STAT3 or AP-1. 261,264,280
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mainly used experimental models of Crohn's disease, a brotic condition of
the intestines, and bleomycin-induced pulmonary brosis in mice, therefore,
it would be important to establish if this signal also occurs in the human
lung. The activation of AP-1 by IL-13 via IL-13R2 could be investigated
using the overexpression model of this receptor and western blotting for c-Jun
phosphorylation. If this model demonstrated the induction of phosphorylated
c-Jun in response to IL-13, this could then be conrmed in primary bronchial
broblasts in the presence and absence of a neutralising antibody against IL-
13R2. However, despite these suggestions of IL-13-mediated signalling via
IL-13R2, it is important to note that the soluble form of this receptor,
which lacks the intracellular tail, can ameliorate the eects of IL-13. As this
is the case, it is unclear whether the regulation of IL-13 occurs mainly, or
entirely via sequestration and, if a signal such as AP-1 activation does occur,
whether this specically is a disease-related eect.
Previous studies have shown IL-13 to elicit pro-brotic eects. 337 There-
fore, if IL-13 can mediate activation of the TGFB1 promoter via IL-13R2,
this could play a role in airway brosis. TGF has already been implicated
as an important contributor of airway brosis, and the presence of high
quantities of IL-13 in the lungs of \Th2 high" asthmatics could therefore
be partially responsible for the remodelling observed in the asthmatic lung.
Whilst sequestration or direct signalling via only IL-13R2 could be
involved in the regulation of IL-13, it is not likely to be the case for IL-4,
as this cytokine is unable to bind directly to IL-13R2. 165,249 Therefore,
any regulation of IL-4 by IL-13R2 would require the presence of an IL-4
binding protein. Andrews, Nasir et al. have previously demonstrated that
a physical interaction occurs between the intracellular tail of IL-13R2 and
IL-4R in the presence of IL-4. 165 As the extracellular domain of IL-13R2
cannot bind IL-4 directly 165 this could be essential for the regulation of
IL-4 by IL-13R2. This association between IL-13R2 and IL-4R could
prevent the recruitment of IL-13R1 or c (Figure 6.1b), thus blocking the
heterodimerisation required for STAT6 signalling with these receptors. This
physical interaction between IL-4R and IL-13R2 might also result in the
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formation of a unique scaold allowing the mediation of alternative signals
such as the activation of STAT3.
Alternatively, IL-13R2 may bind to the IL-4R subunit of the type II
receptor heterodimer (Figure 6.1c). As the intracellular portion of IL-13R2
appears to be necessary for the regulation of IL-4, which cannot be controlled
by the soluble form of this receptor, 165 this suggests that this region of IL-
13R2 could prevent the normal recruitment of the intracellular signalling
proteins. Whilst the intracellular portion of IL-13R2 is much shorter than
the IL-4/IL-13 signalling receptors, it may be able to block the JAK1 binding
site, Box 1, on IL-4R which is membrane proximal.
Alternatively, the presence of the IL-13R2 tail may form a unique scaf-
fold which could allow the association of an alternative signalling molecule,
that is then able to regulate IL-4 (Figure 6.1d). It is this latter scenario
which may be the case for initiation of a STAT3 signal in response to IL-4.
This interaction between IL-4R and IL-13R2 appears to only occur in the
presence of IL-4, 165,249 and therefore it remains unclear if this is involved
in IL-13R2-mediated regulation of IL-13. To establish whether IL-13R2
binds to IL-4:IL-4R alone or a larger receptor complex, IL-4R could be
immunoprecipitated and the presence of IL-13R2 can be conrmed. This
could then be expanded to see whether anything else co-precipitates with
this complex, such as IL-13R1 or an alternative signalling molecule.
The activation of alternative signalling molecules could be initially studied
using a phosphotyrosine antibody screen (antibody micro-array) of cells
treated with IL-4 or IL-13. For this, the overexpression model could be
compared with primary bronchial broblasts from naturally low and high
expressers of IL-13R2. Any novel phosphorylation changes could then
be further analysed for nuclear localisation of the activated transcription
factors by immunocytochemistry and induction of gene expression using
focussed micro-arrays. Of particular interest would be a specic micro-
array investigating STAT3-regulated genes to establish whether activation
of STAT3 by IL-4 induces anti-apoptotic eects.
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Although IL-4 and IL-13 elicit many overlapping roles, these cytokines
also exhibit some distinct dierences. Previously the dierences between IL-4
and IL-13 have been attributed to the dierential expression of the type I
(IL-4R:c) and type II (IL-4R:IL-13R1) receptors on various cell types.
However, if the regulation of these two cytokines by IL-13R2 diers, it
might be that this is also important.
Several other factors may also aect the signalling pathways of IL-4 and
IL-13. Two of the best known groups of proteins for preventing JAK/STAT
signalling are the Suppressor of Cytokine Signalling (SOCS) and the Protein
Inhibitor of Activated STAT (PIAS) family molecules.
Both IL-4 and IL-13 have been shown to upregulate expression of SOCS-1
and SOCS-3 in a variety of cell types. 338{340 The induction of SOCS-1 mRNA
occurs rapidly, peaking after 1 hour. 338 In comparison, in this project the
upregulation of IL-13R2 mRNA was not found until 8 hours. Whilst none
of these studies have analysed upregulation of SOCS-1 protein expression
it could be that this occurs more rapidly than IL-13R2, and therefore, in
conjunction with IL-4R, these proteins may be involved in the short-term
regulation of these cytokines, prior to upregulation of IL-13R2. In addition,
in this study, an IL-13R2 neutralising antibody restored the responses of
these cells to IL-4 and IL-13 in the presence of high levels of IL-13R2,
again suggesting the role of SOCS proteins may be limited to this short-term
regulation.
Whilst overexpression SOCS-1 has been shown to suppress the activation
of STAT6-responsive genes by both IL-4 and IL-13, the regulation of these
cytokines by SOCS-3 and SOCS-5 has been debated, with one study showing
that although transient overexpression of SOCS-3 had an eect, this was
lost when the cells were stably transfected with this inhibitor. 341,342 More
recently, overexpression models using point mutations in the regions of SOCS-
1 and SOCS-3 proposed to be necessary for this regulatory activity showed
that the STAT6-mediated eects of IL-4 and IL-13 were suppressed in the
presence of wildtype SOCS-1 or SOCS-3, but this regulation was lost when
the mutated forms were present. 343 However, these studies have all used
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overexpression models, which are driven by strong CMV promotors and,
therefore, expression levels of these inhibitory proteins may not relate to
what is found in vivo. These studies have also been undertaken in various
cell lines, such as 293T human embryonic kidney cells or M12.4.1 B cell
lymphoma cells. The natural expression levels of IL-13R2 are unknown in
these cells, and therefore the regulation of IL-4 and IL-13 may dier between
these cell types. As this system appears to be highly complex it would be
important to establish the role of these SOCS proteins in both the short and
long-term regulation of IL-4 and IL-13 in primary human broblasts, using
both overexpression and knock-down models.
Interestingly, like IL-13R2, SOCS proteins also appear to be induced by
Th1 cytokines, such as IFN. 342,344 Further to this, SOCS-1 appears to be
important in the regulation of IFN as mice decient in SOCS-1 die within 3
weeks of birth due to excessive production and response to IFN. 345{348 It is,
therefore, possible that at least a portion of the regulation of IL-4 and IL-13
by these SOCS proteins is due to the regulation of IL-13R2 expression by
IFN. This suggests that the regulation of the Th1 and Th2 cytokines is
highly complex and may involve a range of inhibitors, each of which plays a
role in regulating not only the the overall responsiveness to these cytokines,
but also the magnitude of this response.
6.4 The Role of IL-13R2 in Asthma
In a subgroup of asthmatics, the Th2 phenotype is thought to be especially
important and recently IL-13, and proteins induced by IL-13 such as pe-
riostin, have been proposed as biomarkers for this phenotype. 200{203 These
\Th2 high" patients demonstrate Th2-type inammation with a predomi-
nance of Th2 cytokines, such as IL-4, IL-5 and IL-13, and eosinophilia.
In the broblasts analysed, there was heterogeneity in the IL-13R2
surface expression, both in the absence and presence of IL-4 and IL-13.
Therefore, regardless of the level of expression of these cytokines in the
lung at baseline, dierences are likely to be observed in the responsiveness
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of subjects to IL-4 and IL-13 in vivo. Whilst it might be assumed that
broblasts obtained from asthmatic subjects would express lower levels of
IL-13R2, this was not found to be the case, with no dierence in IL-13R2
surface expression observed between disease states in this study. However,
it is not clear whether IL-13R2 expression levels is consistent between cell
types, and therefore, the higher expression of IL-13R2 on broblasts by one
subject, might be compensated for by lower expression on other cells, such
as epithelial cells.
As there is much heterogeneity in the asthma phenotype, the \Th2 high"
and \Th2 low" subgroups must instead be considered. With IL-13R2 acting
as a regulator for IL-13, biomarkers such as periostin, which is induced by
IL-13, might be more accurate indicators of the \Th2 high" phenotype as
subjects expressing high levels of IL-13 levels as well as high IL-13R2
expression would likely express lower levels of periostin than those with lower
levels of IL-13R2.
In the \Th2 high" group, it could be predicted that the higher levels of IL-
4 and IL-13 would result in increased expression of IL-13R2. However, these
patients also express high levels of IL-13-induced proteins, such as periostin,
suggesting that this may not be the case. This system appears to be highly
complex, and one aspect that must be considered in this scenario is the eect
of genetics on the regulation of these cytokines by IL-13R2, for instance the
rs20541 variant of IL-13 cannot be regulated as eectively by IL-13R2 as the
wildtype form. 281 This polymophism, which is more common in asthmatic
subjects, 147 mediates increased responsiveness to IL-13 and therefore could
result in greater expression of periostin. In patients expressing this mutation,
even if high levels of IL-13R2 were present, the eectiveness of this would
be reduced, which may explain some of the dierences between these \Th2
high" and \Th2 low" subjects.
Asthma is characterised by periods of worsening symptoms, called exacer-
bations. Asthmatic patients exhibit increased susceptibility to RV infections,
which are one of the leading causes of exacerbations, 349{351 as the viral
infection persists in the lower aiways. 352 In these patients \minor" infections
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can impact on morbidity and mortality. Current asthma therapy is ineective
at preventing these exacerbations and existing treatments for viral infection
have only limited eects. Therefore understanding the dierences between
asthmatic and healthy individuals response to viral infection could provide
new insight for asthma therapy.
The Th1/Th2 balance is regulated in vivo by the expression levels of IFN
and IL-4. This balance between Th1 and Th2 states has been considered an
important aspect of both the antiviral response and allergic inammation
and asthma. With IL-13R2 able to modulate the responses of both IL-4
and IL-13, which is important for the regulation of the Th2 response, it is
likely that expression of this receptor plays a key role in switching from a
Th2 bias to a Th1 environment. As this Th1 phenotype is associated with
an innate immune response to bacteria and viruses, 16 increasing levels of IL-
13R2 would enable switching the bias towards this, favouring an antiviral
response, whilst also reducing Th2-mediated inammation.
In Chapter 4 the attempts to develop a knockdown model of IL-13R2 in
primary human bronchial broblasts using siRNA highlighted the induction
of an Interferon response by these cells. As a part of this study it was found
that IL-13R2 surface expression is upregulated in response to both dsRNA
and IFN.
In both bronchial epithelial cells and broblasts, the innate immune
response to dsRNA involves the production of type I (IFN and IFN)
and III (IFN) Interferons. 353 Addition of Poly I:C, a synthetic analogue
of dsRNA, which is often used in an experimental setting to mimic the
replication stage of the viral lifecycle, where epithelial cells release viral
dsRNA, resulted in production of IFN by the broblasts, which in turn
induced the upregulation of IL-13R2. Direct stimulation with either IFN
or IFN was also found to increase surface expression of IL-13R2.
During viral replication double stranded RNA (dsRNA) is formed and
this molecular pattern is detected by cells via RIG-like helicases and Toll-Like
Receptor 3 (TLR3). The response to viral insult diers between epithelial
cells and broblasts, which act in a coordinated manner to ght infection. In
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epithelial cells the Interferon response to virus results in rapid apoptosis
of infected cells, followed by rapid phagocytosis preventing further viral
replication. These cells also release Interferons and pro-inammatory media-
tors, which aids the orchestration of an innate immune response. 354,355 Both
virus infection and stimulation with dsRNA induce an Interferon response
in epithelial cells. In broblasts, on the other hand, IFN is only observed
in response dsRNA, with no signicant increase in Interferon production
detected post infection with human rhinovirus (RV). 307
The other major dierence between epithelial cells and broblasts with
regards to the Interferon response is the location of TLR3 receptors. In
epithelial cells these are found intracellularly whereas broblasts express
TLR3 receptors on their cell surface. 356 In epithelial cells, the intracellular
location of TLR3 allows an autocrine response to viral replication occurring
within the cell. 356 The presence of TLR3 on the broblast surface, on the
other hand, enables these cells to produce a potent antiviral response to
dsRNA, which is released by the epithelial cells infected with virus, allowing
the induction of a robust antiviral response before the virus enters the cell. 307
As IL-13R2 surface expression upregulated by dsRNA stimulation sup-
presses the broblasts responses to IL-13, this suggests that during viral
replication, broblasts exposed to dsRNA and IFN would use this mech-
anism to downregulate the Th2 response, promoting a Th1 phenotype. In
vivo IFN and IL-4 are classically considered the key mediators for switching
the functionally plastic T helper cells between the Th1 and Th2 states,
however these data suggest that this regulation is in fact much broader and
more complex than previously thought. It is therefore hypothesised that the
increased expression of IL-13R2 in response to a range of Th2 and Th1
stimuli aids the phenotypic switch to a Th1 response, which is required to
ght the virus.
Recently it has been demonstrated that bronchial epithelial cells obtained
from asthmatics are unable to produce a sucient Interferon response to virus
infection, with decient induction of IFN, IFN and IFN. 357{359 In the
work presented in Chapter 4, similar responses were observed by broblasts
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obtained from either healthy or asthmatic patients in response to challenge
with IFN or dsRNA. This is similar to what was observed by Bedke, Haitchi
et al., who, in addition, found that broblasts only respond to the dsRNA
signal, and not to direct viral infection when mounting an IFN response. 307
The fact that the broblasts produce IFN in similar quantities in response
to dsRNA regardless of disease status suggests the deciency observed by
Wark, Johnston et al. 357 and Contoli, Message et al. 358 may be specic to
the epithelial cells and alveolar macrophages, both of which are involved in
the rst line response to viral infection. However, this will still have a knock-
on eect on the upregulation of IL-13R2.
Recent studies have investigated the use of IFN or IFN as a therapy for
asthma, due to the deciency observed in the production of these cytokines.
In asthmatic patients, the decient production of Interferons may result
in a less robust switch to an anti-viral, Th1 response by not properly
downregulating the Th2 phenotype. Therefore, providing one or more of
these Interferons directly is thought to promote the Th1 environment. Whilst
IFN is able to do this directly, by acting on na ve or Th2 polarised T cells,
based on the ability of both IFN and IFN to upregulate IL-13R2, one of
the actions of this novel therapeutic may also be increasing the expression of
this receptor, thus favouring a Th1 bias.
Inhaled or oral steroids are commonly used in asthma, either as main-
tenance therapy or specic treatment after an exacerbation. In Chapter 4,
IL-13R2 surface expression was found to be attenuated by steroids. Whilst
this appeared to reduce basal expression of IL-13R2, this was particularly
evident when broblasts were treated with a stimuli which can normally
increase surface expression levels of this receptor, such as dsRNA, where
Dexamethasone was found to completely abrogate this upregulation in re-
sponse to treatment. These data suggest that whilst a non-asthmatic person
exposed to virus would upregulate their expression of IL-13R2 on bronchial
broblasts to help ght the infection, an asthmatic patient taking steroids
would not see this same induction of IL-13R2. This, combined with the
170Chapter 6. Final Discussion
decient production of Interferons by asthmatic subjects, would potentially
reduce their ability to switch to a Th1 environment.
Whilst it could be considered that the steroid-dependent expression of
IL-13R2 would have negative implications in the response to viral infec-
tions for asthmatic patients taking corticosteroid therapy, there has been
some indication that IL-13 itself is also regulated by steroids, resulting in
lower expression of this cytokine, 309,310 and suppressing IL-13-induced gene
expression. In recent years it has been established that patients who are
\Th2 low" appear to respond less well to steroid therapy than their \Th2
high" counterparts. 203 In the \Th2 low" group it could be predicted that
these patients normally express high levels of IL-13R2, which suppresses
the eects of any IL-13 or IL-4 present. However, it is not clear whether
the reduced expression of IL-13R2 would allow any IL-13 present to elicit
a greater eect, therefore reducing the benets of this steroid therapy, or
whether in these \Th2 low" patients IL-13 is not a driving force of their
asthma symptoms.
6.5 Conclusions
The ability of IL-13R2 to regulate the actions of both IL-13 and IL-4, and
thus negatively regulate some of the inammatory responses observed in
asthma has led to the view that a small-molecule mimetic of this receptor
could act as a therapy for asthma. However, in recent years the discovery
that this receptor may induce a signal in response to either IL-4 or IL-13 has
highlighted that IL-13R2 cannot be considered in such simplistic terms
as \a good guy" in the asthmatic lung. The two proposed mechanisms
for IL-13R2 signalling: activation of AP-1 leading to activation of the
TGFB1 promoter, thus inducing probrotic eects, and STAT3 phospho-
rylation, which is known to induce anti-apoptotic proteins, and therefore
could maintain broblast survival, both have the potential to induce brosis.
Parallels can be drawn between these possible roles of IL-13R2 and those of
TGF. Whilst TGF exhibits anti-inammatory eects, this cytokine plays
171Chapter 6. Final Discussion
a negative role in asthma, where high levels are expressed, due to its ability
to promote brosis by activating broblasts. Whilst the suppressive eects
of IL-13R2 on inammatory gene expression have been well documented,
the full eects of this receptor are unclear, and therefore global analysis of
gene expression in response to IL-4 and IL-13 in both naturally high and
low expressers of this receptor is required to clarify how IL-13R2 is eliciting
its eects. The potential for IL-13R2 to drive a probrotic response in the
face of a viral infection, where large quantities of IL-4 and IL-13 may still be
present highlights the urgency of determining which genes are regulated by
this receptor.
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Reagents, Media & Buers
A.1 Cell Culture Media
A.1.1 DMEM Complete
Dulbecco's Modied Eagles Medium (DMEM)
10% (v/v) Heat-inactivated foetal bovine serum (FBS)
50 IU/ml Penicillin
50 g/ml Streptomycin
2 mM L-glutamine
1 mM Sodium pyruvate
1 mM Nonessential amino acids (MEM)
A.1.2 Serum Free Medium (SFM)
UltraCulture
50 IU/ml Penicillin
50 g/ml Streptomycin
2 mM L-glutamine
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A.1.3 siRNA Media
Dulbecco's Modied Eagles Medium (DMEM)
10% (v/v) Heat-inactivated foetal bovine serum (FBS)
2 mM L-glutamine
1 mM Sodium pyruvate
1 mM Nonessential amino acids (MEM)
A.2 PCR Primers
Human c
Sense Primer CGACAATTCTGACGCCCAAT
Anti-sense Primer GAACACAAAACACTGAACCTCTG
Human IL-4R
Sense Primer CCCAGCGAGCATGTGAAAC
Anti-sense Primer GCATAGGTGAGATGATTATACAGGTA
Human IL-13R1
Sense Primer AATGGTCAAGGATAATGCAGGAA
Anti-sense Primer GGTCATCATTGTGGAAGGAGAG
Human IL-13R2
Sense Primer AAACAACAAATGAAACCCGACAA
Anti-sense Primer GTCTTCACCTTCCCAGCATTG
Human IFN-
Sense Primer TTACTTCATTAACAGACTTACAGGT
Anti-sense Primer TACATTAGCCATCAGTCACTTAAAC
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A.3 SDS-PAGE Buers
A.3.1 Reducing Sample Buer
62.5 mM Tris-HCl pH 6.8
10% Glycerol
2% Sodium Dodecyl Sulphate
5% -mercaptoethanol
0.01% Bromophenol Blue
A.3.2 Separation Gel
10% (w/v) Acrylamide/0.8% Bis-acrylamide
1.5 M Tris-HCl pH 8.8
20% (w/v) Sodium Dodecyl Sulphate (SDS)
10% (w/v) Ammonium persulphate (APS)
1% (v/v) TEMED
A.3.3 Stacking Gel
3.75% (v/v) Acrylamide/0.8% Bis-acrylamide
0.5 M Tris-HCl pH 6.8
20% (w/v) SDS
10% (w/v) APS
1% (v/v) TEMED
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A.3.4 Tris-Glycine-SDS Running Buer pH 8.3
25 mM Tris
192 mM Glycine
0.1% (w/v) SDS
A.3.5 Coomassie Brilliant Blue Stain
0.01% Coomassie Brilliant Blue R
45% (v/v) Methanol
10% (v/v) Glacial Acetic Acid
A.3.6 Gel Destain
25% (v/v) Methanol
10% (v/v) Glacial Acetic Acid
A.4 Western Blotting Buers
A.4.1 Transfer Buer pH 8.0-8.3
25 mM Tris
192 mM Glycine
20% (v/v) Methanol
A.4.2 Tris Buered Saline (TBS)
137 mM Sodium Chloride
50 mM Tris
Adjust to pH 7.6 with HCl
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A.4.3 Blocking/Antibody Buer
0.1% (v/v) Tween 20, 5% Dried milk powder in TBS
A.4.4 Wash Buer
0.1% (v/v) Tween 20 in TBS
A.4.5 Stripping Buer
100 mM -mercaptoethanol
2% (w/v) SDS
62.5 mM Tris pH 6.7
A.5 Flow Cytometry Buers
A.5.1 Dulbecco's Phosphate Buered Saline (DPBS)
137 mM NaCl
2.7 mM KCl
8.1 mM Na2HPO4
1.5 mM KH2PO4
pH 7.2 { 7.4
0.2 m sterile ltered
A.5.2 FACS Buer
0.5% Bovine Serum Albumin (BSA) Fraction V, 2 mM EDTA in DPBS
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A.6 ELISA Buers
A.6.1 Dulbecco's Phosphate Buered Saline (DPBS)
137 mM NaCl
2.7 mM KCl
8.1 mM Na2HPO4
1.5 mM KH2PO4
pH 7.2 { 7.4
0.2 m sterile ltered
A.6.2 Wash Buer
0.05% (v/v) Tween 20 in DPBS
A.6.3 Reagent Diluent
1% (w/v) Bovine Serum Albumin (BSA) Fraction V in DPBS
A.7 Methylene Blue Buers
A.7.1 Formal Saline
4% (v/v) Formaldehyde in 0.9% (v/v) saline solution
A.7.2 Methylene Blue
1% (v/v) Methylene blue in 10 mM borate buer pH 8.5
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A.7.3 Elution Buer
1:1 Ethanol: 0.1% HCl solution
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Publication List
B.1 Publications
Campbell-Harding, G; Holgate, ST; Davies, DE; Andrews, A-L (2012)
Expression of IL-13R2 in Human Bronchial Fibroblasts Requires de novo
Protein Synthesis (Manuscript in preparation).
Campbell-Harding, G; Sawkins, H; Bedke, N; Holgate, ST; Davies, DE;
Andrews, A-L (2012) The Innate Anti-Viral Response Upregulates Inter-
leukin 13 Receptor  2 in Bronchial Fibroblasts (Manuscript submitted).
B.2 Oral Presentations
Campbell-Harding, G; Holgate, ST; Davies, DE; Andrews, A-L (2010)
Potential involvement of STAT3 in IL-4 mediated signalling in bronchial
broblasts. BALR Summer Meeting, Swansea, UK
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B.3 Poster Discussions
Campbell-Harding, G; Sawkins, H; Bedke, N; Holgate, ST; Davies, DE;
Andrews, A-L (2012) The Innate Anti-Viral Response Upregulates IL-13R2
In Bronchial Fibroblasts. American Thoracic Society International Meeting,
San Francisco, USA. Abstract accepted.
B.4 Poster Presentations
Campbell-Harding, G; Holgate, ST; Davies, DE; Andrews, A-L (2012) Ex-
pression Of Interleukin 13 Receptor  2 In Human Bronchial Fibroblasts
Requires De Novo Protein Synthesis. American Thoracic Society Interna-
tional Meeting, San Francisco, USA. Abstract accepted.
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International Meeting, Denver, USA. Meeting reported in American Journal
of Respiratory and Critical Care Medicine.
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Medicine.
Campbell-Harding, G; Bondanese, V-P; Holgate, ST; Davies, DE; Andrews,
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